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Abstract 
Obesity has increased globally in epidemic proportions and as have the associated 
disorders. Insulin resistance that could further lead to type 2 diabetes is a major obesity 
associated dysfunction. Studies using insulin resistant mouse models and observations from 
human subjects exhibiting insulin resistance provide evidence for ectopic lipid deposition in 
organs like liver, muscle and heart as one of the major risk factors for developing insulin 
resistance. These observations suggest that deregulated adipose function to sequester and store 
excess energy as fat, could lead to insulin resistance. Furthermore, several studies have 
demonstrated adipose tissue dysfunction leading to inflammation and related syndromes. 
Interestingly, a mouse model with transgenic expression of glucose transporter in the adipose 
tissue exhibited improved glucose tolerance and increased insulin sensitivity despite 
development of obesity, upon high fat feeding. Thus mechanisms that improve adipose function 
could alleviate insulin resistance and associated diseases.  
Mitogen activated protein kinase kinase kinase kinase 4 (MAP4K4) was identified in our 
laboratory as a negative regulator of adipocyte function. Interestingly, siRNA mediated 
knockdown of MAP4K4 promoted PPARγ protein expression. Additionally, silencing of 
MAP4K4 increased adipocyte triglyceride content. Because MAP4K4 is a negative regulator of 
PPARγ expression and adipocyte function, understanding the mechanism by which MAP4K4 
regulates PPARγ expression is of interest. Thus, for the first part of this thesis, I characterized 
the signaling pathways utilized by MAP4K4 to regulate PPARγ expression in cultured 
adipocytes. Here I show that MAP4K4 regulates PPARγ expression through regulation of its 
protein translation. siRNA mediated MAP4K4 gene silencing stimulated PPARγ protein 
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synthesis without changing its mRNA transcription or its protein degradation. This increase in 
PPARγ protein translation was due to an increase in the activity of mammalian target of 
rapamycin (mTOR). The increase in PPARγ protein expression mediated by mTOR activation 
was a specific effect of the 4E-BP1 phosphorylation that leads to its inactivation and was not a 
general increase in mTOR activity towards all of its substrates. Finally, adenovirus mediated 
over expression of MAP4K4 inhibited mTOR activation, and suppressed PPARγ protein 
translation. 
For the second part of this thesis, I assessed the role of MAP4K4 in adipocytes in vivo. 
To accomplish this, a lentivirus mediated shRNA construct was generated to attenuate MAP4K4 
expression selectively in the mouse adipose tissue. First we demonstrate that the MAP4K4 
shRNA construct is able to efficiently silence the expression of MAP4K4 in vitro when co-
expressed with Cre recombinase. Furthermore, we show that following modification of the 
lentiviral conditional vector that was introduced into a mouse embryo at one cell stage, and 
crossing the resulting founders with aP2-Cre mice, adipose tissue specific MAP4K4 gene 
silencing was achieved. Moreover, shRNA mediated gene silencing is a faster and an 
inexpensive means of achieving tissue specific gene knockdown relative to the available 
traditional gene knockout approaches. 
 Utilizing these adipose specific MAP4K4 gene knockdown mice, I reveal that 
MAP4K4 silencing enhanced fat mass as well as PPARγ expression significantly. This is 
accompanied by improved whole body insulin sensitivity. Furthermore, when challenged with 
high fat diet, adipose-specific MAP4K4 silenced mice exhibit enhanced adiposity with decreased 
lean mass. Moreover, adipocyte cell size and triglyceride content are significantly increased. 
viii 
 
Interestingly, despite increased adiposity, hepatic insulin sensitivity is significantly improved 
leading to decreased glucose output. Thus MAP4K4 is an important regulator of adipocyte 
function that mediates whole body glucose homeostasis, through a mechanism that is yet to be 
identified. 
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CHAPTER I: Introduction 
Adipose tissue is a specialized connective tissue that functions to store fat in the 
form of triglycerides. As the major and efficient way of energy storage, fat provides a 
buffer for imbalances when energy intake is not equal to energy output. Great strides 
have been made in the field of adipose biology since Conrad Gessner a Swiss naturalist, 
first identified the adipose tissue in 1551. But adipose tissue continues to be an enigma. 
Instead of being considered a passive storage depot, adipose tissue is now recognized as 
an active metabolic as well as endocrine organ. Lipodystrophy, characterized by the 
selective loss of adipose tissue, and obesity characterized by excess accumulation of body 
fat, represent two extremes of adipose tissue dysfunction. Much attention has been 
focused on obesity, due to the global catastrophic rise in its prevalence and its associated 
metabolic diseases. The risks associated with obesity include and are not limited to 
hypertension, coronary heart disease, stroke, pulmonary abnormalities, arthritis, gall 
bladder disease, cancer and most importantly, type 2 Diabetes. 
Insulin resistance is a hallmark of type 2 diabetes. Insulin is synthesized and 
secreted by the β-cells present in the islets of Langerhans of the pancreas, in response to 
several stimuli that include protein and glucose in the blood produced from the ingested 
food. In mammals, liver, muscle and adipose form the major insulin responsive tissues. 
Along with the key storage function, adipose tissue also communicates with the other 
metabolic tissues, and forms a major source of information of its own nutritional status, 
as well as of the whole organism.  Even though numerous important discoveries made 
2 
 
during the last 15 years have added substantially to the vast knowledge of adipose tissue 
biology, much remains to be known. Better understanding of the mechanisms involved in 
the dysfunction of the adipose tissue, might provide potential new therapeutic strategies 
for the treatment of obesity associated insulin resistance. 
Adipogenesis 
Two types of adipocytes are known in mammals, brown and white, which have 
distinct physical as well as molecular and physiological properties. These adipocytes are 
found in specific regions of the body as adipose depots, as well as in combination with 
other cell types such as connective tissue. Subcutaneous and the visceral areas form the 
two major locations of white adipocytes that differ in their physiological and molecular 
functions, where increase in visceral adipose tissue correlates with elevated risk for 
insulin resistance and cardiovascular disease, while increase in subcutaneous adipose 
tissue does not [1-4].  
Adipogenesis is a complex process involving a temporally regulated set of gene 
expression events that involve cell cycle proteins, transcriptions factors, co-activators and 
co-repressors. Much of the knowledge of adipogenesis is from observations made in cell 
culture systems, such as 3T3-L1 mouse preadipocytes. The process of adipocyte 
differentiation involves two phases (summarized in Figure 1.1). The commitment of a 
pluripotent stem cell to the adipocyte lineage [5] is the first phase, known as 
determination; terminal differentiation is the second phase, where the preadipocyte 
acquires the characteristics of mature adipocyte.   
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FIGURE 1.1: Adipogenesis is a multi step process. Mesenchymal cells proliferate 
(clonal-expansion). Some of these cells differentiate into preadipocytes. Preadipocytes 
proliferate at the site of adipogenesis (clonal-expansion). Preadipocytes undergo a second 
differentiation step and begin to accumulate lipids. Lipids in the cell appear as small 
droplets (multilocular cells) that later fuse into one large droplet (unilocular cells). The 
adipocyte can continue to enlarge by accumulating additional lipids. The average 
mesenchymal cell is 10-20µm in diameter, while primary adipocytes reach 100-200µm in 
diameter.  
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CCAAT/enhancer-binding proteins [6] are a family of transcription factors that 
include the isoforms α, β, γ, δ and CHOP (transcription factor homologous to 
CCAAT/enhancer-binding protein).  While the isoforms α, β, δ exhibit pro-adipogenic 
functions [7], γ and CHOP are anti-adipogenic [8]. C/EBPβ and C/EBPδ expression is 
induced early during adipogenesis. Sequential expression of C/EBPβ and C/EBPδ leads 
to the expression of C/EBPα and peroxisome proliferator-activated receptor-γ (PPARγ) 
[9]. Gain and loss of function studies have identified PPARγ, a nuclear hormone receptor 
and a transcription factor, to be necessary and sufficient for adipogenesis. Studies 
involving mouse embryonic fibroblasts (MEFs) lacking C/EBPα have shown that, ectopic 
expression of PPARγ in these cells induced adipogenesis, however, C/EBPα could not 
rescue adipogenesis in the absence of PPARγ [10], thus establishing PPARγ as the master 
regulator of adipogenesis [11]. Although, transgenic expression of PPARγ was sufficient 
to induce adipogenesis and lipid accumulation, C/EBPα is necessary for acquiring insulin 
sensitivity [10]. Crucial signaling pathways in adipogenesis have been demonstrated to 
converge on the regulation of PPARγ expression or activity [11]. The complex 
transcriptional cascade of that regulates adipogenesis is summarized in Figure 1.2. 
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FIGURE 1.2: A complex transcriptional cascade regulates adipogenesis. PPARγ is at 
the core of the transcriptional cascade that regulates adipogenesis. The expression of 
PPARγ is regulated by several pro-adipogenic and anti-adipogenic factors. PPARγ  itself 
is activated by an unknown ligand. C/EBPα is regulated through a series of inhibitory 
protein-protein interactions. Several members of KLF family of ttransciption factors 
participate in adipogenesis. Black lines – effects on gene expression. Blue lines – effects 
on protein activity.  
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Cell cycle proteins also function as cofactors of adipogenesis. CDK6 binds to and 
activates PPARγ, through phosphorylation [12]. CDK4 is also involved in activating 
PPARγ without affecting phosphorylation [5]. To the contrary, CDK1 has been shown to 
inhibit PPARγ function [13]. Several members of the family of transcription factors 
Krüppel-like factors (KLFs) also regulate adipogenesis. While KLF 5 & 15 promote 
adipogenesis [14], KLF 2 & 7 inhibit adipose differentiation [6, 15-17]. KLF15 also 
induces the expression of the insulin sensitive glucose transporter GLUT4 [17]. The 
differential recruitment of co-repressors and co-activators to PPARγ promoter region 
maintains adipogenesis. TRAP220 (also called as PPAR-binding protein; PBP) is a 
known binding partner of PPARγ [18]. PRIP (PPAR interacting protein) has been 
identified as a co-activator of PPARγ [19]. NCoR (nuclear receptor co-repressor) and 
SMRT (silencing mediator of retinoid and thyroid hormone receptor) function as co-
repressors of PPARγ [20].  Co-repressors recruit HDACs (histone deacetylases) to target 
promoters thereby blocking transcription. PPARγ is required for the release of histone 
deacetylase from C/EBPα promoter, for C/EBPβ to induce the expression of C/EBPα 
[21].  
There are three major subfamilies of MAPKs: the extracellular signal-regulated 
kinases (ERK1/2), the Jun amino terminal kinases (JNK1-3) and the p38 kinases (p38 α, 
β, γ). The initial studies performed to analyze the role of ERK MAP kinase in 
adipogenesis was contradictory, however, further studies demonstrated that ERK1 
activity is required for the proliferative phase of adipogenesis, and this signaling cascade 
has to be turned off during the second phase of terminal differentiation [22].  The 
7 
 
important role played by ERK1 in adipocyte differentiation is further demonstrated by the 
impaired adipogenesis exhibited by the mouse embryonic fibroblasts (MEFs) derived 
from ERK1-/- animals [23]. Furthermore, the residual adipogenesis seen in ERK1-/- cells 
is not inhibited by pharmacological ERK inhibitor. These studies demonstrated that 
ERK2 possibly has no function in adipocyte differentiation. A positive role for p38 
MAPK in adipogenesis was described by Engelman and colleagues where, chemical 
inhibition of p38 decreased 3T3-L1 differentiation [24, 25]. However, expression of an 
upstream activator of p38 for long duration resulted in adipocyte cell death. To the 
contrary, p38 mediated CHOP phosphorylation that subsequently inhibits C/EBP results 
in inhibition of adipocyte differentiation [26]. JNK has not been implicated in regulation 
of adipocyte differentiation. Together, these studies have put forward a complex cascade 
of events that involves a delicate balance of interactions between several different 
families of transcription factors, cell cycle checkpoint proteins, co-repressors and co-
activators that participate in the process of adipocyte differentiation. Along with many 
other hormones and proteins, insulin plays an important and major role in regulating 
adipogenesis. 
Insulin Signaling 
Insulin action is initiated once insulin interacts with its cell surface receptor. 
Preadipocytes express more of IGF1 (insulin like growth factor-1) receptors than insulin 
receptors. This changes as the adipocytes differentiate. Insulin functions through IGF-1 
signaling in the early stages of adipogenesis. The insulin receptor (IR) is composed of 
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two extracellular α subunits and two transmembrane β subunits that are linked together 
by disulphide bonds. Upon insulin binding to the α subunit, a conformational change is 
induced that results in the autophosphorylation of a number of tyrosine residues present 
in the β subunit [27]. The first adaptor protein identified was the insulin receptor 
substrate-1 (IRS-1); it contains phosphotyrosine-binding (PTB) domains that recognize 
these residues [28, 29], and is recruited through it‘s pleckstrin homology (PH) domain. 
Insulin receptor interacts with other adaptor proteins, including IRS-2, -3 and -4 along 
with SHC, GAB2, DOCK1/2, APS [30-32]. However, the majority of insulin‘s metabolic 
effects appear to be mediated by IRS-1 and IRS-2. Receptor activation leads to the 
phosphorylation of key tyrosine residues on IRS proteins, some of which are recognized 
by the Src homology 2 (SH2) domain containing proteins [30]. There are at least 23 
known tyrosine residues phosphorylated on IRS protein [33]. The regulatory subunit of 
PI3K (p85 – a lipid kinase) and the growth factor receptor bound protein-2 (GRB2) form 
the two main branches of insulin signaling, leading to the activation of Akt (also known 
as protein kinase-B (PKB)) and mitogen activated protein kinases (MAPKs) respectively. 
While Akt regulates utilization, production and uptake of glucose, MAPKs regulate cell 
growth, gene expression and differentiation [34]. A brief summary of insulin signaling is 
depicted in Figure 1.3. 
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FIGURE 1.3: Insulin Signaling Mediated Regulation of Metabolic Pathways. Insulin 
binding to the insulin receptor (IR) stimulates its kinase activity that leads to the 
activation of insulin receptor substrate 1 (an adaptor protein) (IRS1). Tyrosine 
phosphorylated IRS1 functions as a docking site for the growth factor receptor bound 
protein 2 (GRB2) and phosphatidylinositol 3-kinase (PI3K). By a cascade of activating 
events extracellular-signal regulated kinase [35] pathway is activated by GRB2. Protein 
kinase B (Akt) pathway is activated by the PI3K mediated signaling events. Downstream 
targets of ERK and Akt regulate the indicated processes. Glycogen synthesis is 
stimulated in the muscle and liver; glucose uptake is regulated in the muscle and adipose 
tissue, gluconeogenesis is inhibited in the liver; lipolysis is inhibited in the adipose tissue. 
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Insulin Activation of PI3K/Akt Pathway 
There are multiple isoforms of PI3Ks that are classified into three classes. Akt is 
activated by Class IA PI3Ks that consists of p110β catalytic subunit and p85α 
adaptor/regulatory subunit in insulin sensitive cells. The catalytic and regulatory subunits 
are derived from alternate splicing of three genes, resulting in 3 catalytic and 8 regulatory 
subunits [34]. The observations that, chemical inhibitors of PI3K like LY294007 and 
Wortmannin, as well as ectopic expression of dominant negative PI3K, could completely 
abrogate insulin stimulated Akt activation, underscores the requirement of PI3K in 
insulin signaling [36]. Stimuli that induce IRS tyrosine kinase activity lead to the 
activation of PI3Ks, to phosphorylate the 3‘- OH of inositol ring in inositol 
phospholipids, generating 3‘-phosphoinositides (PI); thus, resulting in three lipid 
products PtdIns3-monophosphate, PtdIns(3,4)-diphosphate (PIP2) and PtdIns(3,4,5)-
triphosphate (PIP3) [37]. 
PDK1 was identified by its ability to phosphorylate Akt, and this function 
required the presence of PIP2 or PIP3 in vitro, thus giving the name 3‘-phosphoinositide-
dependent kinase-1 (PDK1) [38, 39]. Ubiquitously expressed, this 63kDa 
serine/threonine kinase is a constitutively active cytosolic protein. PIP3 once generated 
by activated PI3K, directs the translocation of PDK1 to the membrane where, it activates 
PKB (Akt) by phosphorylating Thr308 on the activation loop. Complete activation of Akt 
requires the phosphorylation of a second site Ser473 present on the hydrophobic motif. 
The identity of the kinase, considered as PDK2, that phosphorylates this second site on 
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Akt has been obscure. Recent studies have identified mTOR2 complex (consisting 
mTOR, Rictor, mLST8) as the elusive PDK2 [40]. Insulin stimulated Akt-Ser473 
phosphorylation was prevented in the mouse models with genetic ablation of Rictor in fat 
cells [41], as well as studies with muscle specific Rictor knockout [42]. Interestingly, 
mTOR2 complex activates Akt, while mTOR1 complex (made up of mTOR, Raptor and 
mLST8) is one of the downstream effectors of Akt [43]. Akt is a 57 kDa serine/threonine 
protein kinase, and is homologous to the protein kinases A and C (PKA & PKC). Insulin 
stimulated metabolic functions of Akt are elicited by phosphorylation of substrates, that 
include (i) AS160 – functions to regulate glucose uptake through GLUT4 membrane 
translocation in fat and muscle [16] GSK3 – mediates glycogen synthesis regulation in 
liver and muscle [16] inhibition of FOXO nuclear translocation, thus preventing 
gluconeogenesis [15] TSc1 & TSc2 complex that in turn modulate mTOR1 complex to 
regulate cell size, growth & differentiation and protein synthesis (v) PKA – to inhibit 
lipolysis. Several of these pathways involved in the regulation of insulin‘s metabolic 
functions also participate either directly or indirectly in the process of adipogenesis. 
Insulin Activation of MAPK Pathway 
The second branch of insulin signaling through IRS is to the GRB2 adaptor 
protein and its effectors [44]. Shc (src homology 2/α-collagen-related) is a ubiquitously 
expressed cytosolic protein that is stimulated by several growth factors and cytokines, 
competes with IRS as substrate of insulin receptor. Insulin induced Shc tyrosine 
phosphorylation stimulates Shc/GRB2 association [45] [45]. Son of sevenless [46], a 
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guanine nucleotide-exchange factor is constitutively associated with GRB2. SOS 
catalyzes the GDP to GTP exchange, thus activating RAS, a membrane bound GTPase. 
Activated RAS then recruits and activates RAF1 kinase (v-raf-leukemia viral oncogene 
1), that in turn activates MEK1/2 (mitogen activated protein kinase kinase 1 and 2. 
Extracellular-signal regulated kinases 1 and 2 (ERK1/2) are phosphorylated and activated 
by MEK1/2 [47, 48]. ERK1/2 then phosphorylate many substrates that include ELK1, an 
ETS (the ternary complex) family member [48]. ELK1 forms complexes with serum 
response factors and promotes the transcription of serum response element containing 
genes that then regulate cell growth and proliferation [49]. These functions are also 
mediated by p90 ribosomal S6K (p90S6K), another substrate of ERK1/2, that activates 
ribosomal S6 protein to stimulate protein synthesis [50]. Interestingly, JNK activation is 
independent of the PI3K catalytic subunit binding to the p85 subunit; instead it involves 
the small GTPase cell division control protein 42 (CDC42) [51]. However, insulin 
stimulated JNK activation results in insulin resistance that would be discussed later. The 
mechanism of insulin signaling mediated p38 activation is not known. Similar to the Akt 
branch of insulin signaling, the MAP kinases also play an important role not only in the 
metabolic actions of insulin but also regulate adipogenesis [52]. 
Role of mTOR in Metabolic Regulation 
Adipose tissue is an information treasure trove for the nutritional status of the 
whole organism. Possibly, by employing a nutritional sensor, adipocytes recognize, 
assimilate and decipher their own metabolic status that is later relayed to other metabolic 
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tissues. It would not be erroneous to speculate that adipocytes might actually utilize 
mammalian target of rapamycin (mTOR) to this end. Being a master regulator of cell 
growth, TOR plays a central role in development & aging and is associated with 
disorders like cancer, cardiovascular disease, obesity and diabetes. Many cellular 
processes including protein synthesis, ribosome biogenesis, nutrient transport and 
autophagy are controlled by mTOR. Studies from yeast, worms, flies as well as 
mammalian cell lines and animal models have provided the basic understanding of 
mTOR biology. First identified as a target of the anti-fungal & anti-proliferative drug 
rapamycin in yeast, and later also observed in many mammalian cells, mTOR is an 
atypical serine/threonine protein kinase, that belongs to the phosphatidylinositol kinase 
related kinase (PIKK) family [53-57]. Structurally, mTOR is made up of 20 tandem 
HEAT (a protein-protein interaction structure), domains on the N-terminus, followed by 
FAT (FRAP, ATM and TRRAP) domain, FRB (FKBP12/rapamycin binding) domain, 
Kinase domain and FATC (FAT c-terminus) on the C-terminus [58]. mTOR knockout 
mice are embryonic lethal, demonstrating the importance of mTOR in cell growth and 
proliferation [59-61]. Upstream regulators and downstream targets of mTOR are 
summarized in Figure 1.4. 
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FIGURE 1.4: Upstream and Downstream of mTORC1 Signaling in Mammalian 
Cells. The mammalian target of rapamycin complex 1 (mTORC1) consists of mTOR, 
Raptor, mLST8 and PRAS40. Through tuberous sclerosis complex 1 &2 (TSc1/TSc2) – 
Ras homologue enriched in brain (Rheb) axis mTORC1 integrates growth factor 
signaling mediated by protein kinase B (Akt), extracellular-regulated kinase 1 & 2 
(ERK1/2), cellular energy levels through AMP Kinase (AMPK), and amino acid 
signaling through VPS34, to regulate protein translation by phosphorylating S6K1 and 
4EBP1 and to stimulate lipogenesis by activating sterol regulatory element-binding 
protein 1 (SREBP1). 
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Studies by McKnight and his coworkers which identified FKBP51, as an 
immunophilin that bound to rapamycin and inhibited clonal expansion in 3T3-L1 
preadipocytes was the first to implicate mTOR in adipogenesis [62]. Moreover, studies 
by Sorisky and colleagues have shown that rapamycin exhibited potent negative effects 
on triacylglycerol accumulation as well as C/EBPα and PPARγ protein expression in the 
later stages of adipogenesis after clonal expansion, suggesting the continued requirement 
of mTOR for normal adipocyte function [63]. Furthermore, recent studies have 
demonstrated that the amino acid stimulated mTOR and insulin stimulated PI3K/Akt 
pathways operated in parallel to regulate PPARγ activity, illuminating a molecular 
mechanism linking nutrient status and growth factor signaling to adipogenesis [64]. 
mTOR, in a nutrient sensitive mechanism, also regulates insulin stimulated IRS activity 
positively. Although, IRS1 is phosphorylated on several tyrosine residues, in response to 
insulin, and numerous serine residues on IRS1 are identified to be inhibitory 
phosphorylation sites (that would be discussed later), however, phosphorylation of IRS1 
on Ser302 is the only stimulatory serine residue published in the literature so far. White 
and coworkers have shown that through a rapamycin and LY294007 sensitive 
mechanism, insulin/IGF-1 stimulates IRS1 Ser302 phosphorylation, and this plays an 
important role in insulin-stimulated IRS1 tyrosine phosphorylation and signal 
transduction [65]. 
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mTOR Binding Partners 
Initial work using yeast, by M. Hall and his coworkers have identified several 
mTOR interacting proteins. The two functionally and structurally distinct multiprotein 
mTOR complexes are named as mTORC1 (complex 1) and mTORC2 (complex 2) [66, 
67]. mTORC1 comprises of the mTOR, Raptor, mLST8 and the recently identified 
PRAS40 forming the insulin responsive, rapamycin sensitive complex [68-71]. The 
rapamycin insensitive complex mTORC2 is made up of mTOR, Rictor, mLST8 and the 
recently identified protein mSIN1 [72-74].  
mLST8 (also known as GβL) is the common component of both complexes 
mTORC1 & 2. It is the mammalian ortholog of S. cerevisiae Lst8p and consists of seven 
WD40 repeats with high sequence similarity to β subunits of heterotrimeric G proteins. 
GβL interacts constitutively with mTOR kinase domain, and is necessary for the 
formation of nutrient-sensitive interaction with Raptor [69]. Regulatory associated 
protein of TOR (Raptor) is a ubiquitously expressed, evolutionarily conserved 150 kDa 
protein, that forms a tight complex with mTOR under nutrient and growth factor depleted 
condition, thus regulating mTOR kinase activity [70]. Although there are conflicting 
studies, there is a consensus that Raptor functions as a scaffold protein that recruits 
mTOR to its downstream substrates through their mTOR signaling (TOS) motifs [68]. 
Recent studies have identified six different ser/threonine phosphorylation sites on 
Raptor that are responsible for regulation of its function. The phosphorylation events 
follow a hierarchy, with Ser863 being the priming site [75]. Oncogenic Ras, phorbol 
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esters, growth factors as well as mitogenic signals through the MAPK pathway to activate 
p90 ribosomal s6 kinase (p90RSK), that phosphorylates Raptor to regulate mTORC1 
activity [76]. However, in a very recent study Roux and colleagues have shown that 
ERK1/2 can directly phosphorylate Raptor, and mutation of these sites impaired 
mTORC1 kinase activity, thus demonstrating another novel means of mTOR regulation 
[76]. AMPK (5‘ AMP activated protein kinase) has also been shown to directly 
phosphorylate Raptor, which results in binding of 14-3-3 protein and possibly leads to 
either sequestration to a different cellular compartment or degradation of Raptor [77]. 
Similar to mTOR knockout, Raptor knockout mice are embryonic lethal. Tissue 
specific Raptor knockout mouse models have provided immense knowledge, as to the 
role of mTORC1 in regulating metabolic functions of the whole organism. Adipose-
specific Raptor knockout resulted in lean mice with substantially less adipose tissue, and 
the animals were protected from DIO and insulin resistance [78]. The leanness was 
attributed to enhanced energy expenditure due to mitochondrial uncoupling, thus 
providing evidence for a possible role of mTOR in energy homeostasis. However, muscle 
specific Raptor knockout resulted in dystrophy and down regulation of genes involved in 
mitochondrial biogenesis [79]. These studies have shown that mTOR activity is essential 
for cell growth and proliferation while highlighting the tissue specific functions of mTOR 
with wide metabolic implications. 
PRAS40 was first identified as a subunit of mTORC1. Further studies have 
established that PRAS40 functions as a negative regulator of mTORC1 activity, by 
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directly binding to the TOR kinase domain [71, 80]. However, there is also evidence 
showing that PRAS40 associates with mTOR through a Raptor mediated interaction. 
PRAS40 has also been proposed to consist of TOS motif and functions as mTOR 
substrate, and may compete with the known mTOR substrates [81]. Supporting this 
hypothesis, mTOR was found to phosphorylate PRAS40 on the serine 183 residue. Upon 
activation, Akt is known to directly phosphorylate PRAS40 on threonine 246, and hence 
the name proline rich substrate of Akt1-40 (PRAS40). This phosphorylation possibly 
leads to binding of 14-3-3 protein and thus is believed to release the inhibition of 
PRAS40 on mTOR [80, 82]. 
TSC1/TSC2 Mediated mTOR Regulation 
Insulin stimulation leads to the activation of Akt that in turn results in the 
regulation of numerous effectors through phosphorylation. TSC2 (also known as tuberin) 
is one of the well documented substrates of Akt, through which, signals from the insulin 
receptor are transmitted to mTOR. TSC1 (also known as hamartin) and TSC2 physically 
associate and function as a complex, and TSC1 is necessary to stabilize TSC2 and to 
prevent from ubiquitin mediated degradation [35]. Their function as tumor suppressor 
was identified from observations made in autosomal dominant tumor syndrome [83]. The 
140 kDa TSC1 and the 200 kDa TSC2 proteins share homology neither with each other 
nor with other proteins. However, TSC2 contains a GAP domain and has been 
demonstrated to exhibit GTPase activity. The TSC1-TSC2 complex regulates a small G-
protein called ras homologue enriched in brain (Rheb), to modulate mTOR activity [84]. 
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Rheb is a member of the Ras superfamily, is expressed ubiquitously in mammals. Studies 
from fission yeast have demonstrated that the interaction between mTOR and Rheb 
requires, Rheb to be GTP bound. The GAP domain in TSC2 complex stimulates the 
intrinsic GTPase activity in Rheb, thereby converting Rheb-GTP to Rheb-GDP [85-87]. 
Upon growth factor stimulation, Akt activation leads to the phosphorylation and cytosolic 
sequestration of TSC2 by 14-3-3 proteins, thus relieving the repression of Rheb-mTOR 
signaling.  Recent studies using TSC2 null mouse embryo fibroblasts have shown that, 
despite insulin resistance and lack of Akt activity, there was increase in adipogenic 
capacity. This observed enhancement in adipogenesis was dependent on the mTOR 
activity [88]. Furthermore, TSC2 mutants lacking all five known Akt phosphorylation 
sites blocked insulin-stimulated mTORC1 signaling in reconstituted TSC2 null cells, and 
this mutant also inhibited adipogenesis. 
PI3K/AKT Independent mTOR Regulation 
Through numerous phosphorylation events, TSC1-TSC2 complex senses and 
integrates signals from several different pathways, to regulate its downstream effector, 
mTOR. Mitogen stimulation activates RSK and ERK, which then directly phosphorylate 
TSC2 at many serine and threonine residues, to inhibit its function [89, 90]. TSC1 is 
inhibited upon phosphorylation by cyclin dependent kinase 1 (CDK1) and inhibitory κ-B 
kinase β (IKKβ) [91, 92]. Decrease in energy status is reflected in the increase of cellular 
AMP levels that bind to AMP kinase (AMPK), which is further activated by the kinase 
LKB1, a tumor suppressor [93]. One of the mechanisms by which, mTOR senses the 
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intracellular energy status is through the direct phosphorylation of TSC2 by AMPK. 
However, the effect of this phosphorylation on GAP activity toward Rheb has not been 
demonstrated. Moreover, TSC2 phosphorylation by AMPK primes the complex for 
GSK3β mediated activation by phosphorylation that is downstream to Wnt signaling 
pathway but not that of Akt [94]. 
Recent studies have shown that the glycolytic enzyme glyceraldehyde-3 
phosphate dehydrogenase (GAPDH), under low glucose conditions binds to and 
sequesters Rheb, thus inhibiting mTOR signaling. But high glycolytic flux was found to 
suppress GAPDH-Rheb interaction, thus restoring Rheb mediated mTOR activation. This 
GAPDH mediated control of mTOR signaling was observed independent of TSC1/TSC2 
as well as AMPK, thus opening a novel means of regulating mTOR activity [95]. Initial 
observations demonstrating mTOR as an amino acid sensor, came from studies in 
Saccharomyces cerevisiae, the budding yeast, which lack TSC1 and TSC2 homologues. 
The observations provided the first proof for nutritional signaling to mTOR independent 
of these proteins. Furthermore, the class II PI3K, vacuolar protein sorting 34 (VPS34) 
and MAP4K3 (a sterile 20 related kinase), have been recently recognized to mediate 
amino acid cues to mTOR [96, 97]. In an elegant study Sancak and coworkers have 
demonstrated that Rag GTPases bind to Raptor and mediate amino acid signaling to 
mTOR. Interestingly, Rag proteins instead of directly activating mTOR, localized it to a 
Rheb containing intracellular compartment [98]. These studies have opened new 
paradigms of nutrient signaling, to regulate metabolic functions independent of insulin 
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stimulation, although, earlier studies have recognized insulin-Akt-TSC2 signaling 
independent activation of mTOR. 
mTOR Substrates 
Upstream activating signals through Akt-TSC1/TSC2-Rheb dependent 
mechanism results in mTOR phosphorylation on Ser2448 that in turn leads to Ser2481 
autophosphorylation, considered the major indicator of mTOR intrinsic kinase activity 
[43, 99, 100]. Activated mTOR phosphorylates the protein translation regulators p70 
ribosomal S6 Kinase-1 (S6K1) and EIF4E- binding protein-1 (4E-BP1) the well 
characterized mTOR substrates [101-104]. S6K is an AGC family protein kinase, 
synthesized as two isoforms, produced from two alternate translation initiation start sites. 
The larger isoform is localized to the nucleus, while the smaller isoform referred to as 
S6K1 is localized to the cytosol [105]. S6K1 is activated by two phosphorylation events 
one, by mTORC1 at Thr389 on the c-terminal hydrophobic motif; second, by PDK1 at 
Thr229 on the T loop of the kinase domain [106-109]. Activated S6K1 subsequently 
phosphorylates ribosomal S6 protein and eIF4B, to regulate protein synthesis. S6K1 is 
not only implicated in cell growth, protein synthesis and ribosome biogenesis, but has 
also been show to regulate life span [110]. Unlike mTOR and Raptor knockout mouse 
models, S6K1 knockout mice are viable. S6K1 whole body knockout mice are 20% 
smaller in size, owing to the role played by S6K1 in cell growth and protein synthesis 
[111]. Although, earlier studies suggested S6K1 to regulate translation of 5‘ TOP mRNA, 
that encode protein translation machinery [112]; however, their translation was not 
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effected in the S6K1 knockout mice, suggesting either a compensatory mechanism by 
other proteins, or that the earlier observations were an artifact of cell culture model 
systems. Additionally, the S6K1 knockout mice were protected from diet and age induced 
obesity owing to enhanced fatty acid β-oxidation. Furthermore, the animals were 
hypersensitive to insulin but were not hypoglycemic when fasted, as they exhibited 
smaller β cell mass, reiterating the role of S6K1 in cell growth. Tissue specific knockout 
mouse models would be needed to completely analyze the role of S6K1 in regulating 
energy homeostasis. 
4E-BP1, the other well known substrate of mTOR regulates protein synthesis, by 
sequestering eIF4E, the cap-binding protein, rendering it unavailable to the mRNA, for 
protein translation. Once bound to the Raptor-mTORC1 complex, 4E-BP1 is regulated by 
a hierarchical phosphorylation, leading to the dissociation of 4E-BP1 from eIF4E. 
Priming phosphorylation on Thr37/46 that depends on the RAIP (the single letter code 
for its amino acid sequence) motif leads to the subsequent phosphorylation of Ser64; 
followed by Thr70, which are regulated through the mTOR-signaling (TOS) motif [113-
116]. CDK1 has also been shown to phosphorylate Thr70 during cell cycle regulation. 
Phosphorylation at Thr37/46 is maintained by amino acids and is modestly regulated by 
insulin stimulation, and is also insensitive to rapamycin. While Ser64 is highly responsive 
to insulin, Thr70 is variably receptive [117-119]. Although, the role of 4E-BP1 in protein 
translation is well established, the consequences on metabolic functions are not well 
known. Since 4E-BP1 is a negative regulator of protein synthesis, ablation of this protein 
in mice should render the animals anabolic. To the contrary, 4E-BP1 knockout mice were 
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hypoglycemic, exhibited reduced WAT, and displayed increased metabolic rate, 
increased mRNA and protein expression of uncoupled protein 1 (UCP1) and PPARγ 
coactivator-1 α (PGC1α) respectively. This study has placed 4E-BP1 in the forefront of 
adipogenesis and regulation of adipose function [120]. Surprisingly, 4E-BP1 and 4E-BP2 
double knockout mice exhibited elevated sensitivity to diet-induced obesity that was due 
to increased adiposity as a result of accelerated adipogenesis driven by increased 
expression of C/EBPα,δ and PPARγ, accompanied by reduced energy expenditure, 
reduced lipolysis and greater fatty acid reesterification. These animals also displayed 
insulin resistance, which was due to elevated S6K1 activity [121]. 
The central role played by mTOR in cell growth and cell size regulation has been 
revealed by studies using rapamycin treatment that resulted in a reduced cell size 
phenotype. The rapamycin induced cell size decrease was rescued completely or partially 
by the expression of a rapamycin-resistant mutant of mTOR or a partial-rapamycin-
resistant S6K1, respectively [122]. Additionally, in the absence of rapamycin, ectopic 
expression of S6K1 or eIF4E increased cell size; co-expression had additive effect. 
Moreover, expression of a phosphorylation site-defective mutant of 4E-BP1 reduced cell 
size [123]. These studies in mammalian cells, together with many other observations in 
yeast, drosophila and worms have established two independent but synergistic modes of 
cell size regulation by mTOR, through S6K1 and 4E-BP1. 
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mTOR Regulation of Protein Synthesis 
mTOR regulates cell growth by integrating the nutrient signaling and the growth 
factor signaling pathways. The major role of mTOR in stimulating cell growth is through 
regulation of protein synthesis. Protein synthesis involves two main steps initiation and 
elongation, which are complex processes engaging several factors. Very briefly, 
eukaryotic initiation factor-4E (eIF4E) binds to the 5‘ cap region, allowing the formation 
of translation initiation factor complexes at the 5‘ end of the mRNA. Eukaryotic initiation 
factor-4G (eIF4G), the scaffold protein binds to eIF4E and interacts with the helicase 
eukaryotic initiation factor-4A (eIF4A) and poly(A)-binding protein PABP, as well as 
several other proteins, that leads to the circularization of the mRNA leading to the 
initiation of protein synthesis.  
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FIGURE 1.5: mTOR mediated control of protein synthesis. 4D-BPs bind to eIF4E 
and prevent its interaction with eIF4G and thus inhibits translation. Phosphorylation of 
4E-BP by mTOR releases the protein from eIF4E that allows its interaction with eIF4G 
and thereby allows translation to proceed. 
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mTOR regulation of 4E-BP1 through phosphorylation renders it inactive thus 
relieving the inhibition on eIF4E to commence the formation of initiation complex, as 
summarized in Figure 1.5. During the elongation process, eukaryotic elongation factor-1 
and factor-2 (eEF1 & eEF2) promote the translocation, where ribosome moves by one 
codon on the mRNA to facilitate peptidyl-tRNA migration from the ribosomal A site to P 
site after the formation of the new peptide bond. Phosphorylation of eEF2 by eEF2 kinase 
(eEF2K) renders it inactive. mTOR phosphorylates eEF2K on Ser366, leading to its 
inactivation, in a p70S6K1 dependent mechanism and thus promotes protein synthesis. 
This site is also a target for RSKs, the downstream effectors of ERK1/2 signaling 
pathway. mTOR also regulates eEF2K through Ser 359 and Ser78 phosphorylation. 
AMPK mediated direct phosphorylation of eEF2K decreases the rate of elongation. These 
processes are involved in the acute regulation of protein synthesis [124] (and the 
references there in). Interestingly, the long term cellular capacity for protein synthesis is 
regulated by the increase in the number of ribosomes and other components of 
translational machinery. The mRNAs for these factors are believed to contain pyrimidine 
tracts at the 5‘ end of mRNA (5‘-TOP) that suppresses translation under basal conditions. 
However, the role of mTOR in regulation of 5‘TOP containing mRNA is controversial. 
Earlier studies showed that these 5‘TOP sequences are regulated by p70S6K1, although 
later studies showed that, translation of 5‘TOP mRNA is not compromised in conditions 
were both isoforms of S6K1 are absent [125, 126].  
Rapamycin is known to inhibit mTOR function. Studies have demonstrated that 
rapamycin treatment substantially inhibited protein synthesis in short-term treatment of 1-
27 
 
2 hours. Much of what we today know about mTOR signaling pathway has been studied 
in HEK293T (human embryonic kidney) cells. In these cells, rapamycin pretreatment 
decreased both the insulin as well as phorbol ester stimulated protein synthesis by about 
50% [127]. However, in primary rat cardiomyocytes, rapamycin pretreatment lead to 
>50% decrease in insulin as well as phenylephrine (hypertrophic α-agonist PE) induced 
protein synthesis [128]. These results demonstrate the cell type specific regulation of 
protein synthesis. Moreover, the ~40% rapamycin insensitive component of protein 
synthesis in these observations, was found to be significant and thus provided evidence of 
mTOR independent protein synthesis regulation or points to a rapamycin insensitive 
output of mTOR. 
Glucose Metabolism - Glucose Uptake 
Glucose homeostasis is preserved by the precise regulation of glucose uptake by 
the metabolic tissues as well as production by the liver. While liver and muscle each take 
up a third of an oral glucose load; of the remaining third, a bulk is taken up by the 
nervous system including the brain, and the rest is shared between erythrocytes and other 
tissues and organs of the body. Glucose is taken up by different tissue by facilitated 
diffusion that involves transport proteins called glucose transporters (GLUTs). Class I 
proteins comprise GLUT1-GLUT4, the well characterized glucose carriers. GLUT1 is 
highly expressed in erythrocytes and endothelial cells, and is responsible for basal 
glucose uptake. Expression of this transporter is inversely related to the glucose levels. 
GLUT2 is expressed by renal tubular cells, liver and pancreatic β cells, as well as the 
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epithelial cells of the small intestine [129]. Even though GLUT2 is not an insulin 
regulated glucose transporter, insulin stimulated glucose uptake is enhanced in the liver; 
this could be due to the feed forward regulation of the glycogenesis and glycolysis 
pathways that increase the glucose flux into hepatocytes [130]. GLUT3 comprises the 
main glucose transporter in the neurons and the brain. GLUT4 found in the adipose tissue 
and skeletal & cardiac muscle is the well studied insulin regulated glucose transporter; 
although, fatty acids are the fuel of choice for heart muscle. 
Insulin stimulated clearance of glucose is partly depended on the ability of 
adipose and muscle to take up glucose in response to insulin. The role of GLUT4 in 
achieving this is demonstrated by numerous genetic mouse models. Adipose and muscle 
tissue specific over expression or deletion of GLUT4 protected from or promoted glucose 
intolerance & diet induced diabetes respectively [131-133]. Decreased insulin sensitivity 
and tendency toward diabetes was observed in GLUT4 heterozygous +/- mice; and this 
was overcome through muscle specific over expression of GLUT4 [134, 135]. Studies 
using cellular models revealed that GLUT4 translocation to the plasma membrane that 
results in glucose uptake is regulated by insulin through PI3K/AKT signaling mediated 
mechanism [136, 137]. Recent efforts have identified RAB GAP, AS160, as an AKT 
substrate, that regulates GLUT4 translocation [138-140]. Upon insulin stimulation, 
activated AKT phosphorylates AS160, thus releasing GLUT4 from the retained 
intracellular compartment [141]. Although RNAi mediated AS160 depletion released 
only part of GLUT4 intracellular pool, raising the possibility for the existence of other 
AKT substrates that could regulate GLUT4 retention [142]. However, knockin mutation 
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of AS160 on the insulin mediated phosphorylation site led to glucose intolerant and 
altered GLUT4 trafficking in mice [143]. Recent study in cultured adipocytes identified 
pleckstrin homology domain containing protein (PHLDB1) as a novel enhancer of insulin 
stimulated Akt activation as well as GLUT4 translocation [144]. Interestingly, chronic 
activation of ERK or p38 MAPK pathway induced GLUT1 expression while GLUT4 was 
suppressed that resulted in increased basal glucose transport but diminished insulin 
stimulated transport [145].  
Regulation of Glycogen Synthesis 
  The glucose taken up by the metabolic tissues is destined to diverse end products, 
depending on the target organ. Whereas in the muscle it leads to glycogen synthesis, it 
results in triglyceride synthesis in the adipose; however, in the liver both glycogenesis as 
well as lipogenesis occur. Upon uptake, glucose is converted to glucose-6-phosphate (G-
6-P) by hexokinase in the liver, and glucokinase in the muscle. G-6-P is either completely 
oxidized to generate ATP through several steps involving committed as well as rate 
limiting reactions, or stored as glycogen by the insulin sensitive enzyme glycogen 
synthase (GS). Insulin stimulated activation of Akt results in phosphorylation and 
subsequent inactivation of its substrate glucose synthase kinase-3 (GSK3), a key 
modulator of GS activity. Interestingly, increased GSK-3 activity was observed in 
diabetic humans [146], and animals [147] that could lead to deregulation of GS activity. 
Studies in mice using genetic ablation of GSK3 have shown that decrease in GSK3 
activity towards GS is responsible for the increase in glycogen synthesis in the muscle 
30 
 
and liver [148]. Furthermore, GSK3 chemical inhibitors were shown to reduce blood 
glucose levels, by increasing glycogen synthesis in rodents.  
In the adipose, dietary carbohydrates, glucose in particular, contributes to 
triglyceride synthesis by two ways. One, glucose is converted to glycerol 3-phosphate, to 
form the glycerol backbone of triacylglycerols. Two, glucose is catabolized to pyruvate, 
which in a pyruvate dehydrogenase mediated reaction, is converted to Acetyl CoA that 
forms the substrate for de novo lipogenesis (DNL). Upon feeding, insulin stimulates 
lipogenesis in the liver through this second mechanism.  
Gluconeogenesis 
 Decrease in blood glucose as well as insulin levels after about an hour of food 
intake trigger the increase of glucagon concentrations. Glucagon is a peptide hormone 
synthesized and secreted by the α-cells of islets of Langerhans, stimulates glycogen 
breakdown, termed as glycogenolysis. G-6-P generated by this process can be utilized for 
ATP synthesis through the glycolytic pathway, in muscle and also in liver. However, 
liver as well as kidney are the two unique organs that can remove the phosphate on G-6-P 
using the enzyme G-6-Phosphatase, to generate glucose, to be utilized by other cells. 
In conditions of fasting, blood glucose levels are maintained by liver and to a 
lesser extent kidney, through gluconeogenesis; a process by which glucose is generated 
from non-carbohydrate sources such as lactate, amino acids and glycerol. Lactate 
produced from glucose utilization in the muscle and RBC, glucogenic amino acids 
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(except leucine and lysine) generated by protein degradation in the muscle, glycerol and 
fatty acids from the adipose are taken up by the liver and utilized as substrates for 
gluconeogenesis. Most of these substrates are converted to pyruvate so as to generate 
glucose; however, since glycerol enters late into the gluconeogenic pathway, it is 
converted to glucose directly. Whether fatty acids can be converted to glucose in animals 
is a subject of debate [149]. However, odd-chain fatty acids can be oxidized to yield 
propionly CoA, a precursor for succinyl CoA that can then be converted to pyruvate to 
enter gluconeogenesis. Although glyoxylate cycle utilizing fatty acids generates 
substrates for glucose synthesis [150], the existence of this pathway is not established in 
humans. 
Regulation of Gluconeogenesis 
Gluconeogenesis is inhibited by insulin, by suppressing the expression of two 
important enzymes involved in this process, phosphoenolpyruvate carboxykinase 
(PEPCK) [151] and glucose-6-phosphatase (G-6-Pase) [152, 153]. While PEPCK 
catalyzes one of the rate limiting steps, G-6-Pase catalyzes the final step of 
gluconeogenesis. Glucagon, glucocorticoids and catecholamines activate the expression 
of these enzymes during fasting, stress and exercise respectively [154, 155] [156] [157].  
Activated PI3K plays a central role in insulin-mediated suppression of 
gluconeogenesis. This is supported by the observations made using the pharmacological 
inhibitors wortmannin and LY-294002, where both basal and cAMP or dexamethasone 
induced inhibition of PEPCK and G-6-Pase gene expression by insulin was abolished 
32 
 
[152, 158-160]. Furthermore, adenoviral mediated over expression of a dominant 
negative mutant of PI3K increased PEPCK & G-6-Pase gene expression as well as in 
vivo hepatic glucose production[161]. Several studies investigated the signaling 
mechanism downstream to PI3K and observed a decrease in the gene transcription of 
PEPCK and G-6-Pase in hepatoma cells as well as in primary hepatocyte cultures, upon 
AKT overexpresssion [158, 159, 162]. Additionally, several proteins including Foxo1 
and cAMP response element-binding protein (CREBP) have been identified to mediate 
this Akt effect. 
DAF-16 the C. elegans homolog of the mammalian proteins Foxo1, 3 & 4 was 
identified by genetic studies as the insulin sensitive AGE1 (PI3K homolog) downstream 
effector [163]. Foxo proteins are transcription factors that have been found to be 
phosphorylated by Akt at three conserved serine/threonine residues, rendering the 
proteins inactive and leading to their nuclear exclusion [164-170]. Direct binding of these 
factors to the promoter region of PEPCK & G-6-Pase has been demonstrated using 
electromobility shift assay as well as reporter gene analysis. Furthermore, over 
expression of wild type or a dominant negative mutant of Foxo1 led to increase and 
suppression of G-6-Pase expression respectively [159, 164, 171]. In an insulin resistant 
mouse model, haploinsufficiency of Foxo1 correlated with blood glucose and insulin 
normalization. Additionally, expression of a constitutively active Foxo1 increased 
PEPCK and G-6-Pase expression resulting in elevated fasting blood glucose levels [172]. 
Additionally, studies have shown that insulin stimulated signaling events result in 
dissociation of glucocorticoid receptor (GR) and Foxo1 from PDK4 promoter [173]. 
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Together, these observations have established the insulin-PI3K-AKT signaling to regulate 
Foxo1 activity, as the mechanism for regulation of hepatic gluconeogenesis. 
Treatment of hepatoma cells with AICAR, a pharmacological activator of AMPK 
the cellular energy sensor, mimicked insulin effect on G-6-Pase and PEPCK gene 
expression [174]. Moreover, the widely used drug Metformin has been show to exhibit 
some of its anti-diabetic effects through AMPK activation that is required for the increase 
in the expression of SHP (small heterodimer partner), which inhibits C/EBPα function 
towards PEPCK promoter, and thus downregulates  gluconeogenesis [175-177]. These 
studies show the convergence of multiple signaling pathways and several modes of 
regulating PEPCK and G-6-Pase gene expression that in turn regulate hepatic glucose 
production. 
Lipid Metabolism - Lipogenesis 
The process of lipid synthesis from either glucose (de novo lipogenesis) or 
reesterification of dietary fatty acids to triglycerides is termed as lipogenesis. Both these 
processes of lipid synthesis are employed by hepatocytes and adipocytes. The pathway of 
reactions involved and the enzymes that mediate triglyceride synthesis from glucose are 
well documented. Glucose through the glycolytic pathway is converted to pyruvate that 
through a series of reactions in the mitochondria leads to the synthesis of acetyl-CoA. 
Two carbon unit additions to this intermediate in the cytoplasm, mediated by enzymes 
that form a multienzyme complex called fatty acid synthase (FAS), leads to the synthesis 
of fatty acyl-CoA. Thus synthesized fatty acids are esterified with glycerol to form 
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triglycerides. Dietary lipids as well as the triglycerides synthesized in the liver, complex 
with lipoproteins, phospholipids and cholesterol to form very low density lipoproteins 
(VLDLs) that are released into the blood stream in the fasting state as well as 
postprandially. Dietary lipids are transported by the intestinal mucosa as chylomicrons, 
that contain triacylglycerols and apolipoproteins, including apoB-48, apoA-1, II and IV. 
In the bloodstream, chylomicrons acquire apoC-II and apoE from plasma HDLs (high 
density lipoproteins). In the capillaries of adipose tissue and muscle, by the action of 
lipoprotein lipase (LPL), present on the surface of capillary endothelial cells, 
chylomicrons similar to VLDLs from the liver, release their fatty acids; the glycerol 
backbone of the triacyglycerols is returned to the liver and kidneys by the blood. The 
fatty acids taken up by the adipocytes are reesterified to synthesize triacylglycerol. The 
glycerol backbone is provided by dihydroxyacetone phosphate (DHAP), a glycolytic 
intermediate.  
Regulation of Lipogenesis 
Insulin potently stimulates lipogenesis by increasing the uptake of glucose, as 
well as by activating lipogenic enzymes. The flux through lipogenesis is increased by 
insulin signaling that leads to activation of pyruvate dehydrogenase (PDH) by 
dephosphorylation; that catalyzes the conversion of pyruvate to acetyl-CoA. Acetyl-CoA 
carboxylase is similarly activated through dephosphorylation by insulin signaling, to 
increase malonyl-CoA synthesis from acetyl-CoA. Using adipocytes in culture and 
transgenic mice expressing reporter gene driven by FAS, Kim and his colleagues 
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demonstrated insulin stimulated, PI3K/Akt signaling dependent regulation of FAS 
expression [178]. Serum response element binding proteins (SREBPs 2, 1a & 1c) are a 
family of transcription factors that regulate the expression of genes involved in 
cholesterol and fatty acid synthesis. Studies involving mice with SREBP-1a or 1c over 
expression in the liver showed elevated expression of lipogenic genes, leading to the 
conclusion that SREBP-1 activates lipogenesis in liver [179]. To the contrary, adipose 
specific SREBP-1c transgenic mice exhibited no change in the expression of genes 
involved in fatty acid and triglyceride synthesis; although expression of genes implicated 
in cholesterol metabolism were elevated. Strikingly, adipose tissue mass was reduced in 
these mice, that was accompanied by decreased expression of PPARγ and C/EBPα [180]. 
These observations raise the possibility of differential regulation of SREBP-1 functions 
in liver and adipose tissue. Recent studies have implicated protein kinase C beta (PKCβ) 
in the insulin-stimulated regulation of hepatic SREB-1c and its target lipogenic genes. 
RNAi or pharmacological inhibitor mediated silencing of PKCβ inhibited SREBP-1c 
activation [181].  
Expression of lipogenic genes is downregulated by polyunsaturated fatty acids by 
inhibiting the mRNA expression as well as the proteolytic processing of SREBP-1 [182-
185]. Studies using adenovirus mediated constitutively nuclear FOXO1 expression in the 
liver, demonstrated stimulation of hepatic lipogenesis, through inhibition of PPARα 
[186]. This is further supported by the increased lipid content observed in the liver of 
PPARα knockout mice [187]. Furthermore, studies using luciferase assays demonstrated 
that PPARα activation could suppress LXR-SREBP-1c pathway, to inhibit lipogenic gene 
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expression in the liver [188]. Together, these observations show that SREBP1 regulation 
forms the important mechanism for hepatic lipid synthesis. Although insulin is the major 
stimulus for lipogenesis, an insulin independent mechanism of lipid synthesis in the liver 
has been proposed. Under insulin resistance conditions, in the liver, IR/PI3K/Akt 
signaling to inhibit gluconeogenesis, and to stimulate glycogen synthesis is imparied; 
however, SREBP1 mediated lipogenesis remains active. Recent studies have identified 
mTOR to be responsible for this paradox. Even in the absence of insulin signaling to Akt 
in the liver, nutrient signaling is believed to stimulate mTOR activity towards SREBP1 
that mediates increase in lipogenesis [189]. It remains to be seen if adipose lipid synthesis 
is regulated in a similar manner. 
Lipolysis & Fatty Acid Oxidation 
During states of energy deprivation, fat stores from adipose tissue are mobilized 
to meet the energy requirement of the organism. To this end, triacylglycerols are 
hydrolyzed to fatty acids and glycerol that are released to be used as energy substrates. 
Although at steady state, the adipose lipid pool is in a constant state of flux leading to a 
futile cycle of lipolysis and reesterification [190]. Triacylglycerol (TAG) is sequentially 
hydrolyzed to diacylglycerol (DAG), then to monoacylglycerol (MAG), releasing fatty 
acid at each step and finally glycerol. In the fasting state, the fatty acids generated by 
lipolysis in the adipose tissue forms the major sources of VLDL synthesis in the liver. 
This process of lipolysis is acutely regulated by hormones, neurotransmitters and 
other effector molecules. The catecholamine norepinephrine is an important stimulator of 
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fasting induced lipolysis. It binds to the β-adrenergic receptors that are coupled with G-
protein coupled receptor-s (Gs-proteins) on the adipocyte plasma membrane and thus 
transmits activating signal to adenylyl cyclase to generate cyclic AMP (cAMP). Upon 
binding to protein kinase A (PKA), cAMP activates the kinase to phosphorylate its 
substrates. Glucagon also activates lipolysis through adenylyl cyclase mediated 
mechanism [191]. Activated PKA phosphorylates and stimulates hormone sensitive 
lipase (HSL) translocation from the cytosol to the lipid droplet [192] . HSL was 
considered the major adipose lipase to initiate lipolysis until recently [193]. The 
accumulation of DAG observed in HSL null mice demonstrated the existence of HSL 
independent TAG lipase activity [194, 195]. This enzyme was identified as adipose 
triglyceride lipase (ATGL). However, serum TAG and non-esterified fatty acid (NEFA) 
levels were decreased in the HSL-null mice. This indicates that HSL-independent 
lipolysis is not adequate for the maintenance of fatty acid output for energy substrates and 
VLDL synthesis [196, 197]. The accumulation of MAGs in an in-vitro reaction using 
isolated HSL, lead to the identification of MAG-lipase (MAGL) [198].   
ATGL is a TAG specific lipase, whose expression is induced upon fasting and 
inhibited upon refeeding, in mice. Glucocorticodis have been shown to increase the 
expression of ATGL in a concentration dependent manner in 3T3-L1 adipocytes [199]. 
Furthermore, the observed decrease in the expression of ATGL in the genetically obese 
ob/ob and db/db mice, suggests a possible role for this lipase in the development of 
obesity [199]. Interestingly, ATGL over expression in adipose tissue increases lipolysis, 
and expression of genes involved in FA oxidation and thermogenesis is elevated as well, 
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resulting in resistance to diet-induced obesity in mice [200]. Perilipin is one of the 
earliest identified lipid associated proteins. It coats the lipid droplet and functions to 
prevent unrestrained basal lipolysis [192]. This is supported by the constitutively elevated 
basal lipolysis observed in perilipin null mice [201]. As expected, over expression of 
perilipin in 3T3-L1 adipocytes resulted in increased TAG stores and also lead to reduced 
lipolyis [202]. Similar to HSL, perilipin is also phosphorylated by PKA upon adrenergic 
stimulus [192]. Mutations in these phosphorylation sites of perilipin blunted stimulated 
lipolysis [203]. Presence of perilipin on the lipid droplet appears to be necessary for 
PKA-mediated stimulation of HSL translocation [204]. However, recent evidence shows 
that perilipin phosphorylation is not necessary for HSL translocation [203].   
Lipolysis mediated synthesis of fatty acids by the adipocytes is not required in the 
fed condition. Insulin levels are elevated upon feeding and this hormone is believed to be 
a major inhibitor of lipolysis.  The ability of insulin to lower cellular cAMP levels and 
therefore decrease PKA activity accounts for its ability to inhibit lipolysis. This is 
achieved by AKT dependent phosphorylation and activation of phosphodiesterase 3B 
(PDE3B) [208]. PDE3B hydrolyzes cAMP thus reducing its cellular levels leading to the 
inactivation of PKA and thus HSL and possibly perilipin activity. This signaling 
mechanism appears to be disrupted in type 2 diabetic patients contributing to elevated 
serum free fatty acid levels [209].  The general process of fat storage and lipolyis is 
summarized in the Figure 1.6.  
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FIGURE 1.6: Lipid Storage and Lipolyis in Adipocytes. Free Fatty Acids (FFAs) 
released from lipoporteins by lipoprotein lipase mediated catalysis enter adipocytes 
through passive diffusion and active transport. Inside the cell, FFAs are first converted to 
acyl-CoA by acyl-CoA synthase (ACS). Glycerol-3-phosphate (G3P) generated by 
glucose metabolism is acylated by glycerol-3-phosphate acyltransferase (GPAT) and 
acylglycero-3-phosphate acyltransferase (AGPAT) sequentially and is converted to 
diacylglycerol (DAG) by phosphatidic-acid phosphohydrolase (PAP). Monoacylglycerol 
(MAG) is acylated by MAG acyltransferase (MGAT). DAG synthesized by these two 
mechanisms is then acylated by diacylglycerol acyltransferase (DGAT) to generate 
triacylglycerol (TAG). Lipid droplets generated from the ER are coated by proteins such 
as perilipin (PER), adipose differentiation-related protein (ADRP) and tail interacting 
protein of 47 kDA (TIP47). β-adrenergic receptor activation mediated cyclic-AMP 
(cAMP) dependent protein kinase A (PKA) activation leads to PER and hormose-
sensitive lipase (HSL) phosphorylation, resulting in hydrolysis of TAG to FFAS that are 
released from the adipocytes. Insulin signaling inhibits lipolysis. LPA, lysophosphatidic 
acid. PA, phosphatidic acid. 
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Insulin Resistance 
The inability of insulin to elicit cellular responses is termed as insulin resistance. 
In the muscle and adipose tissue, insulin resistance leads to reduced glucose uptake and 
storage as glycogen and triglycerides respectively.  In the liver it results in decreased 
glycogen synthesis and storage as well as failure to suppress glucose production. 
Deregulation of all these metabolic functions combine to increase serum concentrations 
of glucose and FFAs, characteristic feature of insulin resistance. Unrestrained insulin 
resistance can progress to type 2 diabetes.  
In addition to genetic factors in both humans and model systems, insulin 
resistance has been observed to be caused by several acquired factors and conditions, 
including and not limited to obesity, increased levels of FFAs, chronic inflammation, 
sepsis and aging. Drugs such as glucocorticoids are also implicated in insulin resistance. 
Even though, most of the factors that cause insulin resistance are observed in conditions 
of obesity, and studies using mouse model systems have revealed several deregulated 
metabolic pathways, the exact cause of obesity associated insulin resistance still remains 
unknown. Although insulin resistance observed in conditions of obesity mainly refers to 
resistance to insulin-stimulated glucose disposal [210], interestingly, all obese individuals 
do not exhibit insulin resistance, a paradox that needs rigorous investigation.    Elegant 
studies in mouse model system, using knockout, knockin and a combination of both, have 
contributed immensely to the vast knowledge that we have today about the pathways, 
mechanisms and possible contributing factors in insulin resistance and associated 
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metabolic disorders however, much remains to be known. The signaling mechanisms that 
are dysfunctional, the role of various metabolites & tissue specific secreted products, and 
the cross talk between different metabolic tissues, which are involved in mediating 
insulin resistance, will be discussed. The mechanisms involved in the regulation of these 
processes are briefly summarized in the Figure 1.7. 
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FIGURE 1.7. Regulation of Insulin Resistance – Mediators and Pathways. Insulin 
signaling to p70S6K1 results in the activation of negative feedback loop and IRS1 
serine phosphorylation. Diacylglycerol (DAG) generated from TAG hydrolysis 
activates several proteins which subsequently activate inhibitor of κappa B protein 
kinase-β (IKKβ) to inhibit IRS1.  TNFα signaling pathway stimulation activated JNK 
and IKKβ that leads to the inhibitory phosphorylation of insulin receptor substrate 1 
(IRS1). IKKβ is also activated by interleukin-1 receptor (IL-1R) and toll like receptor 
4(TLR4) stimulation. IKKβ activation results in nuclear factor-κB (NF-κB) nuclear 
translocation and inflammatory gene expression. IL-6 mediated suppressor of cytokine 
signaling 1 (SOCS1) and SOCS3 activation results in ubiquitin-mediated IRS1 
degradation.  
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Role of Insulin 
Binding of insulin to the insulin receptor, leading to tyrosine phosporylation of 
IRS forms the initial events in the insulin signaling cascade. However, prolonged insulin 
stimulation in cells leads to IRS phosphorylation on serine residues, leading to the 
inhibition of insulin signaling, suggesting a feed-back mechanism possibly involving 
downstream proteins in the signaling pathway. Although several serine residues on IRS 
are implicated in regulation of insulin sensitivity, the inhibitory phosphorylation of 
Ser307 of IRS functions as the key player in insulin resistance. This serine residue is 
located in the phospho-tyrosine binding domain that is responsible for IRS interaction 
with the insulin receptor and its phosphorylation inhibits the interaction. Several protein 
kinases phosphorylate IRS on Ser307, including the mTORC1 substrate S6K1, cJUN n-
terminal Kinase (JNK), inhibitory κ B Kinase β (IKKβ), protein kinase θ (PKCθ), protein 
kinase ε (PKCε), GSK3 [211]. Phosphorylation of IRS Ser307 possibly leads to its 
degradation and thus termination of insulin signaling; since IRS1 with a point mutation at 
Ser307 is resistant to degradation following long term insulin stimulation [212]. 
Furthermore, recent work from Shulman‘s group demonstrated that mice carrying alanine 
substitution in IRS1 serines 302, 307 and 361 were protected from high fat diet induced 
insulin resistance in the muscle [213]. To the contrary, White and coworkers showed that 
IRS1 Serine 307 promoted insulin sensitivity in mice, as mice with mutation of this 
serine to alanine developed severe insulin resistance and exhibited impaired muscle 
insulin signaling [214]. However, insulin resistance can also be induced by direct 
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inhibition of insulin receptor tyrosine phosphorylation or inhibition of a downstream 
effector such as Akt.  
Role of S6K1 in Inducing Insulin Resistance 
 Wild-type mice fed on high fat diet, as well as the genetic obese mouse model 
ob/ob have been shown to exhibit elevated S6K1 activity as well as increased IRS1 
inhibitory phosphorylation. Furthermore, S6K1 has been identified to directly 
phosphorylate IRS1 on Ser307 as well as Ser636/639 and Ser1104, leading to its 
inactivation and thus resulting in insulin resistance [215, 216]. This is supported by the 
observations of increased insulin sensitivity due to decreased IRS1 inhibitory 
phosphorylation in an S6K1 deficient mouse model. Additionally, these animals 
maintained normal fasting glucose levels and were protected against obesity due to 
enhanced β-oxidation. Moreover, S6K1 gene ablation resulted in reduction of the adipose 
tissue weight [111]. Loss of 4e-BP1 and 4e-BP2 in mice, the other well known 
downstream effector of mTOR, increased their sensitivity to DIO, exhibited enhanced 
adiposity and insulin resistance that was associated with increased S6K1 activity in 
muscle, liver and adipose tissue; that was accompanied by increase in inhibitory IRS1 
phosphorylation [121]. These studies highlight the direct role played by S6K1 in insulin 
resistance.  
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Role of Adipokines in Mediating Insulin Sensitivity and Resistance 
Adipose tissue is now considered not just as an energy storage depot but is 
recognized as an active endocrine organ. The protein hormones synthesized and secreted 
by adipocytes are termed as adipocytokines (adipokines), and include adiponectin, leptin, 
retinol binding protein 4 (RBP4), tumor necrosis factor-α (TNFα), IL-6, and MCP-1. 
TNFα and IL-6 are secreted by other cell types as well and are considered as cytokines.  
Adiponectin 
Adiponectin also named Acrp30 is expressed exclusively by the adipocytes and is 
the most abundant protein secreted by the adipocytes beginning at an intermediate stage 
of adipogenesis [217]. It is a 30kDa protein, and forms aggregates of trimer, hexamer, 
and 12-18 mer as well. Proteolytic cleavage at amino acids 110 generates a c-terminal 
globular protein, although the full length form predominates [218, 219]. Plasma levels of 
adiponectin are observed to be decreased with obesity, insulin resistance, atherosclerosis, 
and type-2 diabetes in both mice and humans [220-222]. Administration of full length as 
well as the globular forms of adiponectin in obese mouse models resulted in insulin 
sensitization. Studies using adiponectin transgenic mice exhibited partial amelioration of 
insulin resistance and diabetes and endogenous glucose production was suppressed [223]. 
As expected, mice deficient for adiponectin were glucose intolerant and insulin resistant 
[224]. Furthermore, adiponectin is also implicated in stimulating insulin secretion by the 
pancreas and thus could alter glucose metabolism, along with its insulin sensitizing 
effects.  
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Interestingly, adiponectin plays an important role in protection from endothelial 
damage and mediates anti-inflammatory action, by potently suppressing TNFα or 
hyperglycemia induced IKKβ activation [225]. The role of these inflammatory mediators 
in insulin sensitivity will be discussed later. Adiponectin levels are also inversely 
correlated with the risk for developing several types of cancers. Work from various 
groups implicated adiponectin in tumor derived angiogenesis regulation. Although there 
are studies against, as well as in support of this hypothesis, observations made by Lodish 
and Sun suggest a role for adiponectin in macrophage infiltration and regulation of tumor 
growth [226]. 
The metabolic effects of adiponectin are mediated by AMPK and ACC, where, 
upon activation by phosphorylation, these effectors cause increased glucose transport and 
lipid oxidation in the muscle and inhibit gluconeogenesis in the liver. Adiponectin also 
leads to increase in expression of PPARα and of its target genes, resulting in decreased 
muscle and liver triglyceride content. Thiazolidinediones (TZDs) stimulate adiponectin 
secretion by adipocytes. The improved insulin sensitivity exhibited upon TZD 
administration is possibly in part due to the increased adiponectin secretion observed in 
mice and humans.  
Leptin 
Leptin is produced predominantly in white adipocytes, as a product of the obese 
(ob) gene. Six leptin receptor isoforms are generated by alternate splicing of the db gene 
of which, Ob-R is the long isoform, expressed predominantly in the hypothalamus [228]. 
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Leptin signaling is considered most important for the regulation of food intake and 
energy homeostasis [229-231].  The main targets of leptin are the appetite centers in the 
brain where, leptin receptor activation of the anorexigenic (catabolic) and inhibition of 
the orexigenic (anabolic) signaling regulates energy intake and expenditure. Leptin 
effects are also observed on insulin action in peripheral tissues, as well as on pancreatic 
β-cells and blood vessels [228, 232, 233].  
Activated leptin receptor stimulates several downstream signaling pathways such 
as, Janus kinase (JAK) and STAT (signal transducers and activators of transcription) 
signaling, RAS-Raf mediated MAPK pathway as well as IRS-PI3K pathway, that 
modulate gene transcription and ion channel functions in the brain. The inability of leptin 
to induce a response in the target organs, even in the presence of high concentrations of 
leptin, as observed in obese individuals is termed as leptin resistance. The ability of leptin 
to activate STAT is inhibited in the high fat diet fed condition as well. Impaired leptin 
transport across the blood-brain-barrier, as well as induction of suppressors of cytokine 
signaling-3 (SOCS-3) and protein tyrosine phosphatase 1B (PTP-1B) expression, can 
block leptin signaling. Increased sensitivity to leptin and resistance to obesity is observed 
in SOCS-3 and PTP-1B deficient animals [234-237].  
Mice expressing mutant leptin receptors deficient in downstream signaling to 
JAK-STAT pathway exhibit severe hyperphagia and obesity. However, these animals 
have only a mild effect on glucose homeostasis, unlike the leptin receptor deficient db/db 
mice [238]. These observations suggested two independent modes of leptin mediated 
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effects; while JAK-STAT signaling regulates body weight and food intake, leptin-
stimulated PI3K signaling regulates glucose metabolism. Leptin also modulates TAG 
accumulation in adipose, as well as liver, muscle and pancreas through a direct effect on 
AMPK, and an indirect effect through central neural pathway, and thus improves insulin 
sensitivity [239-241].  
Role of Fatty Acids and Lipid Mediators in  
Promoting Insulin Resistance 
  High post-prandial circulating concentration of FFAs is an indicator of insulin 
resistance. Insulin stimulated IRS1 tyrosine phosphorylation, PI3K activity as well as 
GLUT4 translocation is inhibited in the muscle in conditions of increased FFA 
accumulation, either due to increased uptake or decreased FA oxidation. Increased TAG 
synthesis due to excess fatty acid availability also raises the levels of the intermediates 
DAG and acyl-CoA. Studies have shown that elevated levels of DAG and acyl-CoA, in 
the muscle result in activation of PKCθ, leading to IRS1 serine phosphorylation. 
Confirming this, studies in PKCθ knockout mice showed prevention of FFA induced 
decrease in IRS tyrosine phosphorylation as well as PI3K activity [242]. These results are 
further supported by the 3-4 hours of lipid infusion induced whole body insulin resistance 
observed in healthy humans [243]. However, different mechanisms are involved in the 
FFA mediated lipotoxic effects in liver and muscle that regulate whole body insulin 
sensitivity. Short-term high fat feeding (3 days) in rats resulted in hepatic lipid 
accumulation and insulin resistance, while muscle remained insulin sensitive. In these 
insulin resistant livers, tyrosine kinase activity of IR was negatively regulated by PKCε, 
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thus leading to inhibition of IRS2 activation [244]. Additionally, silencing of PKCε using 
anti sense oligonucleotides, prevented high fat diet induced hepatic insulin resistance 
[245]. 
Inflammation 
The body‘s first response to tissue damage caused either by pathogens, toxic 
chemical stimuli or tissue injury is termed as inflammation. Acute inflammation involves 
a short-term response resulting in healing that is mediated by leukocyte infiltration, 
removal of the stimulus and tissue repair. To the contrary, chronic inflammation that is 
associated with obesity, arthritis, type 1 & type 2 diabetes and cardiovascular disease, is 
prolonged, dysregulated and involves active inflammation and an attempt to repair 
damaged tissue. In obese conditions, adipose tissue is considered to be an important 
initiator of inflammation.  Inflamed adipose tissue synthesizes and secretes cytokines and 
chemokines that function in an endocrine or a paracrine fashion. Obese mice and human 
adipose tissue is infiltrated with macrophages that can comprise to greater than 40% of 
the total cells [246]. Bone marrow derived macrophages are recruited to the adipose 
tissue in obesity, and the macrophage content correlates to the degree of obesity. The 
resident as well as recruited adipose tissue macrophages (ATMs), upon activation secrete 
chemokines to recruit more macrophages, in a feed-forward mechanism to increase ATM 
content and chronic inflammation. The inflammatory cytokines and chemokines, secreted 
by macrophages further add to the development of insulin resistance in the adipose as 
well as in other metabolic tissues.  
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Immune Cell Recruitment 
Immune cells are recruited to the adipose tissue in response to chemotactic 
molecules, small proteins of 8-10kDa termed chemokines. Other molecules such as small 
peptides (defensins), lipids (prostaglandins, lysophospholipids and leukotrienes) and 
complement factors (C5a and C3a) also can act as chemo-attractants. These molecules 
mediate cellular effects through their interaction with cell surface receptors on target 
cells, majority of which are G-protein coupled receptors. Enhanced expression of 
macrophage chemoattractant protein-1 (MCP-1) expression, both protein and mRNA, has 
been observed in all the adipose depots of diet induced obese mice [247, 248]. 
Correlating to this, expression of F4/80 and CD68, macrophage cell surface receptor 
proteins is also elevated in these tissues. Furthermore, enhanced macrophage migration 
was observed in response to mesenteric adipose tissue conditioned media, in an in vitro 
assay, which was blocked by an antibody against MCP-1 [249]. Although these studies 
establish that an adipose derived factor could be responsible for the recruitment of 
immune cells to the adipose tissue, contradicting results are observed by investigators in 
MCP-1 gene knockout mouse models and studies using the MCP-1 receptor, CCR2 
(chemokine chemo-attractant receptor-2) ablated mice [250].  
 In mouse models and humans, adipocyte size is correlated to ATM content [246]. 
Interestingly, adipose cell death has been proposed as a stimulus for ATM accumulation 
and this was observed in lipoatrophy mouse model. Adipose hypertrophy leads to 
hypoxia resulting in cell death that could trigger ATM recruitment. Genetic inactivation 
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of a pro-apoptotic molecule Bid, prevented adipocyte apoptosis and subsequent 
macrophage infiltration, and protected from systemic insulin resistance and hepatic 
steatosis. Moreover, ATMs are observed to form crown like structures (CLS) associated 
with apoptotic adipocytes and these CLS are observed to be multinucleated cells with 
large lipid droplets. However, adipocyte cell death is not found to be elevated in obese 
humans [251]. Basal lipolyis is considered to be enhanced in obesity and this is more true 
in visceral than compared to subcutaneous adipose tissue and also correlates with the 
ATM accrual [252, 253]. Contrary to the studies where adipose apoptosis was considered 
the cause for ATM enrollment, Kosteli and coworkers have recently demonstrated that, 
increase in circulating concentrations of FFAs due to enhanced lipolysis recruits 
macrophages to the adipose tissue, as a means to sequester the released lipids. 
Furthermore, these ATMs were responsible for the attenuation of lipolysis induced FFA 
release, as pharmaceutical agent mediated macrophage depletion lead to an increase in 
the expression of genes involved in lipolysis [254].  
 Two main phenotypes of ATMs have been identified: the classically activated 
macrophages that secrete pro-inflammatory cytokines such as TNFα, IL-1 IL-6 and the 
alternatively activated anti-inflammatory macrophages. These two kinds of macrophages 
are also categorized as M1 or M2 type based on their cell surface receptors, although 
there is no clear consensus. The alternatively activated macrophages are considered to be 
the adipose tissue resident macrophages that are involved in the repair and remodeling. 
High fat diet induced obese conditions in mouse models increase proportion of classically 
activated macrophages [255]. Although the precise mechanism of the increase and the 
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manifestation of changed activation state is not know. However, studies using 
macrophage specific PPARγ ablation in mice have demonstrated impaired maturation of 
alternatively activated macrophages that lead to DIO, insulin resistance and glucose 
intolerance [256].  
Cytokines 
In disease states, adipocytes as well as the recruited immune cells, specifically 
macrophages secrete pro-inflammatory cytokines. Several cytokines produced by the 
macrophages, are known to stimulate lipolysis in adipocytes. The FFAs thus generated 
further activate the macrophages to secrete pro-inflammatory cytokines, triggering a 
vicious cycle. TNFα (Tumor Necrosis Factor-α) is one of the major pro-inflammatory 
cytokines secreted by activated macrophages. Although, adipocytes are capable of 
expressing and secreting TNFα, studies have shown that, ATMs are the major source of 
TNFα in conditions of obesity-associated inflammation. 
Role of Tumor Necrosis Factor α (TNF α) in  
Mediating Insulin Resistance 
  Cachectin, a mediator of tumor-induced cachexia observed in some cancer 
patients who survived bacterial infections, was later identified as a factor produced by 
macrophages, which inhibited lipoprotein lipase (LPL) activity that is required for fat 
storage. Amino acid sequencing identified cachectin as tumor necrosis factor-α (TNFα), 
an inflammatory cytokine with anti-tumor and immune functions. TNFα is produced as a 
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transmembrane protein of 26kDa that has autocrine and paracrine functions. Upon 
cleavage by metalloprotease, a secreted homotrimer is released [257]. Prevention of this 
maturation of TNFα, by metalloprotease inhibitors protected mice against endotoxin 
mediated lethality [258] . Two distinct receptors TNFα receptor-1 (TNFR1) and TNFα 
receptor-2 (TNFR2) mediate the functions of the cytokine. Binding of TNFα trimer leads 
to the trimerization of the receptor monomers, leading to its activation and subsequent 
intra-cellular signaling. Both receptor TNFR1 and 2 are ubiquitously expressed although 
in different ratios, depending on the cell type. These receptors differ in their amino acid 
composition as well as in their intracellular binding partners.  
NFκB Regulation 
TNFα binding to its receptor, leads to the activation of two major transcription 
factors, activator protein-1 (AP-1) and NFκB, to regulate the expression of inflammatory 
response genes. NFκB is a family of transcription factors comprising of 5 members, p50, 
p52, p65(RelA), RelB and c-Rel. The general term NFκB refers to a heterodimer complex 
usually made up of p50-RelA. The gene regulatory function of NFκB is mediated by 
RelA. In the unstimulated state, NFκB is retained in the cytosol by forming a complex 
with inhibitor κ-B protein α (IκB-α). In the classical NFκB signaling pathway upon 
stimulation by TNFα (or other cytokines), activation of NFκB upstream kinase IKKβ 
(inhibitor κ-B kinase-β), results in the subsequent phosphorylation, ubiquitination and 
degradation of IκBα. Now, NFκB is free to translocate to the nucleus and transcribe 
genes for cytokines, growth factors, cell adhesion molecules as well as pro and anti-
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apoptotic factors. IKKβ exists in a heterotrimeric complex containing IKKα, β and γ. The 
alternate NFκB pathway is active in immune cell types like B cells, where IKKα mediates 
the phosphorylation of IκB-α and thus its degradation. 
Studies in 3T3-L1 adipocytes have demonstrated that TNFα promotes tyrosine 
phosphorylation of IRS1 and its subsequent binding to PI3K. In these studies, the authors 
observed a synergetic effect of insulin and TNFα on IRS1 tyrosine phosphorylation 
[259]. Furthermore, TNFα stimulated NFκB activation has been shown to require Akt 
mediated IKKβ phosphorylation [260]. This is further supported by the study where, 
PTEN blocked the TNFα mediated NFκB activation, through suppression of PI3K/Akt 
signaling [261]. However, the PI3K/Akt/mTOR signaling cascade is implicated in the 
TNFα mediated insulin resistance, through IRS1 serine 636/639 phosphorylation. 
Rapamycin treatment or ectopic expression of PTEN or an Akt kinase-dead mutant 
inhibited TNFα stimulated IRS1 serine phosphorylation [262]. Furthermore, TNFα 
mediated apoptosis and caspase-8 activation was inhibited in mouse hepatocytes with 
S6K1 deletion [263].  These observations show that TNFα utilizes the insulin receptor 
downstream signaling cascade to promote pro-inflammatory gene expression as well as 
insulin resistance. Study by Kim and coworkers identified GβL (mLST8), mTOR binding 
partner, as a negative regulator of TNFα stimulated NFκB signaling. GβL was shown to 
directly interact with IKK and inhibit its phosphorylation [264]. Recent study by these 
authors further demonstrated that, GβL mediated IKKβ dephosphorylation is through its 
interaction with protein phosphatases.  Protein phosphatase 4 (PP4), PP2A and PP6 were 
identified as GβL binding partners [265]. 
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IKKβ has been shown to play an important role in promoting insulin resistance. 
Salicylate treatment inhibited IKKβ activation and improved insulin sensitivity in rodent 
models of obesity and insulin resistance. In addition, HFD fed and ob/ob mice were 
protected from insulin resistance in IKKβ heterozygous (IKKβ+/-) deleted condition. 
Moreover, IKKβ +/- mice were protected from FFA induced insulin resistance [266]. 
Supporting these observations, studies have shown that, the lipid intermediate DAG 
stimulates PKCθ and PKCδ that subsequently phosphorylate IKKβ [267]. Furthermore, 
PKCθ knockout mice were protected from high fat diet induced insulin resistance [242]. 
Mice with liver specific deletion of IKKβ developed muscle and adipose insulin 
resistance in response to HFD, aging and obesity, although they retained hepatic insulin 
sensitivity. The same authors also analyzed the NFκB pathway in the myeloid cells; 
absence of IKKβ in myeloid cells protected mice from whole body insulin resistance 
[268]. These studies show that IKKβ plays an important role in mediating local as well as 
systemic insulin resistance.  
TNFα mRNA expression was found to be enhanced in the adipose tissue of obese 
human subjects when compared to lean individuals and this correlated with the plasma 
insulin levels [269]. Tsigos and coworkers observed 2 fold increase in the circulating 
concentration of TNFα in insulin resistant humans compared to controls [270]. However, 
no correlation was observed between TNFα mRNA levels and BMI in men and women in 
other studies [271, 272]. Neutralization of TNFα improved insulin sensitivity and 
lowered plasma lipid and glucose levels in obese rats [273]. In addition, deletion of TNFα 
receptors or TNFα protected mice against DIO and insulin resistance [274, 275]. 
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Neutralizing TNFα, using anti TNFα antibody, failed to improve insulin sensitivity in 
humans [276, 277]. Moreover, patients who received TNFα neutralizing antibody to treat 
rheumatoid arthritis exhibited improved glycemia, but after the completion of treatment 
there was a relapse [278, 279]. Although circulating levels of TNFα are found to be very 
low in insulin resistant humans and mouse models, however, liver and muscle local 
concentration of TNFα were observed to be elevated in insulin resistance condition [280, 
281]. Saghizadeh and colleagues observed six fold elevated TNFα mRNA levels in 
muscle biopsies from type 2 diabetic subjects [282].  These studies show a possible role 
of locally produced TNFα in mediating muscle insulin resistance, which is supported by 
the observation that muscle insulin resistance was reversed using anti-TNF treatment in 
insulin resistant rats accompanied by decrease in TNFα protein in the muscle but not in 
fat [281]. 
Activator Protein-1 (AP-1) Regulation 
Regulation of AP-1 transcription factor expression as well as activation is the 
other downstream effect of TNFα signaling cascade. AP-1 transcription factor is a 
heterodimeric protein complex comprising members of JUN, FOS and ATF protein 
families. These transcription factors control a number of cellular processes including 
differentiation, proliferation, and apoptosis. The JUN family consists of c-Jun, JunB and 
JunD; while the FOS family is made up of c-Fos, FosB, Fra-1 and Fra-2. These proteins 
are involved in regulating cell proliferation and differentiation [283]. Furthermore, 
studies have shown that immediately after adipocyte differentiation induction, expression 
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of c-Jun, c-Fos, Jun-B, Fos-B and Fra-1 is induced [284]. Additionally, insulin stimulated 
Fra-1 expression in 3T3-L1 adipocytes requires both mTOR and the MAPK pathways 
[285]. Recent studies have implicated ΔFosB (a naturally occurring truncated form of 
FosB) as a negative regulator of adipogenesis both in vivo and in vitro [286]. Transgenic 
expression of ΔFosB resulted in increased energy expenditure and promoted insulin 
sensitivity [287]. 
In response to TNFα stimulus, MAPKs, specifically JNK and p38 are activated 
which in turn induce the expression of AP-1 transcription factors. These MAPKs also 
phosphorylate the AP-1 proteins in response to stimulus. AP-1 gene expression is also 
stimulated by ERK1 and ERK2 MAPKs in response to phorbol esters. Three distinct 
JNKs exist; JNK1 and JNK2 are ubiquitously expressed while JNK3 is restricted to the 
brain, heart and testis. JNKs are activated by threonine and tyrosine phosphorylation by 
MKK4 and MKK7. Through a cascade of upstream kinase mediated phosphorylation 
events, MKK7 and MKK4 are activated, primarily in response to cytokines and 
environmental stress respectively. JNKs are also activated in response to other cellular 
stress such as osmotic stress, ultra-violet light, reactive oxygen species, as well as 
endoplasmic reticulum stress (ER stress). Activated JNK regulates its substrates such as 
cJUN, ATF-2 and other cytosolic and nuclear proteins through phosphorylation. JNK can 
be stimulated through toll like receptor-4 (TLR4) mediated activation. TLR4 is the 
receptor for lipopolysaccharide (LPS) and plays an important role in innate immunity. 
Stimulation of this pathway induces cytokine expression and activates proinflammatory 
pathways. FFAs mediate insulin resistance through activation of JNK cascade through 
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TLR4 pathway. TLR4 deficient mice are protected from lipid-induced suppression of 
muscle insulin signaling and systemic glucose metabolism. Furthermore, TLR4 deficient 
female mice exhibit increased obesity but are partially protected from HFD induced 
insulin resistance [288].  
 In diet induced obese mice, as well as leptin deficient ob/ob mice, expression of 
TNFα is increased and this is associated with enhanced JNK activity. JNK binds to, as 
well as phosphorylates IRS1 and IRS2 on the Ser307 residue, resulting in IRS1 
inactivation. This is further supported by a study in which JNK1 knockout mice are 
protected from high fat diet induced insulin resistance as well as IRS1 Ser307 
phosphorylation. Moreover, these animals were protected from HFD induced obesity and 
adipose tissue expansion. Although JNK1 in hematopeietic cells mediates pro-
inflammatory cytokine synthesis in response to HFD and induces insulin resistance, 
however, mice deficient for JNK1 in myeloid cells and hematopeietic cells did not differ 
from the control mice, in their glucose and insulin response. Interestingly, adipose 
specific JNK1 knockout mice were protected from HFD induced insulin resistance in the 
liver that was due to decreased IL-6 synthesis by the adipose tissue. 
p38 MAPK exists as four isoforms α, β, γ and δ. Similar to JNK, p38 is also 
activated by phosphorylation in response to cellular stress. Through the MAPK cascade, 
activated MKK6 phosphorylates all the p38 isoforms, while MKK3 activates p38α, γ and 
δ, and MKK4 activates only p38α. Studies in cultured endothelial cells have shown that 
TNFα mediated insulin resistance by inhibition of PI3K/Akt/eNOS (endogenous nitric 
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oxide synthase) pathway, is a p38 MAPK dependent function [289]. Furthermore, recent 
studies in hepatocytes demonstrated the important role played by JNK and p38 MAPK 
pathway in palmitate induced hepatic insulin resistance [290].  
Role of Interleukins in Promoting Insulin Resistance - Interleukin-1 
The interleukin -1 family of cytokines consists of interleukin-1α (IL-1α) and 
interleukin-1β (IL-1β), two low molecular weight proinflammatory cytokines. IL-1β is 
produced as a ~31kDa precursor that is proteolytically processed by caspase-1, to its 
active 17.5 kDa form; however, both the precursor and the mature forms of IL-1α are 
biologically active. Calpain, a calcium-activated cysteine protease mediates the 
processing of IL-1α. The two cytokines also differ in the cell types where they are 
produced. While IL-1α is constitutively produced by epithelial cells and keratinocytes, 
variety of other cells such as macrophages, monocytes, fibroblasts, endothelia cells, can 
synthesize and secrete this cytokine, but only upon stimulation.  In vitro studies have 
implicated IL-1α in a wide variety of functions including, induction of pro-collagen type 
I & III synthesis, prolifereation of fibroblasts, collagenase secretion and IL-6, induction 
of TNFα release by endothelial cells and many more. In vivo, it induces synthesis of 
proteases and subsequent proteolysis of muscle, stimulates acute phase protein synthesis, 
fibroblast and lymphocyte proliferation and induces fever. In contrast, IL-1β is produced 
by activated macrophages and is an important mediator of inflammatory response and 
other cellular functions, including cell proliferation & differentiation and apoptosis.  
Inspite of these differences, the two cytokines share the same receptor interleukin-1 
60 
 
receptor I and II (IL1R1 & IL1RII). Only IL1R1 has a biological functional, while IL1RII 
lacks a cytosolic domain and is non functional. IL-1 receptor antagonist, another member 
of IL1 family also binds to the IL1R1, but does not induce a cellular response and thus 
antagonizes the effects of IL-1α and β. 
IL-1β exerts its biological functions through IL1R1/IKK/NFκB pathway, and has 
been demonstrated to utilize ERK, JNK and p38 MAPKs. Recently IL-1β has been 
shown to be involved in mediating insulin resistance. IL-1β concentrations are found to 
be elevated in nondiabetic offspring of diabetic individuals and this correlates with 
metabolic syndrome [291]. Furthermore, studies have shown that, individuals with 
elevated circulating levels of both IL-1β and IL-6 are at more risk of developing type 2 
diabetes, than of IL-6 levels alone. Additionally, in the visceral adipose tissue of obese 
subjects, and epididymal adipose tissue of diet induced obese and genetically obese 
(ob/ob) mouse models, increased expression of IL-1β and IL1R1 is observed. Studies in 
3T3-L1 as well as human adipocytes demonstrated IL-1β to stimulate ERK, JNK and p38 
MAPK phosphorylation, as well as IκBα degradation. However, expression of C/EBPα, 
AP2 and PPARγ was found to be unaffected in acute treatment, but inhibited in chronic 
stimulation. Long-term treatment with IL-1β inhibited adiponectin mRNA as well as 
protein expression. Additionally, insulin stimulated glucose uptake and GLUT4 
expression were inhibited. This was possibly due to the observed specific decrease in 
IRS1 mRNA expression and diminished tyrosine phosphorylation, however, IRS2 
tyrosine phosphorylation was not affected. Furthermore, pharmacological inhibition of 
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ERK1/2 prevented the IL-1β mediated suppression of insulin stimulated Akt, as well as 
AS160 and GLUT4 translocation to the plasma membrane [292, 293]. 
The role of IL-1α in insulin resistance is not known. Although, in a recent study in 
3T3-L1 adipocytes, IL-1α treatment, within 15 minutes induced activation of IKK, JNK, 
ERK as well as p70S6K1 and also caused IRS1 serine phosphorylation on several 
residues. Pharmacological inhibitor induced inhibition of these kinases prevented serine 
phosphorylation of IRS1. However, IL-1α alone did not inhibit insulin stimulated glucose 
uptake or Akt phosphorylation, but exhibited a synergistic inhibition in the presence of 
IL-6 [294]. Owing to the effects observed on insulin signaling in IL-1α and IL-1β 
treatment condition, ablation of IL1RI should render animals insulin sensitive.  To the 
contrary, Garcia and coworkers observed age induced obesity in IL1RI knockout mice. 
Additionally, the animals were glucose intolerant, insulin resistant and partially leptin 
resistant [295]. Furthermore, studies in mice with IL-1R antagonist gene ablation made 
the mice lean and exhibited increased energy expenditure [296]. In a second study, IL-1R 
antagonist knockout animals exhibited decreased levels of serum insulin levels and were 
resistant to diet-induced obesity [297]. Together, these studies show that IL-1 mediated 
regulation of insulin signaling and whole body metabolism is a complex phenomenon and 
more detailed analysis is needed to make definitive conclusions. 
Interleukin-6 
Interleukin-6 (IL-6) is a pro-inflammatory cytokine with pleotropic effects, and 
has tissue specific functions that differ in humans and rodents. Although, IL-6 promotes 
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chronic inflammation, it displays anti-inflammatory properties as well, during acute 
inflammatory stimuli. Due to the contradicting effects exhibited by IL-6, understanding 
its role in insulin resistance is quite complicated. During states of obesity-associated 
inflammation, increased secretion of IL-6 by the adipocytes is observed. Additionally, 
elevated levels of circulating IL-6 correlates with adiposity in humans, however, it does 
not reflect insulin sensitivity. Although, experiment from cell culture model systems and 
studies using rodents demonstrate that IL-6 promotes insulin resistance. Furthermore, IL-
6 neutralizing antibody treatment improved hepatic insulin signaling in ob/ob mice. 
Surprisingly, IL-6 deficient mice became obese and insulin resistant, which could be due 
to increased TNFα and leptin levels. To the contrary, IL-6 over expression caused obesity 
and insulin resistance in mice. Despite these contradicting observations, it is interesting to 
note that IL-6 induces lipolysis in the adipose tissue and increases FFA for muscle 
oxidation during exercise. IL-6 administration was found to increase glucose uptake in 
human muscle. In the liver, IL-6 signaling through the JAK/STAT pathway leads to the 
induction of suppressor of cytokine signaling 3 protein (SOCS3) and thus suppresses 
insulin signaling. Studies in cultured hepatocytes have demonstrated a role for IL-6 to 
induce gluconeogenesis and in vivo studies have further corroborates this where 
increased glucose output was observed. A recent study in mice has shown that IL-6 
expression in the adipose is regulated by JNK1 and adipose specific knockout of this 
MAPK decreased high fat diet induced increase in circulating IL-6 levels and protected 
the animals from hepatic insulin resistance that was due to decreased SOCS3 function. 
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Role of PPARs in Insulin Sensitivity and Resistance 
Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear 
receptor proteins that function as transcription factors, were first identified in Xenops as 
receptors that induce the proliferation of peroxisomes. Three types of PPARs have been 
identified PPARα, PPARδ (β) and PPARγ. PPARα is expressed in liver, kidney, heart, 
muscle, adipose as well as in other cell types. PPARα is activated by long chain fatty 
acids and plays an important role in the transcriptional regulation of genes involved in 
peroxisomal and mitochondrial fatty acid oxidation pathways. Mice deficient for PPARα 
had impaired fatty acid uptake and oxidation in the liver, exhibited hypoglycemia and 
increased inflammation. While the decrease in glycemia is due to shift from fat oxidation 
to glucose utilization, increase in NFκB activity and expression of inflammatory genes 
and pro-inflammatory lipid mediators caused elevated inflammatory state. Treatment 
with fibrates, synthetic PPARα agonists improved serum lipid levels, due to enhanced 
hepatic fatty acid uptake and oxidation.  
PPARδ is expressed as two splice variants and is expressed in wide range of 
tissues. The major function of PPARδ is regulation of fatty acid oxidation and 
thermogenesis in muscle and also mediates muscle fiber type programming. PPARδ 
knockout mice die at early age due to placental and mylenations defects. PPARδ is not 
required for fat storage in adipose tissue, as fat mass was not reduced in adipose specific 
PPARδ deletion. Additionally, PPARδ has been shown to suppress macrophage derived 
inflammation as well as mediate alternate activation, thus regulating whole body insulin 
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sensitivity. Furthermore, studies have demonstrated its role in decreasing hepatic glucose 
output, and increasing fatty acid transport and oxidation in the heart.  
By differential promoter usage PPARγ gene gives rise to three different 
transcripts. PPARγ1, expressed in all tissues is encoded by exon A1, A2 and exon 1-6.  
PPARγ2 is 30 amino acids longer and is expressed mainly in the adipose tissue and is 
encoded by exon B and exon 1-6. While PPARγ3 is identical to PPARγ1, its expression 
is restricted to human white adipocytes and few other cell types and is encoded by exon 
A2 and exon 1-6. However, exon A1 and A2 are not translated. Ligand mediated 
activation of PPARγ and its dimer formation with retinoic X receptor (RXR) results in 
transcription of genes containing PPREs (PPARγ response element).  
The role of PPARγ as an essential component of glucose homeostasis, lipid 
metabolism, regulation of inflammation and atherosclerosis is supported by vast data 
[298]. As discussed earlier, PPARγ plays a central role and is required for adipogenesis. 
PPARγ deficiency in mature adipocytes of mice lead to a significant reduction in both 
brown and white adipose tissue mass and was accompanied by hyperlipidemia elevated 
serum TG, FFAs and decreased adiponectin and leptin levels. Furthermore, these animals 
exhibited hepatic insulin resistance and lipid accumulation. However, muscle insulin 
sensitivity was maintained on chow diet but the mice developed insulin resistance on 
HFD [299].  
Along with its primary role in adipose tissue, PPARγ plays a central role in other 
insulin sensitive tissues such as muscle and liver, to maintain whole body insulin 
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sensitivity, even though it is expressed at low levels in these tissues. Loss of muscle 
PPARγ resulted in adipose tissue and liver insulin resistance [300]. While decreased 
hepatic steatosis, increased adiposity, hyperlipidemia and insulin resistance was observed 
in the liver PPARγ deficient animals. Furthermore, PPARγ was found to be required for 
macrophage alternate activation; as, myeloid specific depletion of this nuclear receptor 
resulted in DIO, insulin resistance, and glucose intolerance [256]. These studies have 
demonstrated the important role played by PPARγ in regulating the communication 
between different metabolic tissues. 
Regulation of PPARγ 
Interestingly, in adipocytes, TNFα suppressed adipogenic gene expression, but 
stimulated preadipocyte as well as cytokine gene expression, which were mediated by 
NFκB activity [301]. TNFα mediated decrease in expression of lipogenic genes as well as 
its function leading to dedifferentiation of mature adipocytes is believed to be through 
repression of PPARγ gene expression. It is well known that C/EBP/delta binds to and 
activates PPARγ promoter. TNFα exhibits its inhibitory effects on PPARγ in a 
mechanism involving decrease in C/EBPδ expression [302]. Additionally, TNFα 
stimulated NFκB association to PPARγ inhibits the ligand dependent transcriptional 
activity of PPARγ. Furthermore, TNFα mediated IκBα degradation resulted in 
translocation of cytoplasmic histone deacetylase-3 (HDAC3) to the nucleus, which then 
bound to PPARγ and prevented its transcriptional activity. Studies from several groups 
have demonstrated inhibition of adipogenesis through ERK1/2 and JNK mediated PPARγ 
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Ser112 (γ2) and Ser82 (γ1) phosporylation [303-306]. Moreover, DIO was prevented in 
downstream tyrosine kinase-1 (Dok1) knockout mice, by ERK mediated PPARγ 
Serine112 phosphorylation [307]. Recently, TNFα has been shown to mediate PPARγ 
protein cleavage through caspase-3, -6 and -8 activation, which resulted in PPARγ 
nuclear exclusion in cultured cells [308]. Additionally, AMPK mediated PPARγ 
phosphorylation represses both the ligand-dependent and independent transactivating 
functions [309]. Taken together, these studies suggest that TNFα potently downregulates 
PPARγ function in fat cells and NFκB as well as MAPKs seem to play an important role 
in this process. 
MAP4K4 
Mitogen activated protein kinase kinase kinase kinase-4 (MAP4K4), a 
serine/threonine that belongs to a large family of protein kinases related to yeast Ste20p 
(sterile 20 protein) kinase. The mammalian STE20 family consists of about 28 kinases 
related in their catalytic domains. Based on their domain structure, these proteins are 
classified into two classes, the p21-activated protein kinases (PAKs) and the germinal 
center kinases (GCKs). The GCK class or proteins are categorized under eight groups 
GCK-1 to GCK-VIII. MA4PK4 mouse ortholog HGK (hepatocyte progenitor kinase-
like/GCK-like kinase), is part of the GCK-IV group of kinases along with three other 
members TNIK, MINK and NRK. This group of kinases is implicated in various 
intracellular regulatory functions, including cell cycle progression, differentiation, 
transcription, apoptosis, cytoskeleton rearrangement and cell motility [310].  
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MAP4K4 was first identified as a kinase interacting with the SH3 domains of 
Nck, an adaptor protein composed of one SH2 and three SH3 domains and was named 
NIK (Nck interacting kinase) [311, 312]. MAP4K4 shares a high homology in its kinase 
domain and C-terminal domains, with TNIK and MINK while the intermediate domain is 
variable. The C-terminal domain is a citron homology domain (CNH), is important for 
protein-protein interaction. NIK was shown to interact with MEKK1 as well as 
cytoplasmic domain of ß1-integrin receptors through this domain. misshapen (msn) in 
Drosophila melanogaster and mig-15 in Caenorabditis elegans, are MAP4K4 orthologs, 
which share about 80% amino acid identity in both kinase and CNH domains.  
Initial studies using transient over expression of NIK identified MAP4K4 as a 
stress-activated protein kinase (SAPK/JNK) activating kinase, functioning upstream to 
MEKK1. Furthermore, using transient transfection of HGK in 293T cells, it has been 
demonstrated that TNF-alpha stimulated MAP4K4 activity specifically towards JNK but 
not ERK1/2 or p38 MAPK [312]. Recent studies in human skeletal muscles further 
supported this, where silencing MAP4K4 prevented TNF-alpha stimulated JNK 
activation. However in this study, the authors demonstrated that TNF-alpha regulated 
ERK1/2 activation in a MAP4K4 dependent manner [313]. MAP4K4 was found to 
interact with Rap2 (Ras-related protein family member) through its CNH domain. Rap2 
in the GTP bound form enhanced MAP4K4 induced JNK activation [314]. Although, 
numerous studies have demonstrated JNK activation by exogenously expressed 
MAP4K4, there are no studies in the literature till date showing endogenous MAP4K4 
mediated JNK activity. Studies from our laboratory identified TNFα stimulated TNFR1 
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signaling to c-Jun and ATF2 in a JNK1/2 and p38 SAP kinase dependent mechanism, to 
regulate Map4k4 gene expression in 3T3-L1 adipocytes, thus establishing MAP4K4 as a 
JNK1/2 transcriptional target [315]. 
Stimulation of ephrin receptor family, which are cell surface ligands involved in 
cell migration and tissue remodeling has been shown to activate NIK, implicating 
MAP4K4 in cell morphogenesis [316]. Consistent with this, MAP4K4 knockout mice 
(NIK-/-) exhibit embryonic lethality during early embryogenesis, with mesodermal 
differentiation and cell migration defects [317]. Although JNK has been identified as a 
downstream effector of MAP4k4, owing to the differences in the time line, when the 
embryos die post-gastrulation, (Nik-/- die between day 9.5-10.5 while JNK1&2-/- die at 
11.5), and the morphological differences observed in the two kinds of embryos, the 
embryonic lethality observed in the NIK-/- mice might not be due to JNK effects [318]. 
Moreover, MAP4K4 has been shown to be associated with several types of cancers and 
also has been identified as a promigratory kinase [319]. Together, these functions of 
MAP4K4 are possibly through activation of p38 MAPK that subsequently inhibits E-
Cadherin protein, thus preventing its inhibitory function on epithelial to mesenchymal 
transition (EMT) and mesoderm migration [320].  
MAP4K4 expression has been observed to be elevated in the preadipocytes of 
obese individuals, thus preventing adipocyte differentiation and maturation leading to 
insulin resistance [368]. Recent studies have implicated MAP4K4 in TNF-alpha induced 
insulin resistance. Silencing MAP4K4 in myotubes from insulin-resistant type 2 diabetic 
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patients restored insulin stimulated glucose uptake to the level observed in healthy 
subjects. Furthermore, the authors demonstrated complete prevention of TNF-alpha 
induced insulin resistance on Akt, AS160 as well as IRS1, which was through MAP4K4 
dependent JNK1/2 and ERK1/2 activation [321]. Moreover, MAP4K4 has been shown to 
play a role in beta cell function. Human and rat primary pancreatic beta cells were 
protected from TNF-alpha induced inhibition of glucose stimulated insulin secretion, as 
well as decrease in IRS-2 expression in the absence of MAP4K4. Additionally, MAP4K4 
was required for the TNF-alpha activation of Akt, AS160, ERK, JNK and p70S6K1. 
However, NFκB and p38 MAPK were unaffected [322]. Interestingly, recent study from 
our laboratory has identified MAP4K4 as a mediator of cytokine expression and thus 
assigning a new role for this MAPK in inflammation. Silencing MAP4K4 using an 
innovative siRNA delivery system in vivo, the authors demonstrated protection from LPS 
induced lethality that was due to inhibition of TNFα and IL-1β production [323]. 
Interestingly, Tang and colleagues from our laboratory, in an siRNA mediated screen in 
3T3-L1 adipocytes, identified MAP4K4 as a novel protein kinase involved in regulation 
of insulin stimulated glucose uptake. Silencing MAP4K4 lead to an increase in GLUT4 
expression accompanied by significantly enhanced glucose uptake. Furthermore, C/EBPα 
and PPARγ protein expression, as well as triglyceride content were observed to be 
elevated in the absence of MAP4K4 [324]. This study was the first to recognize the 
important role of MAP4K4 as a negative regulator of insulin stimulated hexose transport, 
PPARγ synthesis and hence modulates adipose function. Map4k4 functions in different 
cell types are summarized in Figure 1.8. 
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FIGURE 1.8. Role of Map4k4 in Inducing Insulin Resistance. In the muscle Map4k4 
inhibits insulin stimulated glucose uptake, and mediates TNFα induced insulin resistance. 
TNFα induced inhibition of glucose-stimulated insulin secretion is mediated by Map4k4 
in the pancreatic beta cells. Map4k4 regulates cytokine expression in macrophages and 
thus plays a role in mediating inflammation. In the adipocyte, GLUT4 expression, insulin 
stimulated glucose uptake, PPARγ expression and TAG synthesis are inhibited by 
Map4k4. 
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Specific Aims 
Studies from our laboratory have identified Map4k4 as a negative regulator of 
insulin stimulated glucose uptake and adipogenesis. Furthermore, Map4k4 was also 
found to regulate PPARγ expression. PPARγ is considered to play a central role in 
modulating adipogenesis and is also the target of the diabetic medication TZDs [325]. 
Understanding the mechanism by which Map4k4 regulates PPARγ expression could lead 
to better manage obesity induced insulin resistance and associated complications. 
Map4k4 is also implicated in TNFα synthesis, as well as TNFα signaling to 
induce insulin resistance in muscle.  Additionally, Map4k4 is also responsible for the 
TNFα induced inhibition of glucose stimulated insulin secretion by beta cells.  Given the 
involvement of Map4k4 in inflammatory pathways, insulin signaling & secretion, insulin 
resistances, as well as preliminary studies implicating Map4k4 in regulation of adipose 
function, I embarked on determining the role of Map4k4 in regulating adipocyte function 
in-vitro as well as in-vivo. To address this RNAi strategy was employed for the in vitro 
study and a recently published novel strategy was utilized in the in vivo investigation. 
The specific aims of these studies were: 
To identify the signaling pathway by which Map4k4 regulates PPARγ protein 
expression in vitro, utilizing 3T3-L1 adipocytes as model system. 
To determine the role of Map4k4 in regulating adipose function in vivo, using a 
mouse model system with adipose-specific Map4k4 gene silencing 
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CHAPTER II: Map4k4 Negatively Regulates Peroxisome Proliferator-
activated Receptor (PPARγ) Protein Translation by Suppressing the 
Mammalian Target of Rapamycin (mTOR) Signaling Pathway in 
Cultured Adipocytes 
 
Disclaimer: All experiments were performed by the author except for Figure 1 which 
was done in colaboration with Adilson Guilherme and me; Figure 2 and Figure 3A were 
done by Adilson Guilherme; and Figure 6 was done in colaboration with Liting Xue and 
me. Anil Chawla prepared the construct to generate adenovirus for Map4k4 
overexpression. Xiaoqing Tang made the original observation that Map4k4 gene 
silencing enhances PPARγ protein level. I did all the statistical analysis in this chapter. 
 
 
This Chapter is in the format published: Kalyani V. P. Guntur, Adilson Guilherme, 
Liting Xue, Anil Chawla, and Michael P. Czech1. Map4k4 Negatively Regulates 
Peroxisome Proliferator-activated Receptor (PPAR)γ  Protein Translation by Suppressing 
the Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Cultured 
Adipocytes. J Biol Chem 285: 6595-6603. 
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Abstract 
The receptor peroxisome proliferator-activated receptor γ (PPARγ) is considered 
a master regulator of adipocyte differentiation and promotes glucose and lipid 
metabolism in mature adipocytes. We recently identified the yeast Sterile 20 (Ste20) 
protein kinase ortholog, Map4k4, in anRNAinterference-based screen as an inhibitor of 
PPARγ expression in cultured adipocytes. Here, we show that RNA interference-
mediated silencing of Map4k4 elevates the levels of both PPARγ1 and PPARγ2 proteins 
in 3T3-L1 adipocytes without affecting PPARγ mRNAlevels, suggesting that Map4k4 
regulates PPARγ at a post-transcriptional step. PPARγ degradation rates are remarkably 
rapid as measured in the presence of cycloheximide (t1⁄2=2 h), but silencing Map4k4 had 
no effect on PPARγ degradation. However, depletion of Map4k4 significantly enhances 
[35S]methionine/cysteine incorporation into proteins, suggesting that Map4k4 signaling 
decreases protein translation. We show a function of Map4k4 is to inhibit rapamycin-
sensitive mammalian target of rapamycin (mTOR) activity, decreasing 4E-BP1 
phosphorylation. In addition, our results show mTOR and 4E-BP1 are required for the 
increased PPARγ protein expression upon Map4k4 knockdown. Consistent with this 
concept, adenovirus-mediated expression of Map4k4 decreased PPARγ protein levels and 
mTOR phosphorylation. These data show that Map4k4 negatively regulates PPARγ post-
transcriptionally, by attenuating mTOR signaling and a 4E-BP1-dependent mechanism. 
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Introduction 
Adipose tissue has long been recognized as the major storage depot for excess 
food-derived energy and has more recently been identified as an endocrine organ critical 
in the hormonal regulation of energy homeostasis [326]. Dysfunctions in these roles, 
which occur as a result of adipose tissue expansion in obesity, appear to be key elements 
in the development of insulin resistance and ultimately type 2 diabetes [327]. 
Maintenance of adipose tissue functions, including lipid sequestration as triglyceride 
stores, depends in part on appropriate levels of expression of genes required for 
triglyceride synthesis and storage. Many such genes are regulated by the nuclear hormone 
receptor PPARγ a nuclear hormone transcription factor. It is considered a master 
regulator of adipocyte differentiation [328] and essential for the increase in adipose mass 
associated with obesity [329]. Additionally, PPARγ is activated by lipid ligands [330] 
and plays an important role in glucose homeostasis and regulation of lipid metabolism in 
mature adipocytes. Understanding the regulation of PPARγ, a major metabolic 
modulator, would provide a better comprehension of its role in whole body homeostasis. 
PPARγ expression could be regulated at different levels, transcription, protein turnover 
and degradation, and possibly translation. Tumor necrosis factor-α mediated IκB kinase 
stimulation activates NF-κB signaling thus potently decreasing PPARγ transcription [301, 
331, 332]. Studies have shown that phosphorylation of PPARγ promotes its degradation 
through a ubiquitin-proteasome-dependent pathway [333, 334]. Stephens and co-workers 
have shown that PPARγ protein has a rapid turnover, and interferon γ treatment further 
enhanced the protein turnover [334].  
75 
 
In a screen for regulators of adipocyte functions, including glucose uptake, we 
recently identified Map4k4 as an inhibitor of PPARγ expression [324]. Map4k4 is a 
serine/threonine protein kinase that belongs to a large group of protein kinases related to 
Saccharomyces cerevisiae Ste20. The potential involvement of Map4k4 as an element in 
obesity-associated adipocyte dysfunction was suggested by the observations that it is 
acutely activated [335] and increased in expression by tumor necrosis factor-α [315], a 
cytokine overproduced in adipose tissue associated with obesity in animal models as well 
as human patients [269]. Silencing Map4k4 has been shown to improve glucose uptake 
and insulin sensitivity as well as triglyceride synthesis in cultured adipocytes [324]. In 
our previous studies, enhanced expression of PPARγ upon Map4k4 gene silencing in 
3T3-L1 adipocytes was observed [324]. However, our preliminary data suggested that 
this enhancement is not the result of increased PPARγ mRNA levels. We have thus 
focused on the synthesis of PPARγ protein as a potential control point for Map4k4 
effects. Of the three phases of protein translation, initiation is a complex process that is 
mediated by many different proteins [336, 337]. Global control of protein synthesis is 
achieved by changes in the phosphorylation state of initiation factors or their interacting 
regulators. One of the first steps of initiation of protein synthesis and a rate-limiting step 
is the formation of a ―ternary complex‖ by Met-tRNA and GTP-bound eIF2-α. Another 
means of translation regulation involves modulation of eIF4e (cap-binding protein) 
availability that is achieved by eIF4e-binding proteins called 4e-BPs. 
Hypophosphorylated 4e-BPs bind to eIF4e and prevent interaction between the 43 S 
preinitiation complex and mRNA that leads to inhibition of translation initiation. 
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Association of eIF4e and the scaffold protein eIF4G is through a small domain also 
present in 4e-BPs. Nonphosphorylated 4e-BP binds tightly to eIF4E preventing its 
association with eIF4G. Phosphorylated 4e-BP is inactive and dissociates allowing eIF4e 
to engage eIF4G to form the complex that facilitates translation initiation [338, 339]. 
Mammalian target of rapamycin (mTOR) is a conserved Ser/Thr kinase and a major 
regulator of cell growth and proliferation via modulating protein synthesis in response to 
environmental cues. 4E-BP1 and S6K1 are well known downstream targets ofmTORand 
are phosphorylated upon insulin stimulation [340]. Insulin is a major upstream effector of 
mTOR that enhances protein synthesis as part of regulating anabolic processes in 
response to glucose. Thus, impaired mTOR signaling might play a role in the 
development of glucose and insulin resistance and type 2 diabetes. In this study we have 
examined the role of Map4k4 in regulating PPARγ protein and embarked on identifying 
the players that are regulated by Map4k4 that potentially would regulate PPARγ protein 
expression. 
EXPERIMENTAL PROCEDURES 
Materials—Antibodies against eIF2-α (total (catalog no. 9722) and phospho-Ser-
51 (catalog no. 9721)), 4E-BP1 (total (catalog no. 9452), phospho-Thr-37/46 (catalog no. 
9459), Ser-65 (catalog no. 9451), and Thr-70 (catalog no. 9455)), 4e-BP2 (catalog no. 
2845), and mTOR (total (catalog no. 2972) and phospho-Ser-2448 (catalog no. 2971)) 
were purchased from Cell Signaling Technology, Inc. Antibody against PPARγ (catalog 
no. sc-7273) was purchased from Santa Cruz Biotechnology. Antibody against actin was 
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purchased from Sigma (catalog no. A2228). Rapamycin was purchased from Calbiochem 
(catalog no. 553210). All siRNA was purchased from Dharmacon (Lafayette, CO). 
[35S]Met protein labeling mix was purchased from Perkin Elmer Life Sciences. 
Cell Culture and siRNA Transfection—3T3-L1 preadipocytes were cultured and 
differentiated into adipocytes as described previously [341]. For siRNA transfection, cells 
4 days post-induction of differentiation were used as described previously (11). Briefly, 
5.625*105 cells were electroporated using 7.5 nmol of siRNA for scrambled, Map4k4, or 
1.87 nmol of siRNA for 4E-BP1 and 4e-BP2 and then plated in 4 wells of a 24-well plate. 
Cells were recovered in complete Dulbecco‘s modified Eagle‘s medium (10% fetal 
bovine serum, 50 units/ml penicillin, and 50 µg/ml streptomycin) and were cultured for 
48 or 72 h after the transfection before beginning the experiments.  
[35S]Met/Cys Labeling—3T3-L1 adipocytes 4 days post-differentiation induction 
were transfected with 7.5 nmol of scrambled or Map4k4 siRNA. 56 h later, cells were 
starved for methionine and cysteine using methionine- and cysteine-free Dulbecco‘s 
modified Eagle‘s medium. 16 h later, 45 µCi/ml [35S]methionine/cysteine protein 
labeling mix was added to the cells for 1, 3, or 6 h. Cell lysates were prepared, and total 
DNA and RNA were harvested. An equal volume of protein was analyzed to measure 
35S incorporation on a scintillation counter. Cell lysate was resolved on SDS-PAGE and 
transferred onto a nitrocellulose membrane, and 35S incorporation was detected by 
autoradiography. The incorporation of radioactivity was normalized to total DNA content 
of that sample. 
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Rapamycin Treatment—For 3T3-L1 adipocytes, 72-h post siRNA transfections 
were treated with the indicated concentration of rapamycin for 0.5, 1, or 2 h. In all 
experiments, cells were washed with ice-cold phosphate-buffered saline and harvested on 
ice as described previously [342]. Protein samples were separated on a 7% (for mTOR) 
or a 15% (for 4e-BP) SDS-polyacrylamide gel and transferred to a nitrocellulose 
membrane. Membranes were then analyzed by Western blot analysis. Changes in 
phosphorylation were determined through densitometry using Adobe Photoshop and 
normalized for loading against the nonphosphorylated protein or actin as appropriate. 
Cell Size Determination—3T3-L1 adipocytes after transfection with the 
appropriate siRNA were seeded on coverslips in a 12-well plate. After 72 h, cells were 
washed in ice-cold phosphate- buffered saline. The cells were fixed in 4% formaldehyde 
at room temperature for 0.2 h, quickly rinsed three times in ice-cold phosphate-buffered 
saline, briefly dried, and mounted on Vectashield mounting medium (H1000). The 
coverslip was sealed using nail polish. Cell images were collected under a microscope 
(Zeiss inverted microscope) using bright field at X20 magnification. Saved images were 
analyzed for cell size by measuring the cell circumference of 150 randomly picked cells 
using the ImageJ program (National Institutes of Health). Average cell circumference for 
each siRNA transfection was calculated and graphically represented using Microsoft 
EXCEL.  
Isolation of RNA and Quantitative Real Time PCR—RNA isolation was 
performed according to the TRIzol reagent protocol (Invitrogen). Briefly, media were 
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aspirated, and the cells were washed once with ice-cold phosphate-buffered saline. 1 ml 
of TRIzol reagent was added to each well. The concentration and the purity of the RNA 
were determined by measuring the absorbance at 260/280 nm. To further determine the 
quality of the RNA, 1µg of total RNA was run on a 1% agarose gel, and the quality of the 
28 S and 18 S ribosomal bands was inspected visually. cDNA was synthesized using 1 µg 
of RNA and the iScript cDNA synthesis kit (Bio-Rad). The cDNA was synthesized 
according to the protocol provided by the manufacturer in a 20 µl reaction volume. For 
real time PCR, 1 µl of the synthesized cDNA was loaded into 1 well of a 96-well plate 
for detection of a specific target gene. Primers were designed with primer bank [343] and 
listed in Table 2.1. 36B4 was used as an internal control because its expression did not 
change with the silencing of the genes used in this study. 10 pmol of forward and reverse 
primer along with 12.5 µl of the iQ SYBR Green Supermix (Bio-Rad) was added to each 
well along with DNase/RNase-free water for a final volume of 25 µl. Samples were 
analyzed on the MyIQ real time PCR system (Bio- Rad). Relative gene expression was 
determined using the (Δ)Ct method [344]. 
Adenovirus Expression—Four days after differentiation, 3T3-L1 adipocytes were 
infected with the indicated amount of viral particles. Briefly, 10,000 cells were infected 
using 40 µl (1.43 *1012 particles/ml) of HA control virus or 3HA-Map4k4-HA virus. 72 h 
post-infection, cells were washed with ice-cold phosphate- buffered saline and harvested 
on ice as described previously (21). Protein samples were separated on a 7% SDS-
polyacrylamide gel and transferred to a nitrocellulose membrane. Membranes were then 
analyzed by Western blot analysis. Changes in total protein level or phosphorylation were 
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determined through densitometry using Adobe Photoshop and normalized for loading 
against actin or the nonphosphorylated protein as appropriate. The virus was generated as 
described previously [345]. 
Statistics—The characteristics of the outcomes were evaluated by visual 
inspection of histograms generated using Microsoft EXCEL, and the observed effects 
were evaluated by either one-way or multifactorial analysis of variance [79]. 
Computations were performed using the ezANOVA program. Regression analysis was 
performed using Microsoft EXCEL. The data are presented as the means  S.E. 
RESULTS 
Map4k4 Gene Silencing Enhances PPARγ Protein Expression at a Translational 
Step—We have previously shown that depletion of Map4k4/NIK enhances PPARγ 
expression in cultured adipocytes [324]. To confirm the increase in PPARγ upon Map4k4 
gene silencing, we examined the protein level of PPARγ in 3T3-L1 adipocytes upon 
siRNA-mediated depletion of Map4k4 mRNA (Fig. 2.1A). At 72 h post-transfection, cell 
lysates were prepared from either scrambled or Map4k4 siRNA-transfected 3T3-L1 
adipocytes, and PPARγ protein levels were examined by SDS-PAGE and 
immunoblotting with PPARγ antibody. Map4k4 gene silencing resulted in a 2-fold 
increase in PPARγ1 as well as PPARγ2 protein levels (Fig. 2.1B), consistent with our 
previously published results [324]. To determine whether the increase in the protein level 
is due to increased PPARγ transcription, RNA was isolated from similarly treated cells, 
and PPARγ as well as Map4k4 mRNA levels were compared using quantitative real time 
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PCR. Map4k4 gene expression was decreased by about 80% (Fig. 2.1 D and 2.E); 
however, the expression of PPARγ mRNA did not change upon Map4k4 gene silencing 
(Fig. 2.1C). These results suggest that Map4k4 regulation of PPARγ levels is mediated 
through increased translation and/or decreased degradation of PPARγ protein.  
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FIGURE 2.1. Gene silencing of Map4k4 enhances PPARγ protein but not PPARγ 
mRNA in 3T3-L1 adipocytes. 3T3-L1 adipocytes 4 days post-differentiation induction,  
were transfected with 7.5 nmol of either scrambled (Scr) or Map4k4 siRNA. 72 h later, 
cell lysates were examined by Western blot (A) and densitometry analysis for PPARγ1 
and PPARγ2 (B). Total RNA was harvested and analyzed by quantitative real time PCR 
for PPARγ  mRNA expression (C) and Map4k4 mRNA expression (E). D, Map4k4 
protein expression. *, p<0.01 when compared with scrambled siRNA-transfected samples 
by ANOVA (n = 4). 
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To test whether Map4k4 silencing decreased degradation of PPARγ protein, 3T3-
L1 adipocytes were transfected with scrambled or Map4k4 siRNA and were then treated 
with 5 µg/ml of the protein synthesis inhibitor cycloheximide for the indicated times. Cell 
lysates were analyzed by SDS-PAGE and immunoblotting with anti-PPARγ antibody. As 
expected, initial PPARγ protein levels were enhanced with Map4k4 gene knockdown. In 
the absence of protein synthesis, we observed a rapid decrease in PPARγ protein levels 
with time (half-life 1.5–2 h) [334, 346] in scrambled as well as Map4k4 siRNA-treated 
conditions (Fig. 2.2A), indicating protein degradation. Densitometry (Fig. 2.2B) and 
regression analysis (Figure. 2.3) revealed that despite the higher initial level, Map4k4 
gene silencing does not prolong the half-life of PPARγ proteins. These results show that 
the increase in PPARγ protein level is not due to decreased degradation upon Map4k4 
gene knockdown. Rather, increased protein synthesis is the most likely mechanism for 
enhanced PPARγ protein levels. 
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FIGURE 2.2. Depletion of Map4k4 does not prolong the half-life of PPARγ protein 
in 3T3-L1 adipocytes. 3T3-L1 adipocytes 4 days post-differentiation induction were 
transfected with 7.5 nmol of either scrambled (Scr) or Map4k4 siRNA. 72 h later, the 
cells were treated with 5 µg/ml cycloheximide for the indicated times. Cell lysates were 
examined by Western blot (A) and densitometry analysis (B) for PPARγ1 and PPARγ2. 
Densitometry is representative of three independent experiments. 
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Figure 2.3. Regression Analysis. Graphical representation of regression analysis (A). No 
significant differences in the slope for PPARγ1 or PPARγ2, between scrambled or 
Map4k4 siRNA transfected conditions (B) (n=3). 
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Protein Synthesis and mTOR Activation Are Up-regulated upon Map4k4 Gene 
Silencing—To determine whether enhanced PPARγ protein levels with inhibition of 
Map4k4 expression is due to an increase in general protein synthesis, we exposed 3T3-L1 
adipocytes for 1, 3, or 6 h to [35S]methionine after 72 h of scrambled or Map4k4 siRNA 
transfection. Total protein and RNA were harvested. Equal volumes of protein lysates 
were analyzed for 35S incorporation by scintillation counting, and counts were 
normalized to total DNA content analyzed in parallel. Map4k4 gene silencing resulted in 
about 30% higher protein synthesis as indicated by increased 35S incorporation at all 
time points tested (Fig. 2.4A). These results suggest that the increase in PPARγ protein 
levels after Map4k4 gene silencing is the result of increased protein synthesis. Thus, 
Map4k4 appears to suppress protein translation in cultured adipocytes. We then sought to 
determine the pathways though which Map4k4 might modulate protein synthesis. mTOR 
is an evolutionarily conserved protein kinase that is a central component of the signaling 
mechanism regulating cell growth and proliferation by modulating protein synthesis 
[340]. This is achieved by regulating phosphorylation of effectors of protein synthesis, 
including the mRNA translation repressor 4E-BP1 and the ribosomal S6 kinase S6K1 by 
inactivation and activation, respectively. Studies in rat skeletal muscle have suggested 
that modulation of Ser-2448 phosphorylation by upstream regulators of mTOR have an 
important role in the control of mTOR kinase activity and protein synthesis [347]. We 
thus measured mTOR (Ser-2448) phosphorylation to test whether Map4k4 negatively 
regulates protein synthesis through modulation of the mTOR activation. 72 h after 
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scrambled or Map4k4 siRNA transfection, cell lysates were analyzed by immunoblotting 
using phospho-mTOR (Ser-2448) antibody. Map4k4 gene silencing significantly 
enhanced basal mTOR phosphorylation without changing total mTOR levels (Fig. 2.4 B 
and C). These results suggest that Map4k4 could function as a negative regulator of 
mTOR activity via modulation of mTOR (Ser-2448) phosphorylation (Fig. 2.4D).  
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FIGURE 2.4. Map4k4 gene silencing enhances protein synthesis and mTOR 
phosphorylation. 3T3-L1 adipocytes were transfected with 7.5 nmol of either scrambled (Scr) 
or Map4k4 siRNA 4 days post-differentiation induction. 72 h later, [35S]Met/Cys protein labeling 
mix was added to cells for 1, 3, and 6 h. A, Graphical representation of 35S incorporation as 
detected by a scintillation counter (n =3). The counts/min from each knockdown condition was 
normalized to total DNA content of that sample. Cell lysates were examined for phospho-mTOR 
(Ser-2448) by Western blot (B) and densitometry analysis (C). D, Model depicting possible 
mechanism of PPARγ translational regulation through mTOR. Densitometry and reverse 
transcription-PCR are representative of three independent experiments. **, p < 0.01, *, p < 0.05 
when compared with scrambled siRNA-transfected samples by ANOVA. 
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Map4k4 Depletion Enhances 4E-BP1 Phosphorylation—Because siRNA-
mediated suppression of Map4k4 expression promotes activation of mTOR, we sought to 
examine whether downstream targets of mTOR involved in protein synthesis, such as 4E-
BP1 and p70S6K1, were also affected by Map4k4 gene depletion. 4E-BP1 is a 
translational repressor protein that inhibits cap-dependent translation by binding to the 
eIF4e translation initiation factor [348]. mTOR-mediated hyperphosphorylation of 4E-
BP1 disrupts this interaction and results in activation of cap-dependent translation [339, 
349]. To determine whether Map4k4 gene silencing results in increased protein 
translation via enhanced 4E-BP1 phosphorylation, 3T3-L1 adipocytes were transfected 
with scrambled or Map4k4 siRNA, and then cell lysates were harvested and analyzed for 
changes in the phosphorylation state of 4E-BP1 protein by immunoblotting using 
phospho-4E-BP1 (Thr-36/45/69 and Ser-64) antibodies. As depicted in Fig. 2.5 A, 
Map4k4 gene silencing enhanced 4E-BP1 phosphorylation at all sites tested. Depending 
on the extent of phosphorylation, 4E-BP1 migrates as three distinct bands, α (hypo-
phosphorylated form), β, and γ (hyper-phosphorylated forms), on SDS-PAGE. 
Densitometry analyses revealed that there is a significant increase in the phosphorylation 
of sites that are responsible for the formation of slower migrating β as well as γ forms of 
4E-BP1 upon Map4k4 gene silencing (Fig. 2.5 B). We also examined other downstream 
targets of mTOR involved in the regulation of translation. S6K1 is another downstream 
effector of mTOR and is known to be the enzyme that phosphorylates ribosomal protein 
S6 (rpS6), a component of the small (40 S) ribosomal subunit [338]. S6K1 Thr-389 
phosphorylation by mTOR allows phosphorylation within the catalytic domain resulting 
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in kinase activation [60]. To test if Map4k4 gene silencing mediates changes in S6K1 
phosphorylation, cell lysates from the above-mentioned experiment (as that in Fig. 2.5) 
were subjected to SDS-PAGE and immunoblot analysis. Surprisingly, Map4k4 gene 
silencing does not enhance S6K1 phosphorylation at Thr-389 (Fig. 2.6) despite the 
activation of mTOR. To test if Map4k4-mediated increases in PPARγ protein synthesis 
are due to regulation of other translation initiation factors, we also examined the changes 
in the phosphorylation of eIF2-α by SDS-PAGE and immunoblotting using phospho-
eIF2-α antibody (Ser-51). There was no significant change in the phosphorylation state of 
eIF2-α (Ser-52 in mouse) upon Map4k4 gene silencing (Fig. 2.7). These results suggest 
that the mechanism whereby Map4k4 suppresses protein synthesis is primarily through 
down-regulation of mTOR and activation of 4E-BP1. Taken together, these results put 
forward a new mechanism of Map4k4-mediated regulation of PPARγ protein synthesis in 
an mTOR-dependent manner, through 4E-BP1.  
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FIGURE 2.4. Map4k4 gene silencing in 3T3-L1 adipocytes enhances 4E-BP1 
phosphorylation. 4 days postdifferentiation induction, 3T3-L1 adipocytes were 
transfected with 7.5 nmol of either scrambled (Scr) or Map4k4 siRNA. 72 h later, cell 
lysates were examined for phospho-4E-BP1 (Thr-36/Thr-45) by Western blot (A) and 
densitometry analysis (B). *, p < 0.05 when compared with scrambled siRNA-transfected 
samples by ANOVA. Densitometry is representative of three independent experiments. 
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Figure 2.6. Map4k4 gene silencing does not enhance p70S6K phosphorylation. 3T3-
L1 adipocytes were transfected with 7.5nmol of either scrambled, or Map4k4 siRNA 4 
days post differentiation induction. 72 h later cell lysates were examined for phospho 
p70S6K (Thr389) by Western blot and densitometry analysis. Densitometry is 
representative of three independent experiments. 
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Figure 2.7. Map4k4 gene silencing does not change eIF2-α phosphorylation. (A) 
Hypothetical model for eIF2-α regulation by Map4k4. 3T3-L1 adipocytes were 
transfected with 7.5nmol of either scrambled, or Map4k4siRNA 4 days post 
differentiation induction. 72 h later cell lysates were examined for phospho eIF2-α 
(Ser52) by Western blot (B) and densitometry (C) analysis. Densitometry is 
representative of three independent experiments. 
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4E-BP1 and 4E-BP2 Are Required for Map4k4 Regulation of PPARγ Protein—
4E-BP1 gene silencing should render eIF4e constitutively active, and hence protein 
synthesis should be enhanced. The eIF4e-binding protein exists in three isoforms 4E-
BP1, 4E-BP2, and 4E-BP3. Isoforms 1 and 2 are well studied, and they share similar 
phosphorylation sites [350]. To test if general protein synthesis is affected in the absence 
of 4E-BP1, we examined 35S incorporation in 3T3-L1 adipocytes after silencing 4E-BP1 
and 4e-BP2. Scrambled or Map4k4 siRNA individual transfections were used as negative 
and positive controls, respectively. Total protein and RNA were harvested 72 h later. 
Equal volumes of protein were analyzed for 35S incorporation, using a scintillation 
counter. Global protein synthesis was found to be enhanced as reflected by significant 
increases in [35S]methionine incorporation, upon 4E-BP1 gene depletion (data not 
shown), similar to Map4k4 gene silencing. To test if PPARγ protein synthesis is 
enhanced upon 4E-BP1 and 4E-BP2 gene silencing, cell lysates were analyzed for 
changes in PPARγ protein levels as well as efficiency of gene silencing of 4E-BP 
isoforms using SDS-PAGE and immunoblotting analysis. Map4k4 gene depletion 
resulted in significantly enhanced PPARγ1 as well as PPARγ2 protein levels as expected 
(Fig. 2.8A). Because 4E-BP1 is known to be a negative regulator of protein translation 
[351], phosphorylation of 4E-BP1 renders it inactive; silencing 4E-BP1 should mimic the 
hyperphosphorylated inactive state of 4E-BP1. Surprisingly, 4E-BP1 and 4E-BP2 
knockdown did not result in an enhancement of either PPARγ1or PPARγ2 protein levels 
as revealed by Western blot (Fig. 2.8A) and densitometry analysis (Fig. 2.8B).  
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FIGURE 2.8. 4E-BP1 and 4e-BP2 silencing does not enhance PPARγ protein level. 
3T3-L1 adipocytes were transfected with 7.5 nmol of scrambled (Scr) or Map4k4 and 
1.87 nmol of (each) 4E-BP1 and 4e-BP2 siRNA. 72 h later, cell lysates were examined 
for PPARγ protein levels as well as for efficiency of 4E-BP1 and 4e-BP2 gene silencing 
by SDS-PAGE followed by Western blot (A) and densitometry analysis (B). *, p < 0.05 
when compared with scrambled siRNA transfected samples by ANOVA. Densitometry is 
representative of three independent experiments. 
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To determine whether expression of 4E-BP1 is necessary for the increase in 
PPARγ protein level mediated by Map4k4 silencing, a triple knockdown strategy using 
siRNA against Map4k4 together with 4E-BP1 and -2 was employed. 72 h after siRNA 
transfection, cell lysates were examined by Western blot (Fig. 2.9A), and densitometry 
analysis (Fig. 2.9B) for changes in PPARγ protein level. Map4k4 siRNA treatment 
caused an enhancement in PPARγ protein level as seen in Fig. 2.1A. Furthermore, the 
triple knockdown resulted in no enhancement of PPARγ protein level; additionally, 
enhancement in PPARγ protein level in response to Map4k4 silencing is attenuated in the 
absence of 4E-BP1 and 4E-BP2. These results suggest an important role for 4E-BP1 and 
4E-BP2 in Map4k4 signaling in this pathway. 
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FIGURE 2.9. 4E-BP1 and 4e-BP2 are required for increased PPARγ protein levels 
upon Map4k4 gene silencing. 3T3-L1 adipocytes were transfected with 7.5 nmol of 
either scrambled (Scr) or Map4k4 and 1.87 nmol of 4E-BP1 and 4e-BP2 siRNA. 72 h 
later cell lysates were examined for PPAR_ protein levels by Western blot (A) and 
densitometry analysis (B). *, p < 0.01 when compared with scrambled siRNA transfected 
samples by ANOVA. Densitometry is representative of three independent experiments. 
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Up-regulation of PPARγ Level upon Map4k4 Depletion Is Suppressed by mTOR 
Inhibition—As phosphorylation ofmTORas well as 4E-BP1 is enhanced upon Map4k4 
knockdown, we tested to see if this increase in 4E-BP1 phosphorylation is mediated by 
mTOR. Rapamycin is known to be a potent inhibitor of mTOR function [352] and should 
result in dephosphorylation and activation of 4E-BP1. We thus treated 3T3-L1 adipocytes 
with 20 nM rapamycin for the indicated times, beginning 72 h after transfection with 
scrambled or Map4k4 siRNA. Cell lysates were analyzed by SDS-PAGE and 
immunoblotting using the respective antibodies (Fig. 2.10A). Phosphorylation of mTOR 
(Ser-2448) as well as 4E-BP1 (at Thr-69, Ser-64, and Thr-36/45) was enhanced upon 
Map4k4 gene silencing as expected, and both PPARγ1 and PPARγ2 protein levels were 
found to be increased. In the scrambled siRNA-transfected cells (control), treatment with 
rapamycin resulted in dephosphorylation of 4E-BP1 at all the phosphorylation sites tested 
in a time-dependent manner. Similarly, rapamycin-induced 4EBP1 dephosphorylation (in 
all the sites tested) was not prevented in Map4k4 silenced cells (Fig. 2.10A & B). At the 
same time, PPARγ1 and PPARγ2 protein levels showed a significant decrease in 
expression upon rapamycin treatment in a time-dependent manner (Fig. 2.7A & B). 
These results are consistent with the hypothesis that enhanced 4E-BP1 phosphorylation 
that is observed upon Map4k4 gene silencing is mediated through an mTOR-dependent 
mechanism that regulates PPARγ protein synthesis. 
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FIGURE 2.10. Rapamycin inhibits Map4k4 regulation of 4E-BP1 phosphorylation 
and PPARγ expression. 3T3-L1 adipocytes 4 days post-differentiation induction were 
transfected with 7.5 nmol of either scrambled (Scr) or Map4k4 siRNA. 72 h later, cells 
were treated with 20 nM of rapamycin for 0.5, 1, or 2 h. Cell lysates were examined for 
the appearance of the hypophosphorylated form (4E-BP1α), and changes in the 
phosphorylation levels of 4E-BP1 at Ser-64, Thr-69, and Thr-36/45 were analyzed using 
appropriate antibodies by Western blot (A) (representative blots) and densitometry (B) 
analysis (n = 5). *, p < 0.05 when compared with scrambled siRNA transfected samples 
by ANOVA. 
 
 
 
Enhanced Cell Size upon Map4k4 Gene Silencing in 3T3-L1 Adipocytes—mTOR 
is known to be a central regulator of cell growth [57]. To determine whether up-
regulation of mTOR activity upon Map4k4 gene silencing affected cell growth, we 
measured the changes in cell size upon siRNA-mediated knockdown of these genes in 
3T3-L1 adipocytes. After transfection of adipocytes with scrambled or specific siRNAs, 
bright field cell images were collected, and cell size was analyzed by measuring the 
circumference of 150 randomly chosen cells. Cell size was found to be significantly 
enhanced upon Map4k4 gene silencing (Fig. 2.11), consistent with increased growth as a 
result of increased mTOR activity. 
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Figure 2.11. Depletion of Map4k4 enhances cell size in 3T3-L1 adipocytes. 4 days 
post differentiation induction, scrambled or Map4k4 siRNA transfected cells were seeded 
on cover slips. 72 h later the cells were fixed in 4% formaldehyde and cell images were 
captured under a microscope and cell size was measured using NIH ImageJ program. 
Histogram represents cell size of average of three independent experiments. *=p<0.05 
when compared with scrambled siRNA transfected samples by ANOVA. 
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Adenovirus-mediated Map4k4 Overexpression Decreases mTOR Phosphorylation 
Levels as well as PPARγ Protein— Because siRNA-mediated suppression of Map4k4 
expression enhanced PPARγ expression, as well as promoted activation of mTOR in 
cultured adipocytes, we hypothesized that transgenic expression of Map4k4 would have 
the opposite effect. To test this, 72 h post-infection, cell lysates were prepared from either 
control adenovirus (Ad-control) or Map4k4 adenovirus (Ad-Map4k4) (3HA-Map4k4-
HA)-infected 3T3-L1 adipocytes. We first assessed the level of Map4k4 evoked by 
adenovirus-mediated gene transfer. Analysis of cell lysates harvested from cells infected 
with the Map4k4 adenoviral vector (Ad-Map4k4) revealed efficient production of the 
150-kDa protein. The protein level of Map4k4 was examined using both anti-Map4k4 and 
HA antibody by SDS-PAGE and immunoblotting (Fig. 2.12A). Increases in Map4k4 
expression with higher multiplicities of infection (data not shown) were observed. PPARγ 
protein levels and mTOR phosphorylation at Ser-2448 were examined by Western blot 
analysis with PPARγ and phospho-mTOR antibody, respectively. Adenovirusmediated 
expression of Map4k4 resulted in a modest but significant decrease in PPARγ1 as well as 
PPARγ2 protein levels (Fig. 2.12, A and B) without any change in the mRNA (data not 
shown). At the same time, there was also a diminished basal mTOR phosphorylation at 
Ser-2248, although total mTOR levels were unchanged (Fig. 2.12A). These results 
support the hypothesis that Map4k4 could function as a negative regulator of mTOR 
activity toward PPARγ protein synthesis via modulation of mTOR (Ser-2448) 
phosphorylation. 
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FIGURE 2.12. Adenovirus-mediated overexpression of Map4k4 decreases PPARγ 
protein level as well as mTOR (Ser-2448) phosphorylation in 3T3-L1 adipocytes. 4 
days post-differentiation induction, 3T3-L1 adipocyteswere infected with 40µl (1.4X1012 
particles/ml) of either HA control (Ad-control) or 3HA-Map4k4-HA (Ad-Map4k4) 
adenovirus. 72 h post-infection, cell lysates were examined for PPARγ protein levels as 
well as Map4k4, HA, phospho-mTOR (Ser-2448), and total mTOR by Western blot (A) 
(representative blots) and densitometry (B) analysis (n=4). *, p<0.05 when compared 
with control adenovirus infected samples by ANOVA. 
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FIGURE 2.13. Model for Map4k4-mediated PPARγ protein regulation. Our data 
support the following hypothesis. Silencing Map4k4 in 3T3-L1 adipocytes using siRNA 
enhances mTOR activity, as indicated by an increase in phosphorylation at Ser-2448. 
This in turn inhibits 4E-BP1 activity by enhancing phosphorylation at Thr-36, Thr-45, 
Ser-64, and Thr-69. Phosphorylation of 4E-BP1 renders it inactive leading to its 
dissociation from the translational initiation factor eIF4E. Thus eIF4E is activated, and 
cap-dependent translational initiation, responsible for the increase in PPARγ protein 
levels, is enhanced. However, 4E-BP1 silencing alone does not mimic Map4k4 depletion 
but blocks the Map4k4 effect, indicating it plays an additional role in regulation of 
PPARγ protein expression. 
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Table 2.1. 
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DISCUSSION 
mTOR plays a central role in mediating responses to many stimuli such as 
nutrients, hormones, and stress that result in the regulation of multiple cellular processes 
involved in cell growth and metabolism, including amino acid and protein biosynthesis 
and glucose homeostasis [57]. Treatment with rapamycin, a specific inhibitor of mTOR, 
has been shown to prevent adipocyte differentiation and lipid accumulation [64]. 
Although mTOR-mediated regulation of adipogenesis is not clearly understood, one 
mechanism could be through regulation of PPARγ, because its activity was attenuated by 
rapamycin treatment [64]. mTOR is also known as an important regulator of protein 
synthesis by mediating activation or inhibition of several downstream translation 
initiation and elongation factors directly or indirectly through changing their 
phosphorylation state [124]. The role of mTOR in regulating PPARγ protein synthesis 
has not previously been addressed. In this study, we show that Map4k4, a Ste20 
serine/threonine protein kinase, regulates PPARγ protein expression in 3T3-L1 
adipocytes, by a post-transcriptional mechanism via mTOR-mediated regulation of the 
4E-BP1 initiation factor. The specificity of the effect of Map4k4 silencing to up-regulate 
protein expression is not limited to PPARγ. Fig. 2.4A shows that there is a small but 
significant effect on incorporation of labeled amino acid into total protein in response to 
Map4k4 depletion, indicating that many proteins are up-regulated in addition to PPARγ. 
These may include proteins affected through direct mTOR-dependent modulation of 
translation (e.g. PPARγ), as well as proteins downstream of such transcription factors. 
Our previously published data [324] also showed a significant increase in protein 
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expression of adipogenic genes like CCAAT/enhancer-binding protein α and 
CAAT/enhancer- binding protein β and Glut4 (insulin-responsive facilitated glucose 
transporter isoform 4), upon siRNAmediated Map4k4 gene silencing. We have analyzed 
the mRNA levels of some additional genes known to be transcriptionally controlled by 
PPARγ, and we find that several are indeed also increased by Map4k4 knockdown. These 
include phosphoenolpyruvate carboxykinase, acetyl-CoA acyltransferase, and 
monoglyceride lipase (data not shown). However, other PPARγ-responsive and 
adipocyte-specific genes such as aP2 (or Fabp4, fatty acid-binding protein 4), adipsin, 
adiponectin, and leptin, which we analyzed by reverse transcription- PCR as well as 
immunoblotting, are not apparently affected by Map4k4 silencing in mature adipocytes 
(data not shown). The basis of this differential effect of Map4k4 knockdown on some 
PPARγ-responsive genes and not others is interesting but unknown. Our overall findings 
are summarized in Fig. 2.13. Inhibition of Map4k4 expression results in an enhanced 
phosphorylation of mTOR as well as 4E-BP1. Inactivation by phosphorylation of 4E-BP1 
results in an increase in PPARγ protein synthesis (Fig. 2.13). Active mTOR 
phosphorylates 4E-BP1 leading to the dissociation of the eIF4e-4E-BP1 complex [124]. 
Therefore, stimulating mTOR activity could result in enhanced protein synthesis. Our 
finding of enhanced mTOR (Ser-2448) phosphorylation (Fig. 2.4B) upon Map4k4 
depletion could mean increased mTOR kinase activity, but whether phosphorylation of 
mTOR at Ser- 2448 reflects its kinase activity is debatable [353]. However, 4E-BP1 was 
not protected from dephosphorylation upon rapamycin treatment in Map4k4-depleted 
conditions (Fig. 2.10A) supporting the idea that knockdown of Map4k4 enhances kinase 
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activity of mTOR in the absence of the inhibitor. How this elevated activity of mTOR 
occurs in Map4k4 knockdown conditions remains to be answered. The effect of Map4k4 
gene silencing on activation of mTOR to regulate 4E-BP1 appears to be downstream to 
Akt in the insulin signaling pathway, as Akt phosphorylation is not affected upon 
Map4k4 depletion [324]. Additionally, mTOR-mediated 4E-BP1 regulation appears to be 
distinct from S6K1 (the other well known mTOR substrate) regulation, because Map4k4 
gene silencing did not affect basal phosphorylation of S6K1 (Fig. 2.6). These results are 
consistent with published data showing outputs from mTOR to 4E-BP1 and S6K1 to be 
distinct [117].  
Further work is required to address the question of how activation of mTOR is achieved 
upon Map4k4 gene silencing. Additionally, upon depletion of Map4k4, the increase in 
basal mTOR phosphorylation at Ser-2448, as well as enhanced 4E-BP1 phosphorylation, 
suggests the presence of an additional player upstream of mTOR. Alternatively, a 
component could be functioning in a complex with mTOR to regulate 4E-BP1 
phosphorylation and mTOR kinase activity thereby enhancing PPARγ protein synthesis. 
Our result shows a decrease in PPARγ protein level concomitant with diminished mTOR 
phosphorylation at Ser-2448 upon adenovirus-mediated transgenic expression of 
Map4k4. This result supports the hypothesis that Map4k4 is a negative regulator of 
PPARγ protein translation by suppressing phosphorylation of mTOR. However, a 
detailed analysis of the molecular mechanism involving the regulation of mTOR 
phosphorylation by Map4k4 either directly, by means of downstream substrates, or by 
interacting partners will be necessary to better understand PPARγ translational 
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regulation. In summary, this study shows that Map4k4 regulation of PPARγ protein is a 
post-transcriptional mechanism that is coupled to mTOR signaling through regulation of 
4E-BP1. Furthermore, 4E-BP1 is necessary for enhancement in the PPARγ protein upon 
Map4k4 depletion. Addressing this novel role of 4E-BP1 in PPARγ protein regulation 
may reveal new insights into post-transcriptional regulation of gene expression. 
Considering the central role played by PPARγ in regulating whole body metabolism and 
insulin sensitivity, its regulation by Map4k4 may have important physiological 
implications. 
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Limitations and Future Perspectives 
The results presented in this chapter have provided evidence for translational 
regulation of PPARγ protein expression by Map4k4. Additionally, the increase in PPARγ 
protein levels observed in the MAP4K4 silenced condition is due to enhanced mTOR 
activity towards 4E-BP1, resulting in a modest but significant increase in protein 
synthesis. Although these results are intriguing, several questions remain to be addressed. 
The observation that despite mTOR activation, p70S6K1 activity as evidenced by its 
phosphorylation state is not altered by MAP4K4 gene silencing, is very interesting.  
Differential regulation of mTOR substrates in the MAP4K4 knockdown condition 
could be due to changes in substrate binding site availability on Raptor. mTOR exists as 
two distinct complexes that is determined by the interacting proteins. Hence, it can be 
hypothesized that, mTORC1 could further exist as two distinct complexes by binding to 
an unknown protein ‗A‘ as summarized in Figure XYZ. Since Map4k4 is a protein 
kinase, I speculate that it could possibly function as a regulator of this unknown protein 
by phosphorylation, either directly or indirectly through a kinase cascade. In the 
MAP4K4 knockdown condition the unphosphorylated protein-A blocks p70S6K1 
binding site on Raptor and thus inhibiting its phosphorylation and activation by mTOR. 
Studies to identify distinct mTOR and/or Raptor binding partners in MAP4K4 gene 
silencing condition, as well as immuno-precipitation studies to analyze Raptor binding 
capacity of p70S6K1 and 4E-BP1 in the MAP4K4 knockdown condition could provide 
insights into the differential regulation of mTOR substrates. 
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FIGURE 2.14. Map4k4 mediated differential regulation of mTOR substrates 
p70S6K1 and 4E-BP1. (1) In a cell mTORC1 binds to both S6K1 and 4E-BP1 equally. 
Map4k4 could function to phosphorylate an unknown protein A bound to Raptor, thus 
facilitating S6K1 binding to Raptor and its subsequent mTOR mediated phosphorylation 
and activation. (2) In the Map4k4 silenced condition the unphosphorylated protein A is 
still bound to Raptor and blocks S6K1-Raptor interaction and hence prevents its 
phosphorylation and activation by mTOR. In these both conditions 4E-BP1 
phosphorylation is not inhibited. Since S6K1 no longer competes for the Raptor binding 
site, 4E-BP1 can bind to Raptor unhindered and thus results in the observed increase in 
its phosphorylation.    
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4E-BP1 is a negative regulator of protein synthesis. Silencing of this eIF4E-
binding protein should mimic MAP4K4 knockdown effect towards PPARγ protein 
expression. Surprisingly, siRNA mediated 4E-BP1 gene silencing did not increase 
PPARγ protein levels. Studies utilizing transgenic expression of phosphorylation site 
mutants of 4E-BP1 could shed light on the role of 4E-BP1 in the regulation of PPARγ 
protein levels. Furthermore, MAP4K4 silencing mediated increase in PPARγ protein 
levels was abolished in the absence of 4E-BP1&2. This result suggests that 4E-BP1&2 
could be functioning as a positive regulator of PPARγ protein levels, although only in the 
MAP4K4 knockdown condition but not in basal conditions. A decrease in PPARγ mRNA 
level was observed both upon 4E-BP1&2 gene silencing as well as in combination with 
MAP4K4 siRNA.  However, upon differentiation induction, 4E-BP1&2 double knockout 
MEFs exhibited increased PPARγ mRNA levels [121]. This discrepancy in our 
observations and the published data could be in the timing of differentiation induction 
and 4E-BP1&2 knockdown.  Whereas, the MEFs were 4E-BP1&2 deficient even before 
differentiation was induced, while in our studies siRNA mediated 4E-BP1&2 gene 
silencing was performed in differentiated 3T3-L1 adipocytes. Detailed analysis is needed 
to thoroughly understand the role of 4E-BP1&2 in the regulation of PPARγ mRNA and 
protein expression. 
An additional area of investigation remaining is the mechanism by which 
MAP4K4 regulates mTOR activity. Akt is the upstream activator of mTOR. Previously 
published data demonstrated that Akt phosphorylation was not regulated by MAP4K4 
[324]. Hence, MAP4K4 could be acting downstream to Akt to regulate mTOR function.  
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Furthermore, published literature shows that TSC1/TSC2 as well as Rheb-mediated 
mTOR regulation results in modulation of both p70S6K1 as well as 4E-BP1 activity. Our 
results show that upon MAP4K4 gene silencing whereas, mTOR-mediated 4E-BP1 
phosphorylation and hence, its inactivation, is functional, p70S6K1 is not stimulated. 
Hence, MAP4k4 is a possible novel regulator of mTOR differential activity towards its 
substrates. Since TNFα stimulation augments MAP4K4 expression and insulin is a potent 
stimulator of mTOR activity, we also want to determine if MAP4K4 regulates mTOR-
mediated expression of PPARγ in response to TNFα and insulin. Conceivably MAP4K4 
may regulate mTOR activity and PPARγ synthesis in obesity and associated insulin 
resistance. By answering these questions, we might achieve better insight into the 
regulation of the insulin-signaling pathway in the adipocytes that is impaired in insulin 
resistance.  
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CHAPTER III: Adipose-Specific Knockdown of MAP4K4 Results in  
Obese Mice with Enhanced Insulin Sensitivity 
 
 
Contributions: All experiments were performed by me except for Figure 3.1, where the 
ShRNA construct was generated by Nana Hagan and Myriam Aouadi. Data for Figures 
3.1 C&D and Figure 3.2 were generated by Myriam Aouadi. Glucose tolerance test 
(GTT) shown in Figure 3.11A was performed by me in collaboration with Myriam 
Aouadi and Greg Tesz. All mouse dissections were performed by me in collaboration 
with Myriam Aouadi, Greg Tesz, Sarah Nicoloro, Mengxi Wang and Matthieu Prot. Data 
shown in Figure (3.4), (3.5), (3.7), (3.8), (3.9 A, B, & C), (3.10), (3.11 B) were 
performed in collaboration with UMass Mouse Phenotyping Center. The transgenic 
animals used for experiments in this chapter were generated by UMass Transgenic Core 
Facility. Tissue sections used for histological studies were generated by DERC 
Morphology Core Facility at UMass. I did all the statistical analysis in this chapter.  
 
 
 
 
 
 
 
 
115 
 
Abstract 
In an RNAi based screen, the Ste20 protein kinase ortholog Map4k4 was 
identified as an inhibitor of PPAR expression and triglyceride accumulation in 3T3-L1 
adipocytes. The effect of Map4k4 on PPAR appears to be mediated through regulation 
of protein synthesis rather than transcription or protein degradation. To investigate the 
role of Map4k4 suppression on adipose tissue function and whole-body metabolism, we 
produced transgenic mice that express an shRNA that attenuates Map4k4 expression 
selectively in adipose tissue (MAP4K4 - KD). The KD mice displayed significantly more 
adipose tissue with enhanced PPAR protein levels than control mice. This increased 
adiposity in the KD mice was not due to changes in energy expenditure, physical activity 
or caloric intake compared to control mice. Importantly, the KD mice exhibited lowered 
fasting glycemia and were insulin sensitive. This could be attributed to the reduced 
hepatic glucose production observed in the KD mice under basal (in both standard diet 
(SD) & high fat diet (HFD)) and hyperinsulinemic clamp (in HFD) conditions. 
Remarkably, adipocytes from the KD mice exhibited striking hypertrophy with increased 
triglyceride storage. Thus, Map4k4 deficiency in adipocyte improves adipose tissue 
function to store triglyceride, with beneficial effects on liver glucose production and 
whole body glucose homeostasis.   
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Introduction 
Obesity, the accumulation of excess body fat, is a medical condition associated 
with insulin resistance, a phenotype of impaired insulin sensitivity in peripheral tissues 
[209]. Adipose tissue is a dynamic metabolic and endocrine organ that regulates energy 
homeostasis [327, 354] which responds to energy demands by storing excess energy as 
triglycerides and releasing free fatty acids and glycerol when needed. Impaired adipose 
lipid storage capacity leads to ectopic lipid deposition in liver and muscle resulting in 
insulin resistance [355, 356], raising the hypothesis that diminished adipose function in 
states of nutritional excess may contribute to insulin resistance. Impaired metabolic 
function is reflected in the deregulated endocrine secretions of the adipose tissue. Obesity 
associated inflammation that is characterized by increased circulating concentrations of 
pro-inflammatory cytokines [357] and enhanced macrophage recruitment to adipose 
tissues [246] also contributes to insulin resistance.   
In both humans and rodents, liver plays an important role in glucose and lipid 
homeostasis [28, 358]. Under fasting conditions, hepatic glucose production provides fuel 
for the brain and red blood cells. Glucose is released by the liver initially from glycogen 
breakdown, a process called glycogenolysis, followed by gluconeogenesis where glucose 
is produced from lactate and pyruvate [359-361]. Additionally, β-oxidation of fatty acids 
provides alternate fuel source for the brain and heart [362]. Upon feeding, insulin 
suppresses glycogenolysis, gluconeogenesis as well as β-oxidation. In states of metabolic 
deregulation, as in obesity-associated insulin resistance, the ability of insulin to inhibit 
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hepatic glucose production is hampered [363]. Several studies have demonstrated that 
increase in circulating concentrations of free fatty acids [364], as well as adipokines 
induce hepatic insulin resistance [365]. 
Adipose tissue is a major source of pro-inflammatory cytokines and lipid 
mediators in the obesity-associated inflammatory state [364-366]. Thiazolidinediones 
(TZDs) are a class of medication used to treat type II diabetes that act by (i) modifying 
adipocyte differentiation, (ii) decreasing levels of leptin, interleukins, [16] lowering 
plasma free fatty acids, (iv) as well as normalizing hepatic insulin resistance. Most of 
these effects are believed to be in part due to TZDs‘ function to act as ligands and 
upregulate peroxisome proliferator-activated receptor-γ (PPARγ) activity. PPARγ, a 
nuclear hormone receptor and a transcription factor, is required for adipogenesis and is 
considered a master regulator of adipocyte function [327-329]. Furthermore, PPARγ 
regulates glucose homeostasis and lipid metabolism in mature adipocytes [330].  
Map4k4, a serine/threonine protein kinase that belongs to a large group of protein 
kinases related to Saccharomyces cerevisiae Ste20, has been identified as a negative 
regulator of PPARγ protein synthesis [367]. Silencing Map4k4 in 3T3-L1 adipocytes 
improved insulin-stimulated glucose uptake and adipogenesis [324]. Remarkably, TNFα 
acutely increases the expression [315], as well as stimulates the activity (unpublished 
data) of Map4k4. Studies using human skeletal muscle explants have shown that TNFα-
induced insulin resistance requires Map4k4 [321]. Furthermore, Map4k4 silencing in 
human and rat primary beta cells prevented the ability of TNFα to inhibit IRS2 as well as 
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glucose stimulated insulin secretion [322]. Interestingly, in murine macrophages it has 
been demonstrated that Map4k4 expression is required for LPS stimulated expression and 
secretion of TNFα and IL-1β [323]. A recent study demonstrated a correlation between 
an increase in Map4k4 expression and decreased differentiation capacity of preadipocytes 
in the obese human subcutaneous adipose tissue [368]. Together, these studies highlight 
the important role played by Map4k4 in different tissues that could potentially mediate 
obesity-induced inflammation and insulin resistance.  However, the role of Map4k4 in 
regulating adipocyte function in vivo is not known.  
To address this in detail, we embarked on studying a mouse model with reduced 
Map4k4 expression in adipocytes. So as to circumvent the embryonic lethality of mice 
lacking Map4k4 [317], and to quickly generate transgenic mice, in the present study we 
utilized pSico lentiviral vector mediated expression of shRNA [369] against Map4k4. 
Here we describe the phenotype of mice that are deficient in Map4k4 specifically in the 
adipose tissue using an aP2 driven Cre-lox based approach.  
Experimental Procedures 
Generation of Plasmids - Oligos coding for the various shRNAs were annealed 
and cloned into HpaI–XhoI-digested pSico. The following MAP4K4 target region was 
chosen: GCTGTCTGGTGAAGAATTA. All constructs were verified by DNA 
sequencing.  
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Cell transfection - 3T3-L1 preadipocytes were maintained in DMEM 10 % FBS 
and 1 % penicillin/streptomycin. Cells were transfected by lipofectamin with 1 ug of 
pSico, MAP4K4-pSico, or MAP4K4-pSico and Cre. Cells were harvested 48 hours after 
transfection. 
Generation of Transgenic Mice - The standard protocol involves the injection of 
DNA into the pronucleus of 129 strain fertilized eggs (0.5-day-post-coital embryos). 
These injected eggs are then implanted into the oviduct of a pseudopregnant foster 
mother. The injected DNA integrates randomly into the genome in a fraction of the 
implanted embryos.  3 positive founders were genotype by PCR and back-cross 7 times 
to C57BL6/J mice. Transgenic mice were bred with C57BL/6J mice carrying an AP2 
promoter driven Cre recombinase expression. (This is a generous gift from Dr. Roger. 
Davis, University of Massachusetts Medical School, Worcester, MA). Mice were bred to 
create the following genotypes: ShRNA-Map4k4 (C), ShRNA-Map4k4-AP2-Cre (KD), 
AP2-Cre (Cre), Wild Type (Wt).  
pSico primers for genotyping:  
5‘-CCCGTATGGCTTTCATTTTCTCC-3‘; 5‘-AAGGAAGGTCCGCTGGATTGAG-3‘ 
Cre primers for genotyping: 
5‘-GAACGCTAGAGCCTGTTTTGCACGTT-3‘  
5‘ GCATTACCGGTCGATGCAACGAGT-3‘ 
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Phenotypic Evaluation of Mice - Mice were housed on a 12h light/dark schedule 
and have free access to water and food. The study period between 8-16 weeks of age 
involved standard chow diet fed male C (n=5), KD (n=7); high fat diet (Harlan-Teklad, 
TD.99249) fed male C (n=6), KD (n=9). Study period between 16-26 weeks of age 
involved, high fat diet (Harlan-Teklad, TD.93075) fed male C (n=4), KD (n=5). Study 
involving 18 month old male mice fed standard chow diet C (n=3), KD (n=5). Body 
weight measurements were done weekly for studies using 8-16 and 16-24 week age mice; 
body weight of 18 month old mice was measured once before sacrificing the animals. 
Body composition and energy balance were assessed using Proton Magnetic Resonance 
Spectroscopy (1H-MRS) (Echo Medical System) and metabolic cages (TSE Systems) 
respectively. Blood samples were obtained by tail-cut method. Whole blood was 
collected and the plasma was isolated for analysis of glucose, insulin, adiponectin, leptin 
and cytokines.  
Glucose Tolerance Test - Intraperitoneal glucose tolerance test was conducted on 
23 weeks old  (after 7 weeks of high fat diet feeding) C and KD mice, as well as at 25 
week old (after 9 weeks of high fat diet feeding) C mice, using 1000 mg/kg D-Glucose in 
water, as previously described [370]. 
Hyperinsulinimic Euglycemic Clamp Study - This study was performed as 
previously described [371]. Briefly, Surgery was performed to cannulate jugular vein at 
~5 days before the clamp experiments. Following overnight fast, a 2-hr 
hyperinsulinemic-euglycemic clamp was perfomed in conscious mice with primed-
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continuous infusion of human insulin (2.5 mU/kg/min) and a variable infusion of 20% 
glucose to maintain euglycemia. 3H-gluocose was infused during the clamp to measure 
glucose turnover, and 14C-2-deoxyglucose was bolus injected at 75 min of clamp to 
measure glucose uptake in individual organs. Tissues were taken at the end of clamps for 
biochemical and molecular analysis. 
Assays of plasma or tissue - Plasma glucose concentration was measured with 
Accu-check active Insulin, leptin and adiponectin were measured using Luminex. 
Tissue triglycerides were extracted as previously described previously [372] and 
triglyceride content determined using Triglyceride Determination Kit (Sigma TR0100).  
Preadipocyte Isolation - Preadipocytes from adult tissue were isolated from sub-
cutaneous fat pads and maintained in DMEM 10 % FBS and 1 % penicillin/streptomycin. 
Two days post-confluent cells were treated 48h with the adipocyte differentiation cocktail 
containing 5µg/ml insulin, 0.25µM dexamethasone and 0.5mM 3-isobutyl-1-
methylxanthine (IBMX). The medium was then replaced for 6 days by DMEM 10 % FBS 
and 1 % penicillin/streptomycin. 
Histology - Adipose tissue samples were obtained at the end of the study period 
from all groups of mice. Samples were fixed in 10% neutral buffered formalin and 
embedded in paraffin. Sections were cut and subsequently stained using H&E according 
to standard protocol.  Liver tissue samples were obtained at the end of the study period 
from all groups of animals. Samples were fixed in OCT, on dry ice. Sections were cut 
and subsequently stained using H&E according to standard protocol. Histology sections 
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and staining were done by Pathology Department, University of Massachusetts Medical 
School, Worcester, MA. 
Western Blot Analysis - Tissues samples were homogenized in RIPA buffer 
(composition). Western blot analysis was used to assess protein levels of PPARγ, actin, 
tubulin; protein and phosphorylation levels of Akt. Preadipocytes that were differentiated 
in culture were homogenized in HEPES buffer. Intensity of the bands on the 
immunoblots was plotted as graphs, expressed in terms of arbitrary densitometry units.  
Quantitavie RT-PCR - RNA isolation was performed according to the Trizol 
Reagent Protocol from (Invitrogen, Carlsbad CA). The cDNA was synthesized from 1 µg 
of total RNA using iScript cDNA Synthesis Kit according to the manufacturer‘s 
instructions from (Bio-Rad, Hercules CA).  For real time PCR, synthesized cDNA 
forward and reverse primers along with the iQ SYBR Green Supermix (Bio-Rad, 
Hercules CA) were run on the MyIQ Realtime PCR System (Bio-Rad). The ribosomal 
mRNA, 36B4 was used as an internal loading control. 
Northern Blot Analysis - For the small RNA Northern blotting, 15 μg of total 
RNA was isolated with TRIzol (Invitrogen) according to the manufacturer's instructions, 
and was resolved on a 15% denaturing polyacrylamide gel, transferred to a nylon 
membrane, and was cross linked. The membrane was hybridized overnight to a 32P 5′-
labeled DNA probe corresponding to the sense strand of the MAP4K4 shRNA 
(GCTGTCTGGTGAAGAATTA). Hybridization and washes were performed at 42°C. 
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Calculations and statistical analyses - The characteristics of the outcomes were 
evaluated by visual inspection of histograms generated using GrapPad Prism 5 or 
Microsoft EXCEL, and the observed effects were evaluated by either student ttest or 
multifactorial analysis of variance [79]. The data are presented as the means  S.E. 
Results 
Generation and Validation of Adipose-Specific Map4k4 Knockdown Mice. 
shRNA-pSico vector construct - The U6 promoter has been widely used to drive the 
expression of shRNAs and a U6-based lentiviral vector for the generation of transgenic 
mice has been recently described [369]. To create a conditional U6 promoter, a 
cytomegalovirus (CMV)-enhanced GFP stop/reporter cassette was inserted between two 
loxP sites so that after Cre-mediated recombination the cassette would be excised, 
generating a functional U6 promoter (Fig. 3.1A). Importantly, the CMV-GFP cassette 
marks transfected cells and loss of GFP expression indicates successful Cre-mediated 
recombination. The ability of pSico vector to conditionally silence endogenous genes was 
demonstrated by insertion of a hairpin designed to inhibit expression of MAP4K4 (Fig. 
3.1B). The resulting plasmid was named pSico-MAP4K4. The construct was then tested 
in 3T3-L1 preadipocytes. The empty vector was used as a control (Mock). High-
efficiency transduction by these vectors was achieved as indicated by GFP expression in 
MAP4K4-pSico transfected cells. As shown in Fig. 3.1C, after transfection with a Cre-
expressing plasmid, recombination with concomitant loss of GFP fluorescence was 
observed for the pSico-MAP4K4 vector. Consistent with the decrease in GFP expression, 
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Cre-mediated recombination resulted in a reduction of MAP4K4 expression in cells 
transfected with MAP4K4-pSico and Cre compared to the control cells transfected only 
with MAP4K4-pSico (Fig. 3.1D).  
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FIGURE 3.1. Generation of shRNA and gene silencing of MAP4K4 in 3T3-L1 cells. 
(A) Schematic representation of pSico before and after Cre-mediated recombination. (B) 
Nucleotide sequence of MAP4K4 shRNA. (C) 3T3-L1 preadipocytes were transfected 
with the empty pSico plasmid (Mock), MAP4K4-shRNA containing pSico (MAP4K4-
pSico) or MAP4K4-pSico and a Cre expressing plasmid. Cells were analyzed by 
fluorescence microscopy to detect GFP. Similar cell density and identical exposure time 
was used for all images. (D) Real-time PCR showing MAP4K4 knock-down in cells co-
transfected with MAP4K4-pSico and a Cre expressing plasmid. 
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Conditional RNAi in Mice - One motivation for using a conditional U6 cassette 
into a lentiviral vector was to rapidly generate conditional knock-down mice. To avoid 
any side effects of the GFP expression in mice, only a small DNA fragment missing the 
LTRs and the 3‘ UTR polyA tail necessary for GFP expression was injected in the eggs. 
The DNA fragment was injected in eggs at 1 cell stage that were then injected into 
pseudo-pregnant females at 2 cell stage. The genomic DNA was extracted from the 
obtained mice and subjected to PCR for genotyping. The mice were apparently normal 
and fertile, indicating that the presence of the nonexpressing pSico-MAP4K4 shRNA 
before Cre activation did not affect MAP4K4 expression and was compatible with normal 
mouse development. To achieve tissue-specific activation of the MAP4K4 shRNA, 
MAP4K4-pSico mice (C mice) were crossed to aP2-Cre transgenic mice that express Cre 
under the control of aP2 promoter, which is specifically expressed in the adipose tissue. 
Genotyping of the offspring was done by PCR for the detection of the transgene 
(MAP4K4-pSico) and the Cre (Fig. 3.2 A). To detect MAP4K4 siRNA expression, a 
northern-blot was performed on RNA extracted from white adipose tissue (WAT) and a 
control tissue, muscle. MAP4K4-siRNAs were detected in WAT from MAP4K4-
pSico/Cre (KD mice), whereas no MAP4K4-siRNA was observed in WAT from C mice 
in the absence of Cre expression, confirming the complete suppression of U6 promoter 
activity by the loxP-CMV-EGFP-loxP cassette (Fig. 3.2 B). Furthermore, no MAP4K4 
siRNA was detected in muscle from both KD and C mice, confirming that MAP4K4 
shRNA was specifically expressed in adipose tissue. Consistent with functional 
MAP4K4-siRNA expression by the MAP4K4-pSico vector, Cre-mediated recombination 
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resulted in a significant reduction of MAP4K4 mRNA in WAT of KD mice.  MAP4K4 
expression was also measured in in brown adipose tissue (BAT), liver and muscle. As 
expected, MAP4K4 expression was reduced in BAT, whereas no difference was observed 
in liver or muscle (Fig. 3.2 C). Although the aP2-Cre transgenic mice used in our studies 
express Cre recombinase specifically in the adipocyte, since macrophages also express 
aP2, we sought to confirm the specificity of Cre recombinase expression.  We measured 
the expression of MAP4K4 in macrophages isolated from the adipose tissue as well as 
from PECs. As expected, MAP4K4 expression did not change in the KD mice as 
compared to the control animals, both in the adipose derived macrophages as well as in 
the PECs (Fig 3.3 A & B). These results establish that MAP4K4 was specifically silenced 
in adipose tissue of KD mice. 
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FIGURE 3.2. Conditional knockdown of MAP4K4 in transgenic mice. (A) PCR 
detection of Cre recombinase and MAP4K4-pSico in genomic DNA extracted from the 
tail of mice derived from a cross between MAP4K4-pSico and aP2-Cre mice. (B) 
Northern blot analysis using RNA extracted from white adipose tissue (WAT) and 
muscle from the indicated genotype. (C) Knock-down of MAP4K4 in the WAT and 
BAT. Knockdown,‗KD‘, compared to control ‗C‘ mice. (n=4). *p<0.05 by Student‘s t-
test analysis.  
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FIGURE 3.3. Specificity of Map4k4 gene silencing. Map4k4 mRNA levels were 
measured by real time qPCR in (A) Macrophages isolated from adipose tissue and (B) 
PECs. 
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Map4k4 Deficiency in Adipose Tissue Enhances Adiposity - As a first analysis of 
the effect of adipose-specific Map4k4 gene silencing, we monitored the body weight of 
KD and control littermates over 8 weeks between 8-16 weeks of age. On a standard chow 
diet, there was no significant difference in the total body weight between KD and control 
animals (Fig. 3.4 A). To further analyze the body composition of KD mice, fat mass was 
examined.  Even though there was no difference in the total body weight at 16 weeks of 
age, KD animals exhibited an increase in fat mass on a standard chow diet feeding that 
was measured using proton magnetic resonance spectroscopy (Fig. 3.4 B). The observed 
increase in fat mass was not due to increased food intake or decreased physical activity 
(Fig. 3.5 A & B).  
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FIGURE 3.4. MAP4K4 silencing in adipose tissue enhances adiposity. (A) Body 
weight of 16 week old male mice (n=5-7). (B) Increase in fat mass in 16 week old male 
mice fed with standard diet (n=5-7).  *p<0.05 by Student‘s t-test analysis. 
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Contribution of Brown Adipose Tissue to the Map4k4 Knockdown Phenotype - 
We have observed a significant decrease in the expression of Map4k4 in the BAT as 
shown in Fig. 3.2C, and an increase in total fat mass as shown in Fig 3.3B. Since brown 
adipose tissue is a major tissue responsible for thermogenesis and energy expenditure in 
mice, one hypothesis for the increase in adiposity by MAP4K4 silencing could be a 
decrease in energy expenditure. Therefore, we compared energy expenditure, oxygen 
consumption and carbon dioxide release in the 16 week old KD and control littermates. 
We observed no differences in any of these parameters (Fig. 3.5 C, D & E). This result 
suggested that MAP4K4 might not play a role in regulation of energy expenditure in the 
young adipose-specific Map4k4 knockdown animals. 
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FIGURE 3.5. Metabolic Parameters. (A) Food intake (B) Physical Activity (C) Energy 
expenditure (D) Oxygen consumption and (E) Carbon dioxide production were measured 
in 16 week old KD and C mice fed a standard diet. 
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Map4k4 Knockdown in the Adipose Tissue Enhances PPARγ Protein Expression - 
Our previously published data showed that Map4k4 gene silencing enhances PPARγ 
protein levels in 3T3-L1 adipocytes, by a translational mechanism [324, 367]. To 
investigate if KD animals exhibit a similar increase in PPARγ protein levels, 
subcutaneous stromal vascular fraction-derived preadipocytes were cultured to mature 
adipocytes and PPARγ protein as well as mRNA levels were measured. As expected, 
PPARγ-1 as well as PPARγ-2 protein levels were significantly increased in the KD mice 
as compared to the control animals (Fig. 3.6 A), without any change in the mRNA 
expression (Fig. 3.6 B). Immunoblot analysis of lysates from the whole adipose tissue 
revealed a similar increase in the PPARγ protein levels in the KD mice (Fig. 3.6 C). 
These results suggest that the increase in fat mass in the KD animals could be due to 
increased PPARγ protein levels.  
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FIGURE 3.6. MAP4K4 regulates PPAR synthesis in adipocytes. Adult preadipocytes 
from subcutaneous adipose tissue were differentiated into adipocyte. PPAR mRNA 
levels were determined by (A) real time PCR, normalized to 36B4. (B) Representative 
immunoblot of PPAR in adipocytes, each lane represents an individual mouse. This 
experiment was performed with cells from 3-6 different mice and is expressed +/- s.e.m. 
(C) Densitometry mean PPARγ values as compared to actin +/- s.e.m. of westernblot. (D) 
Representative immunoblot of PPARγ in mouse subcutaneous adipose tissue, each lane 
represents individual mouse. (E) Densitometry mean PPARγ values as compared to 
tubulin +/- s.e.m. of westernblot. *p<0.05 by Student‘s t-test analysis. 
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Adipose Specific Map4k4 Gene Silencing Regulates Whole body Insulin 
Sensitivity - Increase in fat mass is usually associated with deregulated insulin sensitivity.  
To examine the consequences of enhanced adiposity in the KD animals, as a first test, 
basal serum glucose level was examined. Despite an increase in the fat mass, KD mice 
exhibited a significant decrease in basal glycemia (Fig. 3.7 A), indicating improved 
glucose metabolism. Liver plays a major role in maintaining constant serum glucose 
levels. Indeed, hepatic glucose production was found to be significantly decreased in the 
KD animals (Fig. 3.7 B). Additionally, whole body glycolysis was elevated in the adipose 
specific MAP4K4 knockdown animals (Fig. 3.7 C), showing that the animals have 
improved peripheral insulin sensitivity.  Thus, indicating that selective silencing of 
Map4k4 in the adipocytes leads to enhanced whole body basal metabolic parameters.  
To further access insulin sensitivity of the KD mice, hyperinsulinemic euglycemic 
clamp studies were performed.  Glucose infusion rate, glucose turnover and glycogen 
synthesis was not altered in the KD animals (Fig. 3.8 A, B & C). The liver responded 
maximally to insulin and hence there was no difference in the clamp hepatic glucose 
production and hepatic insulin action in the KD animals as compared to the control mice 
(data not shown).  
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FIGURE 3.7. MAP4K4 knock-down mice exhibit enhanced whole body insulin 
sensitivity. (A) Basal plasma glucose level of standard diet fed 16 week old mice (n=5-
7). (B) Basal hepatic glucose output (C) whole body glycolysis. *p<0.05 by Student‘s t-
test analysis. 
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FIGURE 3.8. Glucose metabolism in SD fed condition. Graphical representation of (A) 
GIR (glucose infusion rate) (B) Glucose turnover and (C) Glycogen synthesis measured 
during hyperinsulinimic euglycemic clamp Study in 16 week old KD and C animals. 
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Enhanced Adiposity with Decreased Lean Mass in the Adipose Specific Map4k4 
Knockdown Animals upon High Fat Feeding - Since the adipose-specific Map4k4 
knockdown animals exhibited enhanced basal metabolic parameters and normal insulin 
sensitivity despite increased fat mass, we challenged these animals with high fat diet to 
examine if they retain insulin sensitivity upon diet-induced obesity. When challenged 
with a high fat diet (HFD) during 8-16 weeks of age, KD mice did not show any 
significant change in total body weight (Fig. 3.9 A), but there was a trend toward 
increased fat mass (Fig. 3.9 B). Additionally, KD animals had a significant decrease in 
lean mass (Fig. 3.9 C). However, during 16-24 weeks of age, upon high fat feeding, KD 
animals gained weight more rapidly than the control animals and this increase in weight 
reached statistical significance as early as 3 weeks of HFD.  After 8 weeks of HFD, the 
increase in fat mass in the 24 week old KD animals is reflected in the gained body weight 
that was 60% of their starting weight (Fig. 3.9 D). This increase in total body weight is 
partly due to  a significant increase in the weight of subcutaneous WAT (Fig. 3.9 E), with 
no change in the weight of epididymal WAT or BAT (Fig. 3.9  F & G).  
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FIGURE 3.9. MAP4K4 silencing in adipose tissue increases high fat diet induced 
obesity. (A) Body weight of male mice at 16 weeks of age after 8 weeks of high fat diet 
(n=6-9). (B) Fat mass and (C) lean mass measured using 1H-Magnetic Resonance 
Spectroscopy. (D) Development of obesity in male mice at 24 weeks of age after 8 weeks 
of high-fat diet (n=4-5).  (E) Subcutaneous (F) epididymal and (G) brown fat pad 
absolute weights (n=4-5). *p<0.001, #p<0.02, ¥p<0.05, ǂp=0.065 by Student‘s t-test 
analysis. 
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Map4k4 Deficient Adipose Tissue Regulates Hepatic Insulin Sensitivity - Map4k4 
knockdown animals in the HFD fed condition exhibited a trend towards decreased serum 
glucose level, a primary indicator of insulin sensitivity (Fig. 3.10 A). To further 
investigate the effect of DIO on glucose tolerance, a GTT was performed. Although the 
KD mice were significantly obese, this did not worsen their glucose clearance capacity as 
compared to the control littermates (data not shown). In fact, the KD animals were more 
glucose tolerant than the control animals when matched for weight (Fig. 3.11 A). 
Although glucose tolerance directly correlates to insulin sensitivity, small changes 
contributed by individual metabolic organs cannot be measured. To examine in detail the 
effect of high fat diet on individual metabolic tissues, a hyperinsulinemic euglycemic 
clamp study was performed. When weight matched, KD animals exhibited enhanced 
glucose tolerance as compared to control mice, and as the body weight of the 16 week old 
KD and control animals on HFD fed condition was comparable, the clamp study was 
performed in the 16 week old animals. Whole body glycolysis, glucose infusion rate and 
hepatic insulin action did not change in the KD animals (Fig. 3.10 B, C & D). Even 
though these results might suggest that the KD animals and the control animals could be 
equally insulin resistant, the KD mice exhibited a trend towards decreased basal liver 
glucose output. Strikingly, insulin stimulated hepatic glucose production was 
significantly decreased in the KD mice at the same degree of obesity as the control 
littermates. Whereas the control animals exhibited only a 40% decrease, the KD animals 
exhibited a 57% reduction in insulin stimulated hepatic glucose output (Fig. 3.11 B). 
Finally, the KD animals exhibited an increase in Akt phosphorylation (Thr308) in the 
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liver during the clamp analysis (Fig. 3.11 C), indicating enhanced insulin signaling. 
These results together show that adipose specific Map4k4 gene silencing protects from 
high fat diet induced insulin resistance that is due to improved hepatic insulin sensitivity.   
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FIGURE 3.10. Graphical representation of Metabolic Parameters. (A) Basal 
glycemia (fed). (B) Whole body glycolysis, (C) glucose infusion rate and (D) hepatic 
insulin action measured during hyperinsulinimic euglycemic clamp study in 16 week old 
KD and C animals at the end of 8 week of HFD feeding. 
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FIGURE 3.11. MAP4K4 deficiency in adipose tissue causes increased hepatic insulin 
sensitivity. (A) Glucose Tolerance tests (GTT) were performed after injection of 1g/kg of 
glucose in overnight fasted, weight-matched mice fed a high-fat diet  from the age of 16 
weeks for 8 weeks (KD mice) for 10 weeks (C mice) (n=4-5). (B) Basal hepatic glucose 
production (HGP) and insulin stimulated HGP during clamp in male mice fed a high-fat 
diet from 8 weeks of age for 8 weeks. (C) Representative immunoblot of P-Akt (Thr308), 
total Akt and tubulin in the liver, after the clamp study. **p<0.001,*p<0.01, #p=0.05 by 
Student‘s t-test analysis. 
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Role of Adipose Cell Size in the KD Mouse Phenotype - Adipose-specific Map4k4 
gene silencing resulted in an increase in fat mass in the KD animals in the SD fed 
condition. However, at the same degree of obesity in a HFD fed condition, the KD mice 
exhibited an improved whole body metabolism and glucose homeostasis as a result of 
enhanced hepatic insulin signaling. To look more closely into the role played by Map4k4 
silenced adipose tissue, in regulating liver function, adipocyte morphology was examined 
in the KD animals. Notably, adipocyte cell size was found to be significantly increased in 
the KD animals as compared to the control animals; however this was only in the 
subcutaneous adipose tissue and not in the epididymal adipose tissue (Fig. 3.12 A), as 
measured from the adipose tissue histological sections. This correlates with the 
differential degree of MAP4K4 knockdown observed in these two adipose depots (Fig. 
3.12 B). This effect on adipocyte size is supported by our recent publication [367] where, 
an increase in cell size of 3T3-L1 adipocytes, upon siRNA mediated Map4k4 gene 
silencing was noted. Sherman and colleagues [373] have concluded from their recent 
studies using human obese subjects that, small cell size of subcutaneous adipocytes 
represents immature cells that have impaired triglyceride storage capacity. Extrapolating 
this to our observation of increase in adipocyte cell size in the subcutaneous adipose 
tissue of Map4k4 knockdown animals could suggest that, these larger adipocytes have a 
better lipid storage capacity.  
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FIGURE 3.12. MAP4K4 knockdown results in adipocyte hypertrophy. (A) Graphical 
representation of adipocyte cell size represented as cell area measured using ImageJ 
program from histological sections of epididymal and subcutaneous adipose tissue from 8 
week old male mice fed a high-fat diet for 8 weeks. (B) Map4k4 knockdown in 
epididymal and subcutaneous WAT.  (n=6). **p<0.0001 by Student‘s t-test analysis. 
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To address this, total triglyceride content of adipose tissue was measured. As 
expected, triglyceride levels were enhanced in the KD animals (Fig. 3.13 A). This is 
consistent with the previously published data from our lab where, in 3T3-L1 adipocytes, 
in an siRNA mediated Map4k4 gene silencing condition, increase in triglyceride content 
was observed [324].  
 
 
FIGURE 3.13. Adipose tissue and liver triglyceride content. Total tissue lipid was 
extracted and triglyceride content measured by calorimetric analysis in (A) white adipose 
tissue and (B) liver, in male mice fed on high fat diet for 8 weeks starting at 8 weeks of 
age (n=6). (C) Representative histological sections of liver stained with hematoxylin and 
eosin.  
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Since, Map4k4 gene silencing in the adipose tissue regulates hepatic insulin 
sensitivity, additionally, KD animals exhibited an increase in adipocyte cell size that was 
accompanied by an increase in the TG content, it is logical to see if these changes would 
result in decreased ectopic lipid deposition in the KD mice, particularly in the liver in the 
high fat fed condition.  Surprisingly, KD animals and the control mice had a similar 
degree of hepatic lipid deposition as visualized by liver histology sections, as well as 
similar TG content in the liver (Fig. 3.13 B & C). These results show that, even with a 
similar degree of hepatic lipid deposition in the high fat fed condition, adipose tissue 
specific Map4k4 gene silencing protects the animal from high fat diet induced insulin 
resistance. 
Discussion 
Here, we described the generation and phenotypic characterization of conditional 
Map4k4 knockdown mice. Knockdown of Map4k4 specifically in adipose tissue (KD) 
results in mice that have enhanced fat mass. KD mice also exhibit an overall better 
metabolic profile than control mice including enhanced glucose tolerance and improved 
hepatic insulin sensitivity was due to an increase in hepatic insulin signaling, despite diet-
induced obesity. Furthermore, we present evidence that the increase in fat mass is a 
consequence of improved adipose lipid storage capacity as reflected by an increase in cell 
size and elevated levels of adipose tissue triglyceride content. These results suggest that 
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Map4k4 in adipose tissue plays an important role in the control of both adipose 
metabolism as well as whole-body glucose homeostasis. 
Similar to adipose-specific Map4k4 knockdown, whole-body knockout of 
collagen VI, results in mice that are obese due to expansion of individual adipocytes and 
is associated with significant improvements in whole body glucose homeostasis [374]. 
Furthermore, the authors demonstrated that treatment with a PPARγ agonist reduced the 
expression levels of a majority of collagens in adipose tissue. Additionally, Xu and 
coworkers [375] have shown that PPARγ interacts with CIITA-RFX5 complex to repress 
type I collagen gene expression. Although the effect of adipose-specific Map4k4 
knockdown on collagen expression needs to be determined, the above mentioned 
observations raise the possibility that collagen expression could be down-regulated in the 
Map4k4 deficient adipose tissue through a PPARγ-dependent mechanism, thus resulting 
in adipocyte hypertrophy.  
Adipose-specific PPARγ knockout mice exhibited elevated levels of plasma FFAs 
and TG as well as decreased levels of leptin and adiponectin, accompanied by increased 
hepatic glucogenesis and insulin resistance . Additionally, PPARγ2 in the adipose has 
been shown to prevent lipotoxicity by promoting adipose tissue expansion in conditions 
of excess nutritional availability [376]. Furthermore, PPARγ activation in adipocytes was 
shown to be sufficient for systemic insulin sensitization [377]. Most of our observations 
in the KD animals are consistent with these studies of a PPARγ centric regulation of 
adipose tissue function as well as whole body glucose homeostasis. However, contrary to 
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the observations made in the above mentioned studies, KD mice exhibited (i) a decrease 
in basal hepatic glucose production, (ii) adipocyte hypertrophy, [16] and no change in 
plasma levels of insulin and leptin (Fig. 3.14 A & B), as compared to the control animals. 
PPARγ also regulates the expression of adiponectin. To this end, adiponectin transgenic 
mice exhibited morbid obesity, accompanied by reduced triglyceride levels in the liver, 
leading to improved insulin sensitivity [378]; on the contrary, KD animals had similar 
levels of TG in the liver and did not show any change in the circulating levels of 
adiponectin (Fig. 3.14 C). However, eventhough, PPARγ is essential to maintain normal 
adipose function and whole body insulin sensitivity, the elevated PPARγ protein levels 
observed in the adipose specific Map4k4 knockdown animals might not be sufficient to 
explain the observed whole body phenotype.  
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FIGURE 3.14. Circulating hormone levels. Graphical representation of (A) Insulin (B) 
Leptin and (C) Adiponectin concentration in the plasma of SD and HFD (8 weeks) fed 16 
week old KD and C mice.  
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The mechanism by which Map4k4 knockdown in the adipose tissue regulates 
liver insulin sensitivity remains to be elucidated. Li et al. [379] demonstrated that both 
lipogenesis and gluconeogenesis depend on the insulin receptor-PI3K-Akt axis for their 
regulation. Brown and coworkers [380] have demonstrated that in obesity-induced 
hepatic insulin resistance, while the ability of insulin to stimulate lipogenesis is sustained, 
insulin‘s ability to inhibit gluconeogenesis is impaired. Interestingly, the HFD fed KD 
animals display decreased hepatic glucose output, which is a reflection of diminished 
gluconeogenesis. However, they display a similar degree of liver TG content, indicating 
stimulation of lipogenesis as a result of InsR-PI3K-Akt axis activation that supports a 
normal, insulin-sensitive liver function. This is confirmed by the observed increase in Akt 
phosphorylation in the KD mouse liver during the clamp study.  
The increase in fat mass observed in obese conditions is correlated with chronic 
systemic inflammation [246, 381] that is characterized by the increased production of 
cytokines including TNFα, IL-1, IL-6 and resistin [382]. Loss of IL-6 has been shown to 
improve hepatic insulin action in obese mice [383]. Additionally, IL-1β induced insulin 
resistance in HepG2 and in primary rat hepatocytes [384]. However, though LPS-induced 
TNFα and IL-1β production was shown to be inhibited upon Map4k4 silencing in 
macrophages [323], plasma levels of these cytokines did not change in the KD mice fed a 
HFD. Remarkably, IL-1α and IL-6 plasma concentrations were significantly diminished 
in the KD animals (Fig. 3.15). Therefore, improved hepatic insulin sensitivity in the KD 
animals could be as a result of decreased levels of IL-1α and IL-6. IL-6 is synthesized 
and secreted by adipocytes [385, 386], however, it is not known whether adipocytes 
154 
 
secrete IL-1α, however, BAT is known to be a source of IL-1α [387]. Furthermore, 
macrophages do secrete both IL-6 and IL-1α. Moreover, altering the activation state of 
adipose resident macrophages has been show to change not only the inflammatory status 
of the adipose tissue, but also alter the serum cytokine profile [388]. However, changes in 
IL-1α and IL-6 were observed only in the 16-24 week but not in the 8-16 week study 
period. Therefore, a more detailed analysis is needed to determine the role of 
inflammatory cytokines in the regulation of liver function, in the KD mice. 
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FIGURE 3.15. Graphical representation of plasma cytokine levels. Serum levels of 
cytokines in KD and C animals fed on HFD for 8 weeks starting at 16 weeks of age. 
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Enhanced adipose tissue inflammation that results in deregulated metabolic 
functions is a consequence of chronic stimulation of adipose tissue macrophages (ATMs). 
Increased macrophage recruitment to adipose is observed in obesity (39, 40), as a 
response to enhanced basal lipolysis [254]. Although the increase in fat mass was not 
outwardly visible in younger KD animals, there was visible obesity as the animals aged 
(Fig. 3.16 A) that resulted in a significant increase of total body weight (Fig. 3.16 B). 
This contributed to an increase in the weight of all the fat depots examined epididymal, 
subcutaneous (auxiliary & inguinal) as well as brown adipose tissue (Fig. 3.16 C, D & E). 
Additionally, adipocyte cell size was observed to be enhanced in the 18 month old KD 
mice Supplementary Fig. 3.16 F). Furthermore, fasting glycemia was comparable in the 
KD and control animals (Fig. 3.16 G) suggesting insulin sensitivity despite obesity. In the 
overnight fasted 18 month old KD mice, ATGL protein levels as well as P-HSL levels 
were significantly reduced (Fig. 3.16 H), indicating a decrease in basal lipolysis. 
Furthermore, the number of macrophages in the adipose tissue of the KD mice was lower, 
suggesting diminished recruitment of ATMs (Fig. 3.16 I). However, the macrophage 
number did not differ in the younger animals fed a HFD (data not shown), suggesting a 
nutritional status-dependent differential regulation of macrophage recruitment. One may 
hypothesize that adipose tissue-specific Map4k4 knockdown provides a 
microenvironment that is conducive to alternate activation of ATMs; the data showing a 
decrease in serum levels of IL-1α and IL-6 along with no change in the adipose tissue 
macrophage content in the KD mice on HFD fed condition supports this hypothesis.  
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FIGURE 3.16. Enhanced Adiposity in 18 month old mice. (A) Representative picture 
depicting visible obesity in 18 month old male KD mice fed a standard diet. (B) Body 
weight (C) epididymal  (D) subcutaneous and (E) brown adipose tissue fat pad absolute 
weights. (F) Epididymal and subcutaneous adipocyte cell area (G) Basal glycemia 
(fasting) (H) Immunoblot showing ATGL, P-HSL protein levels in Epididymal adipose 
tissue lysates. GAPDH is the loading control (I) Representative pictures of epididymal 
and subcutaneous adipose tissue sections stained for macrophage cell surface protein 
F4/80, detected using Immunofluorescence microscopy with Alexafluor-647. Arrows 
show macrophages forming crown like structures. (n=3-5). **p=0.01, *p<0.05 by 
Student‘s t-test analysis. 
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To summarize (Fig. 3.17), inhibition of Map4k4 expression in the adipose tissue 
results in enhanced adiposity leading to improved lipid storage capacity that could be in 
part due to an increase in PPARγ protein levels. Therefore, altering adipocyte fat 
sequestration & synthesis potential, as well as PPARγ function, could favor an alternately 
activated inflammatory state of the adipose tissue. Thus, the changed adipose tissue 
environment augments insulin sensitivity in the liver, which modulates whole body 
glucose homeostasis. 
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FIGURE 3.17. Map4k4 in the adipose regulates liver insulin sensitivity. Silencing 
Map4k4 in the adipose tissue results in adipocyte hypertrophy leading to enhanced lipid 
storage capacity. This possibly leads to a change in the adipose tissue milieu, resulting in 
a decreased synthesis and secretion of pro-inflammatory cytokines by the adipocytes 
and/or macrophages. This altered adipose tissue function leads to an increase in hepatic 
insulin sensitivity, thus regulating whole body metabolism. 
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Briefly, we have shown that shRNA mediated gene silencing using the pSico 
lenti-viral system is a quick and efficient way of generating knockdown mouse models. 
Furthermore, the adipose-specific Map4k4 knockdown animal has proven to be a good 
model system to study the role of Map4k4 in regulation of adipose tissue function. 
Although much work needs to be done to completely understand the intriguing phenotype 
presented by the adipose-specific Map4k4 knockdown animals, it may be concluded that, 
silencing Map4k4 in the adipocytes results in an insulin-sensitive obese state. 
Limitations and Future Perspectives 
The results presented in this chapter are intriguing; however several questions 
remain to be addressed to completely understand the role of MAP4K4 in regulation of 
adipose function that in turn modulates the whole body metabolic function. First, studies 
are required to determine the molecular link between adipose tissue and the liver in the 
adipose-specific MAP4K4 knockdown animals based on the observed suppression of 
hepatic glucose output. Although silencing a gene in the adipose tissue that results in 
decreased hepatic glucose production has been previously observed in adipose-specific 
JNK1 knockout animals; the observation of improved hepatic insulin sensitivity 
accompanied by diminished glucose output despite enhanced adiposity in the adipose-
specific MAP4K4 knockdown condition, is novel. Additionally, the observed decrease in 
plasma levels of IL-1α in the KD mice (Figure 3.15) is very interesting. Furthermore, 
Vaartjes and coworkers demonstrated that IL-1α could acutely promote hepatic glucose 
release, in freshly isolated rat hepatocytes [389]. Therefore, I hypothesize that adipose-
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specific MAP4K4 regulates hepatic glucose production through regulation of IL-1α. The 
decrease in the plasma levels of IL-1alpha observed in the KD animals could be due to 
disruption of IL-1α gene due to MAP4K4 transgene integration. However, this might not 
be the case since the control animals also have the MAP4K4 transgene integrated into 
their genome although they do not express the shRNA.  
It is very alluring to speculate that MAP4K4 in the adipose tissue could plausibly be 
regulating the secretion of IL-1α by two mechanisms, as summarized in Figure 3.18. 
Adipocytes themselves could be synthesizing and secreting IL-1α, although it is not 
known if white adipocytes secrete this cytokine. Alternately, MAP4K4 in the adipocytes 
could be regulating the synthesis and secretion of an unknown protein/factor-X that in 
turn regulates the expression and secretion of IL-1α by the endothelial cells, since 
endothelial cells are known to secrete this pro-inflammatory cytokine. Preliminary 
studies involving siRNA mediated MAP4K4 gene silencing in the adipocytes, as well as 
co-culture of 3T3-L1 adipocytes with endothelial cells to study changes in the IL-1α 
secretion into the culture media could provide insight into the tissue specific contribution 
of the cytokine.  
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FIGURE 3.18. Hypothetical model for Map4k4 mediated IL-1α regulation. 
Mechanism (1) Map4k4 regulates adipocyte expression (mRNA and/or protein) of IL-1α. 
Mechanism (2) Map4k4 in the adipocytes regulates the expression of an unknown factor 
X. Factor X secreted by the adipocytes regulates the synthesis and secretion of IL-1α by 
the endothelial cells. Thus released IL-1α from the adipose tissue stimulates hepatic 
gluconeogenesis resulting in elevated plasma glucose levels. 
 
 
 
 
 
164 
 
Second, experiments are required to address if the mTOR signaling pathway 
similarly regulates PPARγ expression in the adipose tissue of the KD animals, as was 
observed in the cell culture studies in Chapter II. MAP4K4 knockdown in 3T3-L1 
aidpocytes resulted in an increase in PPARγ protein levels. Consistent with this, an 
increase in PPARγ protein levels was observed in the KD animals.  Additionally, 
adipocyte cell size was significantly enhanced in the MAP4K4 knockdown condition in 
the cell culture system; similar observation of enhanced adipocyte cell size was made in 
the KD mice.  Together these observations provide strong evidence of a role for mTOR in 
regulation of adipocyte size and PPARγ protein expression, in the context of MAP4K4 
knockdown. The increase in PPARγ protein levels is due to enhanced mTOR activity 
towards 4E-BP1 but not p70S6K1. Studies directed towards addressing the differential 
regulation of p70S6K1 and 4E-BP1 in the adipocytes of adipose-specific MAP4K4 
knockdown animals is needed. The increase in adipocyte cell size as well as enhanced 
triglyceride content in the KD mice could possibly be due to elevated mTOR activity 
towards 4E-BP1 but not p70S6K1 as summarized in Figure 3.19. Since p70S6K1 has 
been demonstrated in the literature to be a negative regulator of IRS and hence insulin 
signaling, it can be hypothesized that, in the absence of MAP4K4, elevated mTORC1 
activity results in differential regulation of mTORC1 downstream substrates providing 
conditions for constitutive activation of insulin signaling pathway towards mTORC1 to 
regulate PPARγ, adipocyte cell size as well as lipogenesis, in the adipose-specific 
MAP4K4 knockdown animals. It would be interesting to see whether these properties of 
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adipocytes in the KD animals are inhibited upon rapamycin treatment thus providing 
evidence for role of mTORC1 in MAP4K4 cellular functions.  
 
 
FIGURE 3.19. Map4k4 regulates p70S6K1. Map4k4 in adipocytes plays an important 
role in inducing insulin resistance by promoting mTORC1 activity towards S6K1 and 
thus resulting in the activation of the feedback inhibition of IRS. Silencing Map4k4 
results in loss of this signaling to IRS by S6K1 thus resulting in constitutive mTORC1 
activity towards 4E-BP1 thus, preventing its inhibition of PPARγ protein translation. 
mTORC1 activation also leads to increase in cell size. 
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Since, MAP4K4 knockdown in 3T3-L1 adipocytes resulted in differential 
regulation of 4E-BP1 and p70S6K1 despite mTOR activation, and the improved 
adipocyte function in the KD animals could be attributed to the sustained insulin 
signaling to mTORC1 due to absence of p70S6K1 mediated negative feedback inhibition 
of IRS. Although this hypothesis still needs to be tested in the KD mice, it would be 
interesting to see if MAP4K4 gene silencing in hepatocytes would exhibit improved 
hepatic insulin signaling to mTORC1 and a differential regulation of the two downstream 
targets and hence an improved whole body glucose metabolism similar to adipose-
specific MAP4K4 knockdown. Since the improved hepatic insulin sensitivity in the KD 
animals was due to elevated insulin signaling that was reflected in enhanced Akt 
phosphorylation, it can be hypothesized (summarized in Figure 3.20) that upon MAP4K4 
gene silencing in the liver, absence of p70S6K1 negative feedback inhibition to IRS 
would result in sustained Akt activation and hence leading to decreased glucose output 
from the liver. It remains to be seen whether liver specific MAP4K4 gene ablation would 
be sufficient to improve hepatic insulin sensitivity and thus regulate whole body glucose 
homeostasis.  
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FIGURE 3.20. Hypothetical model for Map4k4 function in the liver. Silencing 
Map4k4 in the liver prevents mTORC1 mediated p70S6K1 activation and hence results 
in loss of feedback inhibition of IRS leading to constitutive activation of the insulin 
signaling pathway towards Akt.  Activated Akt inhibits gluconeogenesis and thus results 
in decreased plasma glucose levels contributing to improved whole body glucose 
homeostasis. 
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Third, detailed studies are warranted to understand the role of lipolysis in the 
observed phenotype of adipose-specific MAP4K4 knockdown animals. The KD animals 
exhibited decreased lipolysis as evidenced by diminished expression of ATGL and HSL 
phosphorylation at 18 months of age.  If the KD animals exhibit this at younger age, 
needs to be studied. Kosteli and colleagues have recently shown that macrophages are 
recruited to the adipose tissue in response to enhanced lipolysis, so as to sequester the 
released free fatty acids. Map4k4 in the adipocytes could be a positive regulator of 
lipolysis, thus resulting in macrophage recruitment and/or their activation. Furthermore, 
the activated macrophages would release pro-inflammatory cytokines to regulate hepatic 
function, as summarized in Figure 3.21. Adipose tissue explants from the control and KD 
animals could be used to study fasting induced lipolysis. Furthermore, fasting induced 
lipolysis mediated macrophage recruitment and the activation state of these ATMs would 
be studied using FACS analysis.  
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FIGURE 3.21. Hypothetical model for role of Map4k4 stimulated adipocyte lipolysis 
in regulating macrophage recruitment and thus hepatic gluconeogenesis.  Map4k4 in 
the adipocytes independently or through inhibition of mTORC1 activity stimulates 
lipolysis. Resulting increase in FFAs recruits macrophages to the adipose tissue. 
Activated macrophages secrete pro-inflammatory cytokines that stimulates hepatic 
gluconeogeneis and results in elevated plasma glucose levels. 
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Fourth, the discrepancy in the degree of MAP4K4 knockdown in the 
subcutaneous versus epididymal adipose tissue of the mice needs to be addressed. Studies 
in the animal models have suggested that expression of aP2 is greater in subcutaneous 
adipocytes than in epididymal adipocytes and hence the expression of MAP4K4 shRNA 
could be elevated in the subcutaneous adipose tissue thus resulting in better MAP4K4 
knockdown. Additionally, it is possible that the improved function of the subcutaneous 
adipocytes in the MAP4K4 knockdown mice prevents the expression of the shRNA in the 
gonadal fat, as subcutaneous adipose tissue develops earlier in the life of an animal.  To 
address this, adipose tissue expression of MAP4K4 shRNA needs to be monitored 
throughout postnatal development. We are currently in the process of confirming the 
observed phenotype in an additional mouse founder line, as all the adipose-specific 
MAP4K4 knockdown animals used in the experiments described in this chapter were 
generated from one mouse founder. Furthermore, we plan to generate MAP4K4 tissue- 
specific knockdown animals utilizing a different sequence of shRNA. Although 
MAP4K4 gene silencing was not observed in PECs and adipose derived macrophages, 
we need to confirm the specificity of aP2-Cre expression using bone marrow transplant 
studies. By answering all these questions, we might achieve better insight into the 
regulation of adipocyte function that is impaired in insulin resistance.  
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CHAPTER IV: Discussion 
Adipose tissue is the normal repository for excess energy in the form of 
triglycerides. Obesity-associated insulin resistance may be characterized by a state of 
dyslipidemia, where ectopic accumulation of lipid in liver and muscle is observed. This is 
accompanied by a chronic state of inflammation which leads to co-morbidities including 
type 2 diabetes. To this end, transgenic expression of the insulin responsive glucose 
transporter in mice resulted in improved adipose tissue function, increased adipose 
insulin sensitivity, and prevention of diet-induced obesity [390].  
Studies from our laboratory demonstrated enhanced GLUT4 expression and 
insulin stimulated glucose uptake in the MAP4K4 ablated 3T3-L1 adipocytes [324]. 
Moreover, TNFα treatment enhanced MAP4K4 expression [315]. Additionally, TNFα-
mediated inhibition of GLUT4 expression was prevented by silencing MAP4K4 in 
cultured adipocytes [324]. Thus, the objectives for this thesis were to better understand 
the role of MAP4K4 in adipose function, utilizing cell culture as well as mouse model 
systems.  
PPARγ is necessary for adipogenesis and is considered the master regulator of 
adipocyte function. Thiazolidinediones (TZDs), comprising troglitazone, rosiglitazone, 
and pioglitazone are a class of medications used in the treatment of type 2 diabetes that 
function as PPARγ agonists to improve adipose function, thus contributing to improved 
whole body insulin sensitivity [391, 392]. However, troglitazone has been withdrawn as a 
drug due to incidence of hepatitis and potential liver failure, rosiglitazone has been 
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implicated in increased risk of coronary heart disease and heart attacks, and there is a 
possible association of pioglitazone and bladder cancer, necessitates the discovery of new 
drugs to treat insulin resistance and type 2 diabetes. In light of the previous studies that 
identified MAP4K4 as a negative regulator of adipogenesis and PPARγ expression, 
which provided adequate impetus for developing innovative therapeutics, identification 
of the signaling pathway utilized by MAP4K4 to regulate PPARγ expression was needed. 
Thus in Chapter II, I identified a pathway by which MAP4K4 regulates PPARγ 
expression. Since studies from several laboratories have provided evidence for not only 
the important role played by PPARγ in adipocyte function, but also its role in regulating 
whole body insulin sensitivity, I wanted to determine if MAP4K4 regulated adipocyte 
function in vivo. Thus, in Chapter III, I demonstrated that MAP4K4 regulates adipose 
tissue PPARγ expression in mice and also plays a significant role in whole body glucose 
homeostasis. To achieve adipocyte-specific MAP4K4 gene ablation in vivo, a shRNA 
construct was employed, that was expressed in an aP2-driven Cre-recombinase-
dependent manner. Together, these studies add considerably to understanding the role of 
MAP4K4 in adipose function. 
Importantly, the results from 3T3-L1 cell culture studies established Map4k4 as a 
negative regulator of PPARγ protein expression and adipocyte cell size. Interestingly, 
adipose-specific MAP4K4 gene silencing in mice promoted an increase in PPARγ protein 
levels, TAG accumulation as well as enhanced adipocyte cell size thus confirming the 
observations made in the cell culture model system. 
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Regulation of PPARγ Expression by MAP4K4 in Adipocytes 
In Chapter II of this study, the regulation of PPARγ expression by MAP4K4 in 
adipocytes was characterized. This study was important for determining the mechanism 
by which MAP4K4 regulates adipocyte biology. As mentioned earlier, MAP4K4 was 
identified as a negative regulator of PPARγ and adipogenic gene expression [324]. How 
MAP4K4 regulated PPARγ expression, was not known. Hence these studies provided 
new insights into the mechanisms by which MAP4K4 regulates adipocyte function. 
The finding that mTOR phosphorylation at Ser2448 was enhanced when 
MAP4K4 was silenced, as shown in Figure 2.3B, identified MAP4K4 as an important 
player in the mTOR-mediated insulin signaling pathway regulation. The ser2448 site on 
mTOR is considered the Akt mediated activation site, thus suggesting that MAP4K4 
could be regulating Akt function that subsequently could modulate mTOR activity. 
However, in the previous studies, Akt phosphorylation was not observed to change in the 
MAP4K4 knockdown conditions in 3T3-L1 adipocytes [324]. Hence, MAP4K4 could be 
regulating mTOR at a step downstream to Akt. Although an increase in mTOR Ser2448 
phosphorylation is an indicator of increased mTOR activity it is not direct evidence. The 
increase in phosphorylation of 4E-BP1 on the priming sites thr36/45, as well as on ser64 
and thr69 is definite proof of increased mTOR activity. However, the possibility of a 4E-
BP1 phosphatase being inactive in the MAP4K4 knockdown condition cannot be ruled 
out. Thus, performing an mTOR in vitro kinase assay would be of interest.  
174 
 
Interestingly, MAP4K4 silencing mediated an increase in PPARγ protein levels 
due to increase in protein synthesis, since neither PPARγ mRNA expression (Figure 2.1 
C), nor the protein degradation changed (Figure 2.2 A).  These results show evidence for 
PPARγ translational regulation for the first time in the literature. However, as these are 
indirect evidence, determining the increase in PPARγ protein level by utilization of an 
[35S]met incorporation study to specifically observe an increase in incorporation of 
radioactive amino acid into PPARγ protein would be unequivocal evidence. 
Although 4E-BP1 and p70S6K1 are two downstream substrates of mTOR, the 
differential regulation of these two substrates in the MAP4K4 silencing conditions is 
surprising (Figure 2.6). The observation of no change in the phosphorylation status of 
p70S6K1 upon MAP4K4 knockdown was unexpected. However, studies show that a 
higher mTOR activity is required for the phosphorylation and activation of p70S6K1, 
while only a small increase in the activity in mTOR is sufficient to have an effect on 4E-
BP1 phosphorylation. Furthermore, since 4E-BP1 and p70S6K1 compete for the binding 
site on Raptor, if 4E-BP1 is favored as a substrate for mTOR in the MAP4K4 knockdown 
condition, then p70S6K1 would be inactive. It would be interesting to study if a 
differential binding capacity of the two substrates exists in the MAP4K4 silenced state. 
Rapamycin is an mTOR specific inhibitor. As shown in Figure 2.10 A, rapamycin 
treatment clearly inhibited mTOR activity that is reflected by the decreased 4E-BP1 
phosphorylation. The MAP4K4 silencing-mediated increases in 4E-BP1 phosphorylation 
as well as PPARγ protein levels was prevented by rapamycin, clearly showing that this 
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was a specific effect of inhibition of mTOR activity. Furthermore, adenovirus mediated 
MAP4K4 overexpression decreased mTOR Ser2448 phosphorylation and also resulted in 
diminished PPARγ protein levels (Figure 2.12 A). Thus, the data presented in this body 
of work has provided evidence for MAP4K4 mediated translational regulation of PPARγ 
through an mTOR/4E-BP1-dependent mechanism. 
Adipose MAP4K4 Regulates Hepatic Insulin Sensitivity 
Adipocyte-specific MAP4K4 gene silencing was achieved by expression of a 
lentiviral-based shRNA construct against MAP4K4 and recombination with cre 
recombinase driven by the aP2 promoter. An important discovery in these studies was 
that adipose MAP4K4 regulated liver insulin sensitivity. Silencing of MAP4K4 in the 
adipose tissue resulted in decreased hepatic glucose output (Figure 3.11B) during the 
clamp study, which is possibly due to increased activation of insulin signaling pathway, 
as seen in elevated Akt phosphorylation (Figure 3.11C). These results show that the liver 
retains insulin sensitivity in the adipose-specific MAP4K4 knockdown (KD) conditions, 
even when challenged with high fat diet.  
The KD animals exhibit enhanced adiposity even when fed a chow diet (Figure 
3.4B), and surprisingly, this was accompanied by decreased glycemia (Figure 3.5A). This 
decrease in serum glucose levels could have been due to decreased basal hepatic glucose 
production as well as increased whole body glycolysis (Figure 3.7 B & C). Furthermore, 
MAP4K4 gene silencing resulted in increased PPARγ protein expression (Figure 3.6 A & 
D) as was previously observed in 3T3-L1 adipocytes. Surprisingly, despite improved 
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insulin sensitivity, the liver of the KD mice still had a similar amount of lipid deposition 
as the control mice, in the high fat fed condition (Figure 3.13 B & C). These results 
suggest that hepatic lipid content might not be an indicator of hepatic insulin resistance.  
Previous studies using adipose-specific transgenic expression of PPARγ have 
demonstrated that PPARγ activation in the adipocytes is sufficient to maintain whole 
body insulin sensitivity. However, in the transgenic mice, the basal hepatic glucose 
output did not change. Furthermore, neither the body weight nor the % of WAT varied. 
Moreover, the authors have shown that adipocyte cell size, as well as serum leptin levels 
were significantly decreased [377]. In contrast to these mice, the KD animals display 
decreased basal hepatic glucose output, and increased total body weight (Figure 3.9 D) as 
well as enhanced subcutaneous WAT mass (Figure 3.9 E). The increase in adipose 
function in the KD mice was reflected by increased adipocyte size (Figure 3.12 A) and 
elevated triglyceride content in the adipose tissue (Figure 3.13 A). However, circulating 
levels of leptin in KD mice did not change (Figure 3.14 B). These observations in the KD 
mice are different from the PPARγ transgenic animal data, and suggests that the 
phenotypic effects observed in the adipose specific MAP4K4 knockdown mice is not 
purely due to elevated PPARγ expression. The studies from the KD animals provide 
evidence for PPARγ dependent as well as independent phenotypes in the adipose tissue 
of MAP4K4 KD animals. 
Studies using adipose-specific JNK1 knockout mice demonstrated that, ablation 
of JNK1 in the adipose tissue decreased IL-6 synthesis, which was responsible for 
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improved liver insulin sensitivity after high fat diet. However, these animals exhibited 
elevated basal glucose levels, despite similar body weight and adiposity as the control 
animals [393]. Though serum levels of IL-6 was observed to be decreased in the adipose-
specific MAP4K4 knockdown (KD) animals IL-1α concentrations were also significantly 
reduced (Figure 3.15). Furthermore, the KD mice exhibited an increase in PPARγ protein 
levels, decreased basal glucose levels despite enhanced body weight and adiposity 
compared to the control animals.  Thus the phenotype exhibited by the adipose-specific 
MAP4K4 knockdown animals appears to be unique. 
mTOR is central to growth and cell size regulation.  In Chapter II I have 
demonstrated that MAP4K4 regulated PPARγ protein translation in an mTOR dependent 
manner. These studies provided clear evidence for mTOR signaling pathway in mediating 
the effects of MAP4K4.  The increase in adipocyte cell size in the KD mice is a clear 
indicator of elevated mTOR activity. Furthermore, Chakrabarti and colleagues have 
demonstrated that mTOR promotes fat storage by suppressing lipolysis and stimulating 
lipogenesis [394]. In accordance with this, WAT triglyceride content in the KD mice was 
elevated (Figure 3.9A), a fasting induced lipolysis appears to also be decreased, as 
evidenced by decreased ATGL and phospho-HSL protein levels (Figure 3.16 H). 
However, it remains to be determined whether MAP4K4 knockdown regulates mTOR 
activity in the knockdown mouse model. 
Adipose-specific S6K1 knockout mouse model demonstrated that, despite 
elevated glucose and free fatty acid levels upon high fat feeding, the animals remain 
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insulin sensitive, owing to the absence of the negative feedback to IRS [111]. Since 
p70S6K1 phosphorylation did not change in the MAP4K4 knockdown condition in 3T3-
L1 adipocytes, as shown in Chapter II, silencing MAP4K4 in the adipose tissue could 
possibly regulate S6K1 similarly. The increase in adipocyte cell size and triglyceride 
content in MAP4K4 KD mice are indicators of increased mTOR activity as well as 
improved insulin sensitivity, which could be the reflection of diminished IRS feedback 
inhibition due to the absence of S6K1 activation in these mice.  However, studies need to 
be performed to address if S6K1 activity is not changed, and whether IRS feedback 
inhibition is prevented.   
Collectively, the observations made in the 3T3-L1 adipocyte cell culture system 
as well as mouse model provide evidence for an important role played by MAP4K4 in the 
adipocyte to regulate whole body insulin sensitivity as summarized in the Figure 4. 
Adipose-specific MAP4K4 gene silencing resulted in increased cell size, protein 
translation, lipogenesis, decreased lipolysis and cytokine & chemokine synthesis and 
secretion. It would be naïve to assign a single mechanism or one effector molecule 
responsible for mediating all the above-mentioned MAP4K4 downstream functions. 
Since MAP4K4 is a serine/threonine protein kinase kinase kinase kinase, several 
downstream protein kinases would be involved in mediating the signaling cascade that in 
turn regulate several target proteins. However, the observations point towards mTORC1 
that modulates several adipocyte functions, as the effector molecule responsible for 
MAP4K4 cellular effects.  MAP4K4 functions as a negative regulator of mTORC1 
activity and PPARγ protein expression and hence inhibits cell size, lipogenesis and lipid 
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storage. Furthermore, MAP4K4 could be activating lipolysis, chemokine and cytokine 
synthesis & secretion through mTOR inhibiton or independently, resulting in elevated 
macrophage recruitment and/or activation that further increase adipose tissue local as 
well as systemic pro-inflammatory cytokines levels. Systemic low grade inflammation 
would lead to decreased hepatic insulin signaling and sensitivity resulting in increased 
hepatic gluconeogenesis and elevated plasma glucose levels leading to whole body 
insulin resistance.  
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FIGURE 4. Role of adipocyte Map4k4 in inducing insulin resistance – a 
hypothetical model. At molecular level, Map4k4 functions as a negative regulator of 
mTORC1. mTOR plays an important role in mediating insulin‘s cellular effects by 
activating p70S6K1 and inhibiting 4E-BP1 by phosphorylation. Inactivation of 4E-BP1 
promotes PPARγ protein synthesis. mTOR also regulates SREBP1 activity and its 
protein synthesis. Map4k4 inhibits mTOR activity towards 4E-BP1 but promotes 
p70S6K1 activation, and hence contributes to insulin resistance due to activation of 
feedback inhibition of IRS. At a cellular level, Map4k4 inhibits mTOR functions of 
promoting protein translation, lipogenesis, cell size and glucose uptake and inhibition 
of lipolysis and cytokine & chemokine synthesis. At the level of whole organism, 
Map4k4 in the adipocyte prevents adipose functions of lipid storage and cell growth 
while promoting macrophage recruitment and activation due to elevated FFAs and 
cytokine & chemokine levels that together lead to insulin resistance in the adipose 
tissue. Inflamed adipose tissue promotes systemic low-grade inflammation that 
decreases hepatic insulin sensitivity that further contributes to insulin resistance. 
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Although MAP4K4 silencing improves insulin sensitivity, it also results in 
adiposity and hence MAP4K4 might not be of interest as a potential therapeutic target 
of obesity induced insulin resistance, due to aesthetic considerations. However, our 
mouse model with adipose-specific MAP4K4 gene silencing would be of immense 
utility and would be a great tool to better understand the differences in insulin 
sensitivity exhibited by obese individuals, as all obese people are not insulin resistant. 
Together, the data presented in Chapter II and Chapter III provides evidence of 
a definitive role for MAP4K4 in regulation of adipose function. Thus, I have 
demonstrated that MAP4K4 negatively regulates PPARγ protein translation, adipocyte 
TAG accumulation and cell size as well as provided evidence implicating adipose 
tissue MAP4K4 in modulating whole body insulin sensitivity. 
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